<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmaceutical policies: effects of regulating drug insurance schemes - Pantoja, T - 2022 | Cochrane Library</title> <meta content="Pharmaceutical policies: effects of regulating drug insurance schemes - Pantoja, T - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011703.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmaceutical policies: effects of regulating drug insurance schemes - Pantoja, T - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011703.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011703.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pharmaceutical policies: effects of regulating drug insurance schemes" name="citation_title"/> <meta content="Tomas Pantoja" name="citation_author"/> <meta content="Pontificia Universidad Católica de Chile" name="citation_author_institution"/> <meta content="tpantoja@gmail.com" name="citation_author_email"/> <meta content="Blanca Peñaloza" name="citation_author"/> <meta content="Pontificia Universidad Católica de Chile" name="citation_author_institution"/> <meta content="Camilo Cid" name="citation_author"/> <meta content="Pontificia Universidad Católica de Chile" name="citation_author_institution"/> <meta content="Cristian A Herrera" name="citation_author"/> <meta content="Pontificia Universidad Católica de Chile" name="citation_author_institution"/> <meta content="Craig R Ramsay" name="citation_author"/> <meta content="University of Aberdeen" name="citation_author_institution"/> <meta content="Jemma Hudson" name="citation_author"/> <meta content="University of Aberdeen" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD011703.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/05/03" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011703.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011703.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011703.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Drug and Narcotic Control; Health Expenditures; Insurance, Pharmaceutical Services; National Health Programs; *Prescription Drugs" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011703.pub2&amp;doi=10.1002/14651858.CD011703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="mvgXlmVk";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011703\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011703\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011703\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011703\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","pt","th","ko","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011703.pub2",title:"Pharmaceutical policies: effects of regulating drug insurance schemes",firstPublishedDate:"May 3, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Effective Practice and Organisation of Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011703.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011703.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011703.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011703.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011703.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011703.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011703.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011703.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011703.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011703.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1253 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011703.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-sec-0086"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-sec-0022"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-sec-0023"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-sec-0080"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/appendices#CD011703-sec-0090"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmaceutical policies: effects of regulating drug insurance schemes</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/information#CD011703-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Tomas Pantoja</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/information#CD011703-cr-0005">Blanca Peñaloza</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/information#CD011703-cr-0006">Camilo Cid</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/information#CD011703-cr-0007">Cristian A Herrera</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/information#CD011703-cr-0008">Craig R Ramsay</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011703.pub2/information#CD011703-cr-0009">Jemma Hudson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/information/en#CD011703-sec-0123">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 03 May 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011703.pub2">https://doi.org/10.1002/14651858.CD011703.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011703-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011703-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011703-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011703-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011703-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011703-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD011703-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011703-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011703-abs-0001" lang="en"> <section id="CD011703-sec-0001"> <h3 class="title" id="CD011703-sec-0001">Background</h3> <p>Drug insurance schemes are systems that provide access to medicines on a prepaid basis and could potentially improve access to essential medicines and reduce out‐of‐pocket payments for vulnerable populations. </p> </section> <section id="CD011703-sec-0002"> <h3 class="title" id="CD011703-sec-0002">Objectives</h3> <p>To assess the effects on drug use, drug expenditure, healthcare utilisation and healthcare outcomes of alternative policies for regulating drug insurance schemes. </p> </section> <section id="CD011703-sec-0003"> <h3 class="title" id="CD011703-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, nine other databases, and two trials registers between November 2014 and September 2020, including a citation search for included studies on 15 September 2021 using Web of Science. We screened reference lists of all the relevant reports that we retrieved and reports from the Background section. Authors of relevant papers, relevant organisations, and discussion lists were contacted to identify additional studies, including unpublished and ongoing studies. </p> </section> <section id="CD011703-sec-0004"> <h3 class="title" id="CD011703-sec-0004">Selection criteria</h3> <p>We planned to include randomised trials, non‐randomised trials, interrupted time‐series studies (including controlled ITS [CITS] and repeated measures [RM] studies), and controlled before‐after (CBA) studies. Two review authors independently assessed the search results and reference lists of relevant reports, retrieved the full text of potentially relevant references and independently applied the inclusion criteria to those studies. We resolved disagreements by discussion, and when necessary by including a third review author. We excluded studies of the following pharmaceutical policies covered in other Cochrane Reviews: those that determined how decisions were made about which conditions or drugs were covered; those that placed restrictions on reimbursement for drugs that were covered; and those that regulated out‐of‐pocket payments for drugs. </p> </section> <section id="CD011703-sec-0005"> <h3 class="title" id="CD011703-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data from the included studies and assessed risk of bias for each study, with disagreements being resolved by consensus. We used the criteria suggested by  Cochrane Effective Practice and Organisation of Care (EPOC)  to assess the risk of bias of included studies. For randomised trials, non‐randomised trials and controlled before‐after studies, we planned to report relative effects. For dichotomous outcomes, we reported the risk ratio (RR) when possible and adjusted for baseline differences in the outcome measures. For interrupted time series and controlled interrupted time‐series studies, we computed changes along two dimensions: change in level; and change in slope. We undertook a structured synthesis following the EPOC guidance on this topic, describing the range of effects found in the studies for each category of outcomes. </p> </section> <section id="CD011703-sec-0006"> <h3 class="title" id="CD011703-sec-0006">Main results</h3> <p>We identified 58 studies that met the inclusion criteria (25 interrupted time‐series studies and 33 controlled before‐after studies). Most of the studies (54) assessed a single policy implemented in the United States (US) healthcare system: Medicare Part D. The other four assessed other drug insurance schemes from Canada and the US, but only one of them provided analysable data for inclusion in the quantitative synthesis. The introduction of drug insurance schemes may increase prescription drug use (low‐certainty evidence). On the other hand, Medicare Part D may decrease drug expenditure measured as both out‐of‐pocket spending and total drug spending (low‐certainty evidence). Regarding healthcare utilisation, drug insurance policies (such as Medicare Part D) may lead to a small increase in visits to the emergency department. However, it is uncertain whether this type of policy increases or decreases hospital admissions or outpatient visits by beneficiaries of the scheme because the certainty of the evidence was very low. Likewise, it is uncertain if the policy increases or reduces health outcomes such as mortality because the certainty of the evidence was very low. </p> </section> <section id="CD011703-sec-0007"> <h3 class="title" id="CD011703-sec-0007">Authors' conclusions</h3> <p>The introduction of drug insurance schemes such as Medicare Part D in the US health system may increase prescription drug use and may decrease out‐of‐pocket payments by the beneficiaries of the scheme and total drug expenditures. It may also lead to a small increase in visits to the emergency department by the beneficiaries of the policy. Its effects on other healthcare utilisation outcomes and on health outcomes are uncertain because of the very low certainty of the evidence. The applicability of this evidence to settings outside US healthcare is limited. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011703-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011703-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011703-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011703-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011703-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011703-abs-0012">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011703-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011703-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011703-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD011703-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011703-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011703-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011703-abs-0002" lang="en"> <h3>Effects of policies regulating insurance for drugs</h3> <p>The aim of this Cochrane Review was to find out if drug insurance schemes change people’s use of medicines, the amount of money they spend on medicines, their health, and their use of healthcare. Cochrane Review authors collected and analysed all relevant studies to answer this question. They found 58 studies. Most of these studies were from the US assessing a single policy change (Medicare Part D) implemented in January 2006. </p> <p><b>Key messages</b> </p> <p>The USA’s Medicare Part D offers free prescription medicines to elderly people. This system may increase the amount of medicines elderly people use, but they may spend less money on medicines. We do not know if this system changes people’s health or their use of healthcare services because the certainty of the evidence was very low.  </p> <p><b>What is a drug insurance scheme?</b> </p> <p>In a drug insurance scheme, governments or private organisations offer people the medicines they need at a low cost or free of charge. The medicines are usually paid for through government taxes, people’s employers, people paying for membership in insurance schemes, or a combination of these systems. </p> <p>Many countries have mixed systems of public and private drug insurance. Some drug insurance schemes cover everyone in a country or setting. Other schemes only cover certain groups. For instance, some schemes only cover people in work, while other schemes only cover the poor and the elderly. </p> <p>Successful drug insurance schemes can improve people’s health by giving them the medicines they need either free or at a price they can afford. Drug insurance schemes can also save money for governments and private organisations. For instance, people using the right medicines may need fewer healthcare services. Governments and organisations running these schemes can also negotiate better prices with drug companies. </p> <p><b>What are the main results of the review?</b> </p> <p>The review authors found 58 relevant studies. Most of these studies were from the USA and 54 of them assessed one type of drug insurance scheme: Medicare Part D. </p> <p>Medicare Part D is a drug insurance scheme for elderly people. In this scheme, elderly people who are already on Medicare have free access to their prescription medicines up to a certain sum every year (in 2018, this sum was USD 3750 per person). After this sum is reached, other systems are used. These studies showed the following. </p> <p>‐ Medicare Part D may increase the amount of medicines people use (low‐certainty evidence).</p> <p>‐ Medicare Part D may decrease the amount of money people spend on medicines (low‐certainty evidence). </p> <p>‐ Medicare Part D may lead to a small increase in the number of emergency department visits by beneficiaries of the scheme (low‐certainty evidence). </p> <p>‐ We do not know what the effect of Medicare Part D is on people’s health or on the use of other healthcare services because the certainty of the evidence was very low. </p> <p>One of the reasons for our low confidence in these findings is that we do not know how relevant these results are to countries or settings outside the USA. </p> <p><b>How up to date is this review?</b> </p> <p>The review authors searched for studies that had been published up to September 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011703-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011703-sec-0086"></div> <h3 class="title" id="CD011703-sec-0087">Implications for practice</h3> <section id="CD011703-sec-0087"> <p>The introduction of drug insurance policies such as Medicare Part D in the US health systems may increase prescription drug use and may decrease OOP payments by the beneficiaries of the scheme. However, the effects of this policy on total drug expenditure, on healthcare utilisation, and on health outcomes are uncertain. In addition, the applicability of this evidence to any setting outside the US healthcare system is probably very limited. </p> <p>The increasing costs of pharmaceuticals is one of the common challenges currently faced by virtually every health system, with drug spending skewed progressively towards high‐cost products (<a href="./references#CD011703-bbs2-0226" title="OECD.New Health Technologies: Managing Access, Value and Sustainability. Paris: OECD Publishing, 2017.">OECD 2017</a>), which affects households, insurers and/or governments budgets. This is also being experienced by Medicare Part D in the US, with a growing share of its spending moving towards high‐cost enrollees who reach the catastrophic phase of the scheme mainly because of the greater number of highly expensive biologic products and specialty drugs that have entered the market and are prescribed in the health system (<a href="./references#CD011703-bbs2-0220" title="MEDPAC.Chapter 14: The Medicare prescription drug program (Part D): Status report. www.medpac.gov/docs/default-source/reports/mar18_medpac_ch14_sec.pdf (accessed prior to 10 Jan 2022).">MEDPAC 2018</a>). In that sense, the challenge for decision‐makers across the world is to put in place  policies covering drugs that add value to the money spent, through having being proven to be beneficial for patients (effective) and, ideally, for the health system (cost‐effective) (<a href="./references#CD011703-bbs2-0227" title="OECD.Pharmaceutical Innovation and Access to Medicines (OECD Health Policy Studies). Paris: OECD Publishing, 2018.">OECD 2018</a>). Drug insurance schemes (especially those focusing on who has the authority to make decisions regarding coverage) are potentially one of those policies to address that challenge. </p> <p>Any decision to create or expand existing drug insurance schemes, regardless of the country income level, needs to consider the problem of increases in pharmaceutical expenditure placing pressure on institutional (public and private) and people's budgets. Although the findings of this review do not speak directly to this issue, decision‐makers and funders responsible for the regulation of drug insurance schemes need to consider how to reach a balance between providing sufficient financial protection to beneficiaries and maintaining a financially sustainable system. </p> </section> <h3 class="title" id="CD011703-sec-0088">Implications for research</h3> <section id="CD011703-sec-0088"> <p>Evidence regarding who can or do provide drug insurance, who pays for it, and who has the authority to make decisions regarding coverage remains limited. Nearly all of the studies in this review assessed a single policy implemented in the US healthcare system. Some of the implications for research from this body of evidence are: </p> <p> <ul id="CD011703-list-0012"> <li> <p>It is important that evaluations be conducted of this type of policy in other settings where policies regulating drug insurance schemes are being introduced, especially in low‐ and middle‐income countries. Ideally, evaluations should be planned in advance of introducing the policy, as a routine part of the policy implementation process.  </p> </li> <li> <p> Rigorous evaluation is also needed of different scopes of coverage — for example, coverage of vulnerable populations (e.g. low income groups) or universal coverage for the entire population. Future research should therefore consider these areas as a priority. </p> </li> <li> <p>While randomised trials provide the most robust evidence, they are difficult to conduct in this field and interrupted time‐series designs should be considered. These studies can be easier to conduct where robust prescription registries or databases are available in a health system or subsystem. </p> </li> <li> <p>The outcomes selected should be primarily relevant for both patients and the health system including, for example, access to prescribed drugs, health outcomes, inequities and costs (e.g. out‐of‐pocket expenditures and public spending on pharmaceuticals). </p> </li> <li> <p>If more studies were available, future versions of the review should attempt to analyse the effects of this type of policy by type of health condition or the type of cost (e.g. costs of orphan drugs) being covered. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011703-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011703-sec-0008"></div> <div class="table" id="CD011703-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Enrolment in the drug insurance scheme compared to no enrolment in the scheme</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population: People entitled to the drug insurance scheme (elderly and/or poor population)</b> </p> <p><b>Settings: United States healthcare system</b> </p> <p><b>Intervention: Drug insurance scheme (Medicare Part D or ACA Medicaid expansion) </b> </p> <p><b>Comparison: No enrolment, non‐eligible for enrolment or low likelihood of enrolment into the drug insurance scheme</b> </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Median adjusted<sup>1</sup> relative effect<br/>(IQR)</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of<br/>studies (Nº effect estimates)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Drug use</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Immediately after policy implementation<br/>+3.74% </p> <p>(−9.40% to 22.98%)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 ITS studies<br/>(32 effect estimates) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>2</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Drug insurance policies (such as Medicare Part D) may increase drug use immediately after until up to 12 months after the implementation of the policy. However, the range indicates that the policy may slightly decrease or may increase drug use. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 to 11 months after policy implementation<br/>+8.40% </p> <p>(‐2.88% to 25.19%)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 ITS studies, 1 CBA study<br/>(25 effect estimates) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 year or more after policy implementation<br/>+14.73% (3.11% to 36.0%) </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 CITS study, 10 ITS and 19 CBA studies<br/>(59 effect estimates) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug insurance policies (such as Medicare Part D) may increase drug use from 1 year until up to 60 months after the implementation of the policy.  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Drug expenditure</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Immediately after policy implementation</p> <p>−59.07%</p> <p>(−66.33% to −26.27%)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 ITS studies<br/>(15 effect estimates) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Drug insurance policies (such as Medicare Part D) may decrease drug expenditures immediately and for up to 36 months after the implementation of the policy. </p> <p> </p> <p>When only out‐of‐pocket expenditures were considered (14, 18 and 39 effect estimates, respectively), there was no change in either the magnitude or variability of the summary effect estimates for any of the 3 outcome time points. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 to 11 months after policy implementation</p> <p>−46.96%</p> <p>(−65.98% to −22.98%)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 ITS studies<br/>(19 effect estimates) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>4</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 year or more after policy implementation</p> <p>−43.17%</p> <p>(−57.40% to −19.77%)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 CITS study, 8 ITS studies<br/>and 12 CBA studies (48 effect estimates) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>3</sup> </b> </p> <p> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="4" scope="col" valign="top"> <p><b>Healthcare</b> utilis<b>ation</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Emergency Department visits</p> <p>+9.74%</p> <p>(3.29% to 18.64%)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 ITS studies and 4 CBA studies<br/>(14 effect estimates) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug insurance policies (such as Medicare Part D) may lead to a small increase in  the number or frequency of Emergency Department visits by beneficiaries of the drug insurance scheme. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Hospital admissions</p> <p>‐2.65% (‐9.35% to 0.33%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 ITS study and 6 CBA studies </p> <p>(8 effect estimates)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>The effects of drug insurance policies (such as Medicare Part D) on hospital admissions, outpatient visits and non‐drug medical spending were uncertain because the certainty of the evidence was very low. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Outpatient visits</p> <p>‐28.6%</p> <p>(−69.25% to 22.7%)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> 3 CBA studies<br/>(3 effect estimates) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>7</sup> </b> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Non‐drug medical spending</p> <p>‐11.4% </p> <p>(‐11.5% to ‐8.37%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 CITS and 2 CBA studies </p> <p>(3 effect estimates)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>8</sup> </b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Health outcomes</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> <p> ‐0.50% </p> <p>(‐1.35% to ‐0.35%)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 ITS and 2 CBA studies </p> <p>(3 effect estimates)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>9</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effects of drug insurance policies (such as Medicare Part D) on mortality were uncertain because the certainty of the evidence was very low. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Non‐mortality outcomes: depressive symptoms, activities of daily living  (ADL) limitations, change in specific behaviours, self‐perception of health: the effects included both small positive and negative impacts for these outcomes. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 ITS and 6 CBA studies </p> <p>(17 effect estimates)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>10</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effects of drug insurance policies (such as Medicare Part D) on non‐mortality outcomes were uncertain because the certainty of the evidence was very low. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/>  </p> <p><b>High certainty</b> = This research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different** is low. </p> <p><b>Moderate</b> <b>certainty</b> = This research provides a good indication of the likely effect. The likelihood that the effect will be substantially different** is moderate. </p> <p><b>Low</b> <b>certainty</b> = This research provides some indication of the likely effect. However, the likelihood that it will be substantially different** is high. </p> <p><b>Very low</b> <b>certainty</b> = This research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different** is very high. </p> <p>** Substantially different = a large enough difference that it might affect a decision</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup> Adjusted for baseline differences </p> <p><sup>2</sup> For these outcomes, because most of the body of evidence came from ITS studies, we started at a moderate grade and downgraded by 1 level because of methodological limitations (uncertainties about incomplete outcome data and the potential presence of other policies at the time when part D was implemented) and some concerns about unexplained inconsistency in the direction of effect. </p> <p><sup>3</sup> CBA studies started at a low‐certainty grade due to concerns about methodological limitations. There were no additional concerns. </p> <p><sup>4</sup> For these outcomes, because most of the body of evidence came from ITS studies, we started at a moderate grade and downgraded by 1 level because of methodological limitations (uncertainties about incomplete outcome data and the potential presence of other policies at the time when Part D was implemented).  </p> <p><sup>5</sup> Starting at a low grade (as most of the contributing evidence came from CBA studies), we did not have any additional concerns. </p> <p><sup>6</sup> Starting at a low grade (as most of the  contributing evidence came from CBA studies), we downgraded by 1 level because of some concerns about methodological limitations and some concerns about unexplained inconsistency in the direction of effect. </p> <p><sup>7</sup> Starting at a low grade (as all of the contributing evidence came from CBA studies), we downgraded by 1 level because of some concerns about unexplained inconsistency in the direction of effect and some imprecision. </p> <p><sup>8</sup> Starting at a low grade (as most of the contributing evidence came from CBA studies), we downgraded by 1 level because of concerns about indirectness. </p> <p><sup>9</sup> Starting at a low grade (as most of the contributing evidence came from CBA studies), we downgraded by 1 level because of concerns about imprecision. </p> <p><sup>10</sup> Starting at a low grade (as most of the contributing evidence cane from CBA studies), we downgraded by 1 level because of concerns about imprecision. </p> <p>CBA = Controlled before‐after study<br/>ITS = Interrupted time‐series study </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011703-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011703-sec-0009"></div> <p>Pharmaceuticals are an essential part of modern medicine, playing a major role in protecting, maintaining and restoring people’s health. The provision of appropriate medicines of assured quality in adequate quantities and at reasonable prices is therefore a concern of both global and national policy makers around the world. </p> <section id="CD011703-sec-0010"> <h3 class="title" id="CD011703-sec-0010">Description of the condition</h3> <p>One significant challenge in this field has been the increase in spending on drugs during the last decade. According to the World Health Organization (WHO) National Health Accounts data in 2006, the mean expenditures on pharmaceuticals as a share of total expenditures on health was 24.9% across all countries, but ranged from 30.4% for low‐income countries to 19.7% for high‐income countries (<a href="./references#CD011703-bbs2-0218" title="LuY , HernandezP , AbegunreD , EdejerT .Medicine expenditures. In: The World Medicines Situation. 3rd edition. Geneva: World Health Organization, 2011.">Lu 2011</a>). In 2017, spending on retail pharmaceuticals in countries included in the Organization for Economic Co‐operation and Development (OECD) averaged USD 564 per person, ranging from USD 175 (Costa Rica) to USD 1220 (USA) per capita per year. Most spending on retail pharmaceuticals is for prescription medicines (75%) with the remainder spent on over‐the‐counter (OTC) medicines (19%) and medical non‐durables (5%). This type of expenditure accounted for almost one‐fifth of all healthcare expenditure, and represented the third largest spending component in OECD countries after inpatient and outpatient care (<a href="./references#CD011703-bbs2-0228" title="OECD.Health at a Glance 2019: OECD Indicators. Paris: OECD Publishing, 2019. [DOI: 10.1787/4dd50c09-en]">OECD 2019</a>). </p> <p>Along with growth of spending on pharmaceuticals, there is increasing consumption of drugs due to changes in medical practice and the appearance of more expensive drugs. Although this consumption has grown in all countries, in the non‐hospital sector, the relative growth between 2000 and 2008 has been higher in low‐income countries (29.3%) than in high‐income countries (18.6%) (<a href="./references#CD011703-bbs2-0212" title="HoebertJ , LaingR , StephensP .Phamaceutical consumption. In: The World Medicines Situation. 3rd edition. Geneva: World Health Organization, 2011.">Hoebert 2011</a>). For example, consumption of anti‐diabetic drugs in OECD countries increased from 37 defined daily doses (DDD) per 1000 people per day in 2000 up to 68 DDD per 1000 people per day in 2017; and consumption of antidepressants increased from 32 DDD per 1000 people per day in 2000 up to 63 DDD per 1000 people per day in 2017 (<a href="./references#CD011703-bbs2-0228" title="OECD.Health at a Glance 2019: OECD Indicators. Paris: OECD Publishing, 2019. [DOI: 10.1787/4dd50c09-en]">OECD 2019</a>). </p> <p>Despite the rise in spending and consumption, people in many countries do not have sufficient access to medicines. A study of accessibility of the 15 most commonly used drugs in 50 countries showed that the availability of generics in the private sector ranged between 60.7% and 76.3%, while in the public sector it ranged from 27% to 44.3% (<a href="./references#CD011703-bbs2-0193" title="CameronA ,  EwenM ,  Ross-DegnanD ,  BallD ,  LaingR .Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet2008;373(9659):240-9.">Cameron 2008</a>). The availability of original drugs in the private sector was between 22.3% and 61.8%. </p> <p>The proportion of the total cost for drugs paid for by out‐of‐pocket (OOP) payments by patients is an important indicator of barriers to access to medicines. In 2006, private expenditure on medicines as a share of total pharmaceutical expenditure per capita was 61.2%, 66.5% and 76.9% in upper‐middle‐income, lower‐middle‐income and low‐income countries, respectively (<a href="./references#CD011703-bbs2-0218" title="LuY , HernandezP , AbegunreD , EdejerT .Medicine expenditures. In: The World Medicines Situation. 3rd edition. Geneva: World Health Organization, 2011.">Lu 2011</a>). This reflects the reality that OOP expenditure is the major source of pharmaceutical payments in all but high‐income countries. These OOPs might lead to 'catastrophic' payments, defined as paying more than 40% of household income directly on healthcare after basic needs have been met (<a href="./references#CD011703-bbs2-0224" title="MurrayCJL , XuK , KlavusJ , KawabataK , HanvoravongchaiP , ZeramdiniR , et al.Chapter 38: Assessing the distribution of household financial contributions to the health system: concepts and empirical application. In: MurrayCJL , EvansDB , editors(s). Health Systems Performance Assessment: Debates, Methods and Empiricism. Geneva: World Health Organization, 2003.">Murray 2003</a>). Catastrophic payments are well documented (<a href="./references#CD011703-bbs2-0248" title="Van DoorslaerE , O'DonnellO , Rannan-EliyaRP , SomanathanA , AdhikariSR , GargCC , et al.Catastrophic payments for health care in Asia. Health Economics2007;16(11):1159-84.">Van Doorslaer 2007</a>), and are usually focused on spending on healthcare in general, rather than on pharmaceuticals specifically. Payments for medicines are often, however, a high proportion of OOP spending. Moreover, high OOP payments might lead to discontinuation of essential medicines when people cannot afford to pay for them. </p> </section> <section id="CD011703-sec-0011"> <h3 class="title" id="CD011703-sec-0011">Description of the intervention</h3> <p>Drug insurance schemes, which are systems that provide access to medicines on a prepaid basis, could potentially address some of the problems currently faced by many health systems regarding medicines, such as rising costs and inappropriate OOP payments. They may have multiple — although sometimes conflicting — goals including: </p> <p> <ul id="CD011703-list-0001"> <li> <p>ensuring that everyone has access to essential medicines;</p> </li> <li> <p>ensuring equitable access to drugs;</p> </li> <li> <p>reducing or eliminating OOP payments for essential medicines;</p> </li> <li> <p>preventing catastrophic payments for drugs;</p> </li> <li> <p>containing the amount of public funds that are spent on drugs, for example, by negotiating better prices and reducing inappropriate use of drugs; and </p> </li> <li> <p>ensuring the appropriate use of drugs.</p> </li> </ul> </p> <p>Approaches to drug insurance vary substantially between countries for several reasons, including differences in prioritising the above goals; political differences, for example, the extent of social solidarity; and economic differences. These approaches are a reflection of the way in which governments choose to regulate the governance, financing and provision of drug insurance schemes through determining: </p> <p> <ul id="CD011703-list-0002"> <li> <p>who can provide drug insurance;</p> </li> <li> <p>who receives drug insurance;</p> </li> <li> <p>who pays for drug insurance; and</p> </li> <li> <p>who makes decisions regarding which conditions and which drugs are covered.</p> </li> </ul> </p> <p>Such regulations may apply specifically to drug insurance or may apply more generally to health insurance (with or without drug insurance). </p> <section id="CD011703-sec-0012"> <h4 class="title">Who can provide drug insurance</h4> <p>Drug insurance can either be provided publicly by the government or privately by non‐governmental organisations. Private insurance, in turn, can be either for‐profit or not‐for‐profit (non‐profit). </p> <p>Private insurance can be a substitute for public insurance; can supplement public insurance by providing coverage for drugs beyond that covered by public insurance; or can be in competition with public health insurance by providing alternatives to public drug insurance. Most countries have mixed systems of public and private drug insurance. There is wide variation in the rules set by governments and, consequently, in the extent of public and private insurance, the mix of for‐profit and not‐for‐profit drug insurance, and the mix of substitute, supplementary and competitive private drug insurance schemes (<a href="./references#CD011703-bbs2-0249" title="World Health Organization.Voluntary Health Insurance in the European Union. Brussels: World Health Organization, 2004.">WHO 2004a</a>; <a href="./references#CD011703-bbs2-0250" title="World Health Organization.Reaching Universal Coverage via Social Health Insurance: Key Design Features in the Transition Period. World Health Organization, 2004.">WHO 2004b</a>; <a href="./references#CD011703-bbs2-0255" title="World Bank.Private Voluntary Health Insurance in Development: Friend or Foe?. Washington DC: World Bank, 2007.">World Bank 2007</a>). </p> </section> <section id="CD011703-sec-0013"> <h4 class="title">Who receives drug insurance</h4> <p>Drug insurance may be universal, that is, covering everyone in a jurisdiction; or only available to certain groups, such as the poor or the elderly (<a href="./references#CD011703-bbs2-0250" title="World Health Organization.Reaching Universal Coverage via Social Health Insurance: Key Design Features in the Transition Period. World Health Organization, 2004.">WHO 2004b</a>). Regulations can require that drug insurance is: </p> <p> <ul id="CD011703-list-0003"> <li> <p>universal, meaning that everyone in a jurisdiction is covered;</p> </li> <li> <p>compulsory, meaning that individuals must have drug insurance, but not everyone is covered by public insurance, and public insurance is not provided automatically to everyone; </p> </li> <li> <p>provided to specific groups, for example, the poor, the elderly or the employed; or</p> </li> <li> <p>optional, meaning that the government can also regulate who can or cannot be excluded from enrolling in drug insurance schemes. </p> </li> </ul> </p> </section> <section id="CD011703-sec-0014"> <h4 class="title">Who pays for drug insurance</h4> <p>Premiums (pre‐payments) for drug insurance can be paid out of general tax revenues, earmarked taxes, by employers, or directly by those who are insured (<a href="./references#CD011703-bbs2-0238" title="SavedoffW .Tax-Based Financing for Health Systems: Options and Experience. Geneva: World Health Organization, 2004.">Savedoff 2004</a>). Many countries have mixed systems in which premiums are partially paid by two or more of these sources or where different sources pay the premiums for different groups of people. </p> </section> <section id="CD011703-sec-0015"> <h4 class="title">Who makes decisions regarding which conditions and which drugs are covered</h4> <p>Decisions about coverage can be made by the government, by independent bodies to which the government has allocated authority, or by the owners of private health insurance schemes. There can also be mixed systems where some types of decisions are, for example, made by the government and others are left to the owners of private insurance schemes. In federal systems some decisions may be made by the federal government and others by sub‐national governments or authorities. </p> </section> </section> <section id="CD011703-sec-0016"> <h3 class="title" id="CD011703-sec-0016">How the intervention might work</h3> <section id="CD011703-sec-0017"> <h4 class="title">Who can provide drug insurance</h4> <p>Approaches to the provision of drug insurance operate in different ways and may vary considerably in achieving the goals of drug insurance (<a href="./references#CD011703-bbs2-0238" title="SavedoffW .Tax-Based Financing for Health Systems: Options and Experience. Geneva: World Health Organization, 2004.">Savedoff 2004</a>; <a href="./references#CD011703-bbs2-0249" title="World Health Organization.Voluntary Health Insurance in the European Union. Brussels: World Health Organization, 2004.">WHO 2004a</a>; <a href="./references#CD011703-bbs2-0250" title="World Health Organization.Reaching Universal Coverage via Social Health Insurance: Key Design Features in the Transition Period. World Health Organization, 2004.">WHO 2004b</a>; <a href="./references#CD011703-bbs2-0253" title="World Health Organization.The World Health Report: Health Systems Financing: the path to universal coverage. apps.who.int/iris/bitstream/handle/10665/44371/9789241564021_eng.pdf?sequence=1 (accessed prior to 10 Jan 2022).">WHO 2010</a>; <a href="./references#CD011703-bbs2-0255" title="World Bank.Private Voluntary Health Insurance in Development: Friend or Foe?. Washington DC: World Bank, 2007.">World Bank 2007</a>). Thus, from society’s perspective, public drug insurance might facilitate pursuing all the suggested goals (<a href="#CD011703-tbl-0002">Table 1</a>). Private for‐profit drug insurance, on the other hand, might have disadvantages of limited coverage and lack of protection for vulnerable populations, but might be more effective for cost containment in terms of public spending. Advocates of private for‐profit insurance argue that the creation of a parallel system of private finance can ensure the sustainability of the public system by reducing public cost pressures, and improve quality in the public system through competition. Opponents of parallel private finance argue that it will create a 'two‐tiered' system, which would increase costs, compromise equity, and reduce quality and access as those with the financial means (and often the strongest voice) choose private insurance instead of public insurance. </p> <div class="table" id="CD011703-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Ways in which different policies regarding who provides drug insurance might affect outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Universal coverage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Equitable access</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Catastrophic payments</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cost containment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Availability of essential drugs</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Public drug insurance</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Governments might have incentives to provide universal coverage.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Governments might have incentives to provide equitable access.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Governments might have incentives to protect people from catastrophic payments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Public drug insurance might raise public (government) expenditures.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA*</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Private for‐profit drug insurance</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The key incentive of for‐profit insurance schemes is profit generation. For‐profit schemes might not have incentives to provide universal coverage and are unlikely to provide universal coverage unless subsidised or mandated by the government. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For‐profit schemes might not have incentives to provide equitable access.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For‐profit schemes might not have incentives to provide protection against catastrophic payments. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For‐profit schemes might be motivated to decrease their own costs. However, this might shift costs from the scheme to the insured or the government. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Private not‐for‐profit drug insurance</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Private not‐for‐profit drug insurance schemes are unlikely to provide universal coverage unless subsidised or mandated by the government. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Private not‐for‐profit drug insurance schemes might be motivated to provide access to vulnerable populations (e.g. charitable organisations). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Private not‐for‐profit drug insurance schemes might be motivated to provide protection against catastrophic payments. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Private not‐for‐profit drug insurance schemes should be as concerned with cost‐containment as any other scheme. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*NA = not applicable; i.e. no obvious way that the outcome might be affected</p> </div> </div> <p>Private not‐for‐profit drug insurance schemes may not differ significantly from for‐profit schemes, although they might provide better coverage if resources that would have gone to profits were instead used for the benefit of the insured. Public, private not‐for‐profit and for‐profit insurance schemes can all utilise various mechanisms for cost containment, for example, centralised procurement, price negotiation and co‐payments (OOP payment done by beneficiaries on top of payments by insurance schemes). Their motivations for using these mechanisms may differ, however. </p> </section> <section id="CD011703-sec-0018"> <h4 class="title">Who receives drug insurance</h4> <p>The World Health Assembly considers universal coverage as an optimal strategy to provide wide access to healthcare with no increase in the financial burden of the population (<a href="./references#CD011703-bbs2-0251" title="World Health Organization.Sustainable health financing, universal coverage and social health insurance. www.who.int/health_financing/documents/cov-wharesolution5833/en (accessed prior to 10 Jan 2022).">WHO 2005a</a>). In December 2012, the United Nations General Assembly unanimously adopted a resolution that emphasises health as an essential element of international development, urging governments to move towards providing all people with access to affordable, quality healthcare services, and calling for countries, civil society, and international organisations to include universal health coverage (UHC) in the international development agenda (<a href="./references#CD011703-bbs2-0245" title="United Nations.Resolution on global health and foreign policy, United Nations General Assembly. www.un.org/en/ga/search/view_doc.asp?symbol=A/RES/67/81 (accessed prior to 10 Jan 2022).">United Nations 2012</a>). More recently, the Sustainable Development Goals (SDG) adopted in September 2015 contains several targets related to health, but SDG 3 focuses specifically on ensuring healthy lives and promoting well‐being for all. Under this goal, objective 3.8 highlights the importance to “achieve universal health coverage, including financial risk protection, access to quality essential health‐care services and access to safe, effective, quality and affordable essential medicines and vaccines for all” (<a href="./references#CD011703-bbs2-0246" title="United Nations.Sustainable development goals. www.un.org/sustainabledevelopment/sustainable-development-goals/ (accessed prior to 10 Jan 2022). [DOI: 10.1002/14651858.CD011703]">United Nations 2015</a>). In this context, the issues of ensuring equitable access to affordable, quality‐assured, essential medicines has become central for the global health agenda and drug insurance arises as a policy option to explore in depth (<a href="./references#CD011703-bbs2-0197" title="DasP , HortonR .Essential medicines for universal health coverage (Comment). Lancet2017;389(10067):337-9.">Das 2017</a>). </p> <p>Compulsory insurance can be universal or can be restricted to specific groups, such as civil workers or officially employed workers. Coverage of specific groups might protect more disadvantaged populations, for example, the disabled or the poor, thus reducing inequities, or protect more advantaged populations, such as employed workers, thus increasing inequities. If compulsory insurance focuses on vulnerable populations, it might provide protection from catastrophic payments, since vulnerable populations, such as the elderly, might be at the highest risk of being pushed into poverty (<a href="./references#CD011703-bbs2-0252" title="World Health Organization.Sustainable health financing, universal coverage and social health insurance. www.who.int/health_financing/documents/cov-wharesolution5833/en (accessed prior to 10 Jan 2022).">WHO 2005b</a>). </p> <p>Optional insurance might limit sharing of financial risk and provide limited protection to vulnerable populations. It is more likely to benefit people who are able to pay, such as employed workers. </p> <p>In many countries, there is a mix of policies that determine who receives drug insurance. These policies might supplement each other; for example, there might be compulsory insurance for employed workers, and government‐subsidised insurance for vulnerable populations.   </p> <p>Universal insurance, or compulsory insurance that is universal or includes a large segment of the population, might facilitate cross‐subsidisation across participants and provide more financial protection due to better sharing of financial risk (<a href="./references#CD011703-bbs2-0253" title="World Health Organization.The World Health Report: Health Systems Financing: the path to universal coverage. apps.who.int/iris/bitstream/handle/10665/44371/9789241564021_eng.pdf?sequence=1 (accessed prior to 10 Jan 2022).">WHO 2010</a>). Universal coverage might also facilitate cost containment, by enabling unified policy actions at the national level, and improve access to essential drugs, if these are included in the basic benefit package. </p> <p>See <a href="#CD011703-tbl-0003">Table 2</a>.  </p> <div class="table" id="CD011703-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Ways in which different policies regarding who receives drug insurance might affect outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Universal coverage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Equitable access</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Catastrophic payments</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cost containment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Availability of essential drugs</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Universal coverage</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Provided this policy is implemented, it would ensure universal coverage. However, limited resources or implementation might result in some people not being covered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Universal coverage might guarantee equitable access.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Universal coverage might protect against catastrophic payments, but this would depend on what is covered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Public spending on drugs might increase. At the same time, drug costs might be reduced due to pooling funds and facilitating the implementation of other policies (e.g. purchasing policies). Effects on total healthcare spending might depend on the cost‐effectiveness of drugs that are covered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Universal coverage might guarantee access to essential drugs, but this would depend on what is covered. </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Compulsory coverage</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Provided this policy is implemented, it would ensure universal coverage. However, limited compliance, resources or implementation might result in some people not being covered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compulsory coverage might guarantee equitable access.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Public spending on drugs might increase. At the same time, drug costs might be reduced due to pooling funds and facilitating the implementation of other policies (e.g. purchasing policies), although potentially less than universal coverage due to multiple pools. Effects on total healthcare spending might depend on the cost‐effectiveness of drugs that are covered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compulsory coverage might or might not guarantee access to essential drugs.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Coverage of employed population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited to employed population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vulnerable populations might not be covered.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might or might not have maximum payments or protection against catastrophic payments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Public spending might decrease. Employers’ spending might increase.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Access to essential drugs might be provided only to the employed population.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Coverage of vulnerable populations</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited to vulnerable populations. If coverage used to supplement private insurance (and other populations for the most part have insurance), this might lead to universal coverage. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Providing insurance to the most vulnerable populations might decrease inequities.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Catastrophic payments in vulnerable populations might be prevented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Public spending on pharmaceuticals might increase. Effects on total healthcare spending might depend on the cost‐effectiveness of drugs that are covered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Access to essential drugs might be provided to vulnerable groups.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Optional coverage</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited to those who can afford insurance and elect to purchase it</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vulnerable populations might be less likely to be able to afford and to purchase insurance.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might not have maximum payments or protection against catastrophic payments and vulnerable populations might be less likely to be covered </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effects on public spending would depend on the extent to which healthcare costs are paid directly for people who need care and cannot afford OOP payments. Effects on OOP spending would depend on how many people elect to purchase coverage. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Access to essential drugs limited to those who can afford insurance</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>OOP = Out‐of‐pocket payments<br/>NA = not applicable; i.e. no obvious way that the outcome might be affected </p> </div> </div> </section> <section id="CD011703-sec-0019"> <h4 class="title">Who pays for drug insurance</h4> <p>Collection of premiums via general or earmarked taxes might facilitate universal coverage. Earmarked taxes might protect collected premiums and ensure the availability of funds. They might also make the allocation of funds more transparent. Taxes might also be progressive, facilitating a shift of financial burden from the poor to the rich, and therefore be more equitable (<a href="./references#CD011703-bbs2-0207" title="GliedSA .Health Care Financing, Efficiency, and Equity. National Bureau of Economic Research, 2008.">Glied 2008</a>). Payments by employers or direct payments by individuals only provide coverage for the insured population. This would not provide protection from catastrophic payments for those who were not employed or could not afford insurance and might limit access to essential drugs for those populations. </p> <p>See <a href="#CD011703-tbl-0004">Table 3</a>. </p> <div class="table" id="CD011703-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Ways in which different policies regarding who pays for drug insurance might affect outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Universal coverage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Equitable access</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Catastrophic payments</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cost containment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Availability of essential drugs</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Payment out of general tax revenue</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might facilitate universal coverage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might be progressive and might facilitate access for vulnerable populations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might lead to increased public spending on drugs. Effects on total healthcare spending might depend on the cost‐effectiveness of drugs that are covered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might facilitate coverage with essential drugs</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Payment out of earmarked tax</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might facilitate universal coverage. Might be progressive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might be progressive and might facilitate access for vulnerable populations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might lead to increased public spending on drugs. Effects on total healthcare spending might depend on the cost‐effectiveness of drugs that are covered. Might lead to more transparent collection and spending of funds </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might be more likely to facilitate coverage for essential drugs than payment out of general tax revenue </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Payment by employers</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Restricted to employed people unless there are supplementary policies to ensure coverage for other populations </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vulnerable populations might not have access.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might not have maximum payments or protection against catastrophic payments and vulnerable populations might be less likely to be covered </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Employers’ spending might increase.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Direct payment by individuals</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Restricted to those who can afford insurance unless subsidised by the government</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vulnerable populations might not have access if not subsidised or regulated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might not have maximum payments or protection against catastrophic payments and vulnerable populations might be less likely to be covered </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might increase OOP spending</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>OOP = Out‐of‐pocket payments<br/>NA = not applicable; i.e. no obvious way that the outcome might be affected </p> </div> </div> </section> <section id="CD011703-sec-0020"> <h4 class="title">Who makes decisions regarding which conditions and drugs are covered</h4> <p>Governments might be likely to make decisions that ensure equitable access and provide protection from catastrophic payment, although decisions might be driven by other political considerations or corruption. Due to the technical nature and complexity of coverage decisions, decision‐making might be delegated, for example to health technology assessment (HTA) agencies. This might help to achieve cost containment but could potentially affect the availability of some non‐essential drugs, for example, by only covering cost‐effective drugs (those with a relative value that lies below a 'willingness to pay' threshold set by government or the HTA agency). Relying on private insurance companies for these kinds of decisions might reduce coverage, or shift costs to government or OOP payments in order to maximise profits. Both government bodies and insurance companies might rely on the suggestions made by HTA agencies, enabling a more collaborative approach. Although prescribers are not generally involved in decisions regarding which conditions and drugs are covered, they may be responsible for implementing these policies in clinical practice. </p> <p>See <a href="#CD011703-tbl-0005">Table 4</a>. </p> <div class="table" id="CD011703-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Ways in which different policies regarding who makes decisions about which conditions and drugs are covered might affect outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Universal coverage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Equitable access</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Catastrophic payments</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cost containment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Availability of essential drugs</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Government</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government might have incentives to ensure access to all patients for cost‐effective drugs. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might protect against catastrophic payments for high‐cost drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might raise public expenditures on drugs due to covering expensive drugs, corruption or lobbying. Effects on total healthcare spending might depend on the cost‐effectiveness of drugs that are covered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government might have incentives to provide access to essential drugs.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Public body, authorised by government</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Public body might have incentives to ensure access to all patients.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might protect against catastrophic payments for high‐cost drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might help ensure well‐informed and cost‐effective decisions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might help ensure well‐informed decisions resulting in access to effective drugs</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>For‐profit insurance company</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Motivation to maximise profit might result in decisions that reduce coverage and increase inequities. Competition might mitigate this. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Motivation to maximise profit might result in decisions that reduce coverage and increase the risk of catastrophic payments. Competition might mitigate this. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might shift costs to government or OOP expenditures. Profit and competition might motivate cost‐effective decisions and management. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Not‐for‐profit insurance company</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effects on equity might vary depending on the populations that are targeted, motivation and the size of the risk pool. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effects on catastrophic payments might vary depending on the populations that are targeted, motivation and size of the risk pool. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effects on cost containment might vary depending on the populations that are targeted, motivation and the size of the risk pool. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might have incentives to provide access to essential drugs</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NA = not applicable; i.e. no obvious way that the outcome might be affected</p> </div> </div> </section> </section> <section id="CD011703-sec-0021"> <h3 class="title" id="CD011703-sec-0021">Why it is important to do this review</h3> <p>We have not identified previous systematic reviews that address the effects of policies for regulating the provision of drug insurance. Several published reviews have compared not‐for‐profit and for‐profit delivery of health services (<a href="./references#CD011703-bbs2-0195" title="ComondoreVR , DevereauxPJ , ZhouQ , StoneSB , BusseJW , RavindranNC , et al.Quality of care in for-profit and not-for-profit nursing homes: systematic review and meta-analysis. BMJ2009;339:b2732.">Comondore 2009</a>; <a href="./references#CD011703-bbs2-0199" title="DevereauxPJ , ChoiPT , LacchettiC , WeaverB , SchunemannHJ .A systematic review and meta-analysis of studies comparing mortality rates of private for-profit and private not-for-profit hospitals. Canadian Medical Association Journal2002;166(11):1399-1406.">Devereaux 2002a</a>; <a href="./references#CD011703-bbs2-0200" title="DevereauxPJ , SchunemannHJ , RavindranN , BhandariM , GargAX , ChoiPT , et al.Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers: a systematic review and meta-analysis. JAMA2002;288(19):2449-57.">Devereaux 2002b</a>; <a href="./references#CD011703-bbs2-0211" title="HimmelsteinDU , WoolhandlerS , HellanderI , WolfeSM .Quality of care in investor-owned vs not-for-profit HMOs. JAMA1999;282(2):159-63.">Himmelstein 1999</a>; <a href="./references#CD011703-bbs2-0214" title="KhouryAJ , WeismanCS , JarjouraCM .Ownership type and community benefits of women's health centers. Medical Care Research and Review2001;58(1):76-99.">Khoury 2001</a>; <a href="./references#CD011703-bbs2-0239" title="SchneiderEC , ZaslavskyAM , EpsteinAM .Quality of care in for-profit and not-for-profit health plans enrolling Medicare beneficiaries. American Journal of Medicine2005;118(12):1392-400.">Schneider 2005</a>). These reviews have found important differences in patient outcomes, costs and the quality of care, generally favouring not‐for‐profit delivery of services. Reviews of the effects of social health insurance and community‐based health insurance in low‐ and middle‐income countries have found few comparative evaluations (<a href="./references#CD011703-bbs2-0215" title="LagardeM , HainesA , PalmerN .The impact of conditional cash transfers on health outcomes and use of health services in low and middle income countries. Cochrane Database of Systematic Reviews2009, Issue 4. Art. No: CD008137. [DOI: 10.1002/14651858.CD008137]">Lagarde 2009</a>). Several studies have evaluated the recently implemented Medicare Prescription Drug Plan (Part D) (the federal programme in the USA that subsidises the cost of prescription drugs for Medicare beneficiaries) and they have been summarised in a systematic review based on interrupted time‐series and cross‐sectional studies (<a href="./references#CD011703-bbs2-0232" title="PolinskiJM , KilabukE , SchneeweissS , BrennanT , ShrankWH .Changes in drug utilization and out-of-pocket costs associated with Medicare Part D implementation: a systematic review. Journal of the American Geriatrics Society2010;58(9):1764–79.">Polinski 2010</a>). However, this review only included a search in a single electronic database (Medline) from 2006 to 2009 in the early stages of implementation of the policy. Likewise, another review assessed the impact of Medicare Part D in a specific subgroup of the population: those on long‐term care (LTC) ( <a href="./references#CD011703-bbs2-0231" title="PimentelCB , LapaneKL , BriesacherBA .Medicare Part D and long-term care: a systematic review of quantitative and qualitative evidence. Drugs Aging2013;30:701-20.">Pimentel 2013</a>). However, this population subgroup (compared to those living in the community) has higher levels of functional and cognitive impairment, greater comorbidity burden, more prescription drug use and fewer financial resources, which makes its findings qualitatively different from the general population. Another systematic review by <a href="./references#CD011703-bbs2-0206" title="FadenL , Vialle-ValentinC , Ross-DegnanD , WagnerA .Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: a systematic review of current evidence. Health Policy2011;100(2-3):134-43.">Faden 2011</a> revealed that drug insurance may increase access to medicines and reduce self‐medication, and provided conflicting evidence about the effect on medication spending. The scope of this last review was broader, however, including studies assessing the effect of which medicines were procured or supplied, which medical services were provided, and the implementation of programmes to improve drugs prescribing and use. </p> <p>Given this lack of specific evidence about the effects of policies that regulate drug insurance schemes, a systematic review of the effects of these policies is needed to inform decisions in this policy area. Many countries are in the process of reforming the way in which health systems finance pharmaceutical expenditures, and the topic has gained global concern in recent years. The Lancet Commission on Essential Medicines for UHC published its report in 2017, aiming to analyse how essential medicines policies can be harnessed to promote UHC and contribute to the global SDG agenda (<a href="./references#CD011703-bbs2-0254" title="WirtzVJ , HogerzeilHV , GrayAL , BigdeliM , De JoncheereCP , EwenMA , et al.Essential medicines for universal health coverage. Lancet2017;389(10067):403-76.">Wirtz 2017</a>). Among their recommendations, the Commission called for "governments and national health systems [to] provide adequate financing to ensure the inclusion of essential medicines in benefit packages provided by the public sector and all health insurance schemes," showing the relevance of insurance schemes that might be applied specifically on drugs. In addition, in 2016, the UN convened a High‐Level Panel on Access to Medicines with the aim of addressing the incoherences between international human rights, trade, intellectual property rights, and public health objectives (<a href="./references#CD011703-bbs2-0247" title="United Nations Secretary General and Co-Chairs of the High-Level Panel.The United Nations Secretary-General’s High-Level Panel on Access to Medicines Report: promoting innovation and access to health technologies. www.unsgaccessmeds.org/final-report/ (accessed prior to 10 Jan 2022).">United Nations Secretary General 2016</a>). The Panel stated that there are many reasons why people do not get the healthcare they need, including — among many other factors — the unavailability of health insurance. However, some authors also commented that insurance does not protect people from the high cost of medicines nor does it guarantee access to the medicines they need even in high‐income countries, as there is strong evidence that public, social and private insurance use rationing in providing expensive medicines. This shows how access and affordability of medicines is a current global health issue because of old and new challenges, even in countries with well‐established systems of drug insurance. </p> <p>This review is one of 13 planned or completed reviews of the effects of different types of pharmaceutical policies on rational drug use (<a href="./references#CD011703-bbs2-0190" title="AaserudM , DahlgrenAT , SturmH , KöstersJP , HillS , FurbergCD , et al.Pharmaceutical policies: effects on rational drug use, an overview of 13 reviews. Cochrane Database of Systematic Reviews2006, Issue 2. Art. No: CD004397. [DOI: 10.1002/14651858.CD004397.pub2]">Aaserud 2006</a>). Pharmaceutical policies that are complementary to the regulation of the provision of drug insurance are addressed in other reviews (see <a href="./appendices#CD011703-sec-0091">Appendix 1</a>). These include, for example, policies regarding caps and co‐payments (<a href="./references#CD011703-bbs2-0219" title="LuizaVL , ChavesLA , SilvaRM , EmmerickICM , ChavesGC , Fonseca de AraújoSC , et al.Pharmaceutical policies: effects of cap and co-payment on rational use of medicines. Cochrane Database of Systematic Reviews2015, Issue 5. Art. No: CD007017. [DOI: 10.1002/14651858.CD007017.pub2]">Luiza 2015</a>), restrictions on reimbursement for drugs that are covered (<a href="./references#CD011703-bbs2-0208" title="GreenCJ , MaclureM , FortinPM , RamsayCR , AaserudM , BardalS .Pharmaceutical policies: effects of restrictions on reimbursement. Cochrane Database of Systematic Reviews2010, Issue 8. Art. No: CD008654. [DOI: 10.1002/14651858.CD008654]">Green 2010</a>), and policies that regulate pricing and purchasing (<a href="./references#CD011703-bbs2-0191" title="AcostaA , CiapponiA , AaserudM , ViettoV , Austvoll-DahlgrenA , KöstersJP , et al.Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database of Systematic Reviews2014, Issue 10. Art. No: CD005979. [DOI: 10.1002/14651858.CD005979.pub2]">Acosta 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011703-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011703-sec-0022"></div> <p>To assess the effects on drug use, drug expenditure, healthcare utilisation and healthcare outcomes of alternative policies for regulating drug insurance schemes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011703-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011703-sec-0023"></div> <section id="CD011703-sec-0024"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011703-sec-0025"> <h4 class="title">Types of studies</h4> <p>We included randomised trials, non‐randomised trials, interrupted time‐series studies (including controlled ITS [CITS] and repeated measures [RM] studies), and controlled before‐after (CBA) studies (those studies where a comparison group is selected and outcomes are measured in both groups before and after the implementation of the policy). The possibility of making causal inferences rests on how similar both groups are before the policy and on how small the differences are at that time in relation to the main outcomes (<a href="./references#CD011703-bbs2-0241" title="ShadishWR , CookTD , CampbellDT .Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Boston: Houghton Mifflin Company, 2002.">Shadish 2002</a>). We therefore did not include controlled before‐after studies where the control group was clearly not equivalent to the intervention group prior to implementation of the policy, (because of clear differences in  insurance coverage or sociodemographic characteristics such as age or gender). Likewise, we did not include studies with no control group even when they measured outcomes before and after the implementation of the policy (uncontrolled before‐after studies, also known as the one group pretest/post‐test design) because they generally do not permit reasonable causal inferences (<a href="./references#CD011703-bbs2-0196" title="CookTD , CampbellDT .Quasi-Experimentation. Design &amp; Analysis Issues for Field Settings. Boston: Houghton Mifflin Company, 1979.">Cook 1979</a>). </p> <p>Following EPOC guidance, we only included cluster‐randomised trials and controlled before‐after studies that included two or more sites in each comparison group (<a href="./references#CD011703-bbs2-0202" title="Cochrane Effective Practice and Organisation of Care (EPOC).What study designs can be considered for inclusion in an EPOC review and what should they be called?epoc.cochrane.org/epoc-resources-review-authors (accessed 17 December 2019).">EPOC 2017b</a>). We only included ITS studies if there was a clearly defined point in time when the intervention occurred and at least three data points before and three after implementation of the policy. </p> </section> <section id="CD011703-sec-0026"> <h4 class="title">Types of participants</h4> <p>Healthcare consumers and providers within a large jurisdiction or system of care. Jurisdictions could be regional, national or international. We included studies within organisations, such as health maintenance organisations, if the organisation was multi‐sited and served a large population. </p> </section> <section id="CD011703-sec-0027"> <h4 class="title">Types of interventions</h4> <p>Policies that determined who can provide drug insurance, who receives it, who pays for it and who makes decisions about reimbursement. We defined policies as laws, rules, financial or administrative orders made by governments, non‐government organisations or private insurers. We excluded policies at the level of a single facility and policies that did not specifically regulate the provision of drug insurance. </p> <p>We included the following comparisons.</p> <p> <ul id="CD011703-list-0004"> <li> <p>Any restriction of who can or does provide drug insurance, including private versus public provision of drug insurance and not‐for‐profit versus for‐profit provision of drug insurance; we included any restriction versus any other restriction or no restriction. </p> </li> <li> <p>Any requirement regarding who receives drug insurance, including universal coverage versus coverage for selected groups such as the employed or vulnerable groups versus any other requirement or no requirement. </p> </li> <li> <p>Any policy that determined who pays for drug insurance, including general tax revenues versus employer payments versus direct payment of insurance premiums versus combinations of these. </p> </li> <li> <p>Any policy concerning who has the authority to make decisions regarding which conditions and which drugs are covered and under which circumstances, including the government versus independent bodies to which the government has allocated authority versus the owners of private health insurance schemes versus mixed systems where some types of decisions are, for example, made by the government and others are left up to the owners of private insurance schemes, or in which some decisions are made by the federal government and others by sub‐national governments. </p> </li> </ul> </p> <p>We generally included policies that affected health insurance only if they specifically addressed drug insurance schemes, with or without addressing other healthcare benefits. We also included comparisons of policies that cut across the four categories above, for example, that regulated both who could provide and who received drug insurance. </p> <p>We excluded the following policies from this review: those that determined how decisions are made about which conditions or drugs are covered; those that placed restrictions on reimbursement for drugs that were covered; and those that regulated out‐of‐pocket payments for drugs. These policies are the focus of other Cochrane Reviews (<a href="./references#CD011703-bbs2-0190" title="AaserudM , DahlgrenAT , SturmH , KöstersJP , HillS , FurbergCD , et al.Pharmaceutical policies: effects on rational drug use, an overview of 13 reviews. Cochrane Database of Systematic Reviews2006, Issue 2. Art. No: CD004397. [DOI: 10.1002/14651858.CD004397.pub2]">Aaserud 2006</a>; <a href="./references#CD011703-bbs2-0208" title="GreenCJ , MaclureM , FortinPM , RamsayCR , AaserudM , BardalS .Pharmaceutical policies: effects of restrictions on reimbursement. Cochrane Database of Systematic Reviews2010, Issue 8. Art. No: CD008654. [DOI: 10.1002/14651858.CD008654]">Green 2010</a>; <a href="./references#CD011703-bbs2-0219" title="LuizaVL , ChavesLA , SilvaRM , EmmerickICM , ChavesGC , Fonseca de AraújoSC , et al.Pharmaceutical policies: effects of cap and co-payment on rational use of medicines. Cochrane Database of Systematic Reviews2015, Issue 5. Art. No: CD007017. [DOI: 10.1002/14651858.CD007017.pub2]">Luiza 2015</a>). <a href="./appendices#CD011703-sec-0091">Appendix 1</a> provides a full list of the types of pharmaceutical policies assessed by other Cochrane Reviews. </p> <p>We only included comparisons where we considered the control group was 'equivalent' to the group affected by the policy being assessed. When a non‐equivalent control group was used (such as groups with very different insurance coverage), we analysed those studies as 'uncontrolled' designs. Likewise, because the focus of the review was on assessing the impact of policies on those moving to the specific scheme, we only considered — as a post hoc decision — comparisons between those with no coverage (likely to move to the scheme) and those with generous coverage (unlikely to move to the scheme) prior to the policy implementation. This left a number of other comparisons (e.g. those with some but not generous initial coverage) out of our main analysis. </p> </section> <section id="CD011703-sec-0028"> <h4 class="title">Types of outcome measures</h4> <p>To be included, a study had to include an objective measure from at least one of the following outcome categories. </p> <p> <ul id="CD011703-list-0005"> <li> <p>Drug use (including appropriate and inappropriate use, when this is reported);</p> </li> <li> <p>Drug expenditures (including total expenditures on drugs specifically and on healthcare generally, and catastrophic payments [i.e. OOP payments for drugs that necessitate the sacrifice of other basic needs, sale of productive assets, incurrence of debt, or result in impoverishment]); </p> </li> <li> <p>Healthcare utilisation (as drug insurance schemes may, through increasing the use of pharmaceutical interventions, decrease use of other non‐pharmaceutical services); </p> </li> <li> <p>Health outcomes;</p> </li> <li> <p>Differences in these outcomes between vulnerable (for example low‐income) and less vulnerable groups. </p> </li> </ul> </p> </section> </section> <section id="CD011703-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011703-sec-0030"> <h4 class="title">Electronic searches</h4> <p>We searched PDQ‐Evidence, Epistemonikos Foundation (<a href="http://www.pdq-evidence.org/" target="_blank">www.pdq-evidence.org/</a>) for related systematic reviews on 05 September 2020. We searched the following databases for primary studies: </p> <p> <ul id="CD011703-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), 2020 Issue 9, part of <i>The Cochrane Library: </i><a href="http://www.cochranelibrary.com" target="_blank">www.cochranelibrary.com</a> (searched 05 September 2020); </p> </li> <li> <p>MEDLINE and Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations and Daily 1946 to September 04, 2020, Ovid (searched 05 September 2020); </p> </li> <li> <p>Embase 1974 to 2020 Week 36, Ovid (searched 05 September 2020);</p> </li> <li> <p>EconLit 1969 to present, ProQuest (searched 05 September 2020);</p> </li> <li> <p>INRUD Bibliography: <a href="http://www.zotero.org/groups/659457/inrud_biblio/collections/HBW4TTCK" target="_blank">www.zotero.org/groups/659457/inrud_biblio/collections/HBW4TTCK</a> (searched 05 September 2020); </p> </li> <li> <p>NHS Economic Evaluation Database 2015, Issue 2, part of The Cochrane Library: <a href="http://www.cochranelibrary.com" target="_blank">www.cochranelibrary.com</a> (searched 27 January 2017); </p> </li> <li> <p>PAIS International, Public Affairs Information Service 1914‐current, ProQuest (searched 06 November 2014); </p> </li> <li> <p>Worldwide Political Science Abstracts 1975‐current, ProQuest (searched 06 November 2014). </p> </li> </ul> </p> <p>We did not search the NHS Economic Evaluation Database in 2020 as the databases has not been updated since 2015. We did not search PAIS International, and Worldwide Political Science Abstracts in 2020, as we had no access to these databases. </p> <p>Search strategies are comprised of natural language and controlled vocabulary terms. We applied no limits on language or publication date. In databases where it was possible and appropriate, study design filters were used to limit to the study designs of interest. For randomised trials in MEDLINE, we used a modified version of the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity‐ and precision‐maximising version (2008 revision)( <a href="./references#CD011703-bbs2-0216" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al .Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane 2021. Available from training.cochrane.org/handbook.">Lefebvre 2021</a>) with additional terms for other relevant study designs. Limits were used in Embase to remove MEDLINE records in order to avoid duplication in downloaded results. Remaining results were deduplicated in EndNote against each other. All search strategies used are provided in <a href="./appendices#CD011703-sec-0092">Appendix 2</a>. </p> </section> <section id="CD011703-sec-0031"> <h4 class="title">Searching other resources</h4> <section id="CD011703-sec-0032"> <h5 class="title">Trial registries</h5> <p>We searched the following Trial registries on 07 September 2020:</p> <p> <ul id="CD011703-list-0007"> <li> <p>WHO ICTRP (World Health Organization International Clinical Trials Registry Platform): <a href="http://www.who.int/clinical-trials-registry-platform" target="_blank">www.who.int/clinical-trials-registry-platform</a>; </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov: <a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>. </p> </li> </ul> </p> </section> <section id="CD011703-sec-0033"> <h5 class="title">Grey literature</h5> <p>We searched the grey literature to identify studies not indexed in the databases listed above: </p> <p> <ul id="CD011703-list-0008"> <li> <p>OpenGrey: <a href="http://www.opengrey.eu" target="_blank">www.opengrey.eu</a> (searched 07 September 2020); </p> </li> <li> <p>The Grey Literature Report: <a href="http://www.greylit.org/" target="_blank">www.greylit.org/</a> (searched 08 May 2019). </p> </li> </ul> </p> </section> <section id="CD011703-sec-0034"> <h5 class="title">We also:</h5> <p> <ul id="CD011703-list-0009"> <li> <p>searched the Web of Science Core Collection, Clarivate (Science Citation Index Expanded 1987‐present; Social Science Citation Index 1987‐present; Emerging Sources Citation Index 2015‐present) for articles citing the 58 included studies (searched 15 September 2021); </p> </li> <li> <p>screened the reference lists of all relevant reports that we retrieved and reports from the Background section; </p> </li> <li> <p>Contacted authors of relevant papers, relevant organisations, and discussion lists to identify additional studies, including unpublished and ongoing studies. </p> </li> </ul> </p> </section> </section> </section> <section id="CD011703-sec-0035"> <h3 class="title" id="CD011703-sec-0035">Data collection and analysis</h3> <section id="CD011703-sec-0036"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently assessed the search results and reference lists of relevant reports. We retrieved the full text of potentially relevant references (those considered relevant by at least one author) and two review authors independently applied inclusion criteria to those studies. </p> <p>We resolved disagreements at this stage by discussion and, when necessary, by including a third review author. </p> </section> <section id="CD011703-sec-0037"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data from the included studies. We extracted the following information from the included studies using a standardised data extraction form. </p> <p> <ul id="CD011703-list-0010"> <li> <p>Type of study (randomised trial, interrupted time‐series, controlled before‐after);</p> </li> <li> <p>Study setting (country, key features of the healthcare system and concurrent pharmaceutical policies); </p> </li> <li> <p>Characteristics of the participants;</p> </li> <li> <p>Characteristics of the policies;</p> </li> <li> <p>Main outcome measures and study duration;</p> </li> <li> <p>The results for the main outcome measures;</p> </li> <li> <p>The sponsors of the study.</p> </li> </ul> </p> <p>When a study presented results for more than one main outcome in each of the four outcome groups (drug use; drug expenditures, healthcare utilisation and health outcomes), we chose what we considered to be the most important outcome(s) in each group, either as specified by the study authors or based on discussions among ourselves. In cases where we thought additional main outcomes in the four outcome groups provided important insight, we also included them. </p> </section> <section id="CD011703-sec-0038"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the criteria suggested by the EPOC group to assess the risk of bias of included studies (<a href="./references#CD011703-bbs2-0201" title="Cochrane Effective Practice and Organisation of Care (EPOC).Suggested risk of bias criteria for EPOC reviews. EPOC resources for review authors, 2017. epoc.cochrane.org/epoc-resources-review-authors (accessed before 1 May 2020).">EPOC 2017a</a>). Two review authors independently assessed each study and reached consensus in the assessment. We assessed overall limitations for each main outcome within each study using the following guidelines. </p> <p> <ul id="CD011703-list-0011"> <li> <p>No serious limitations = low risk of bias = all criteria scored as ’met’;</p> </li> <li> <p>Some limitations = moderate risk of bias = one or two criteria scored as ’not clear’ or ’not met’; </p> </li> <li> <p>Serious limitations = high risk of bias = more than two criteria scored as ’not clear’ or ’not met’. </p> </li> </ul> </p> </section> <section id="CD011703-sec-0039"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011703-sec-0040"> <h5 class="title">Randomised trials and controlled before‐after studies</h5> <p>For randomised trials, non‐randomised trials and CBA studies, we planned to report relative effects. For both dichotomous and continuous outcomes, we reported the relative change, adjusted for baseline differences in the outcome measures. When relative effect estimates using specific statistical approaches (e.g. difference‐in‐differences) were reported by authors, we used them as the primary effect estimates. Otherwise, we computed relative effect estimates as: </p> <p>(absolute post‐intervention difference between the intervention and control groups minus the absolute pre‐intervention difference between the intervention and control groups)/post‐intervention level in the control group. </p> </section> <section id="CD011703-sec-0041"> <h5 class="title">Interrupted time‐series, controlled interrupted time‐series and repeated measure studies</h5> <p>For interrupted time‐series and controlled interrupted time‐series studies, we computed changes along two dimensions: change in level; and change in slope. </p> <p>Change in level is the immediate effect of the policy and we estimated it as the difference between the fitted value for the first post‐intervention data point (one month after the intervention) minus the predicted outcome one month after the intervention based on the pre‐intervention slope only. </p> <p>Change in slope is the change in the trend from pre‐ to post‐intervention, reflecting the long‐term effect of the intervention. Since the interpretation of change in slope can be difficult, we presented the long‐term effects in the same way that we calculated and presented the immediate effects. We presented the effects after six months as the difference between the fitted value for the six‐month post‐intervention data point minus the predicted outcome six months after the intervention based on the pre‐intervention slope only. We similarly estimated the effects after one year and annually thereafter, when available. When possible, we reported the relative change, adjusted for pre‐intervention trends in the outcome measures (that is, the post‐intervention level divided by the last pre‐intervention point<i>).</i> </p> <p>Given that policy changes are often announced some months prior to official implementation, we defined a transition phase as the six months from official announcement. Although this may seem arbitrary, we chose this duration for the transition phase based on our informal knowledge of the policy process in our countries (Chile, UK) and also based on the approach used in similar reviews (<a href="./references#CD011703-bbs2-0191" title="AcostaA , CiapponiA , AaserudM , ViettoV , Austvoll-DahlgrenA , KöstersJP , et al.Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database of Systematic Reviews2014, Issue 10. Art. No: CD005979. [DOI: 10.1002/14651858.CD005979.pub2]">Acosta 2014</a>; <a href="./references#CD011703-bbs2-0234" title="RashidianA , OmidvariAH , ValiY , SturmH , OxmanAD .Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database of Systematic Reviews2015, Issue 8. Art. No: CD006731. [DOI: 10.1002/14651858.CD006731.pub2]">Rashidian 2015</a>). When the included interrupted time‐series studies stated a different transition phase, we used the study's definition. All results excluded the transition phase data. </p> <p>When papers with an interrupted time‐series design did not provide an appropriate analysis or reporting of results, but presented the data points in a scannable graph or in a table, we re‐analysed the data using methods described in <a href="./references#CD011703-bbs2-0233" title="RamsayCR , MatoweL , GrilliR , GrimshawJM , ThomasRE .Interrupted time series design in health technology assessment: lessons from two systematic reviews of behavior change strategies. International Journal of Technology Assessment in Health Care2003;19(4):612-23.">Ramsay 2003</a>. The following segmented time series regression model was used. </p> <p>Y(t) = B0 + B1*Preslope + B2*Postslope + B3*Intervention + e(t)</p> <p>... where Y(t) is the outcome in month t; Preslope is a continuous variable indicating time from the start of the study up to the last point in the pre‐intervention phase and coded constant thereafter; Postslope is coded 0 up to and including the first point post‐intervention and coded sequentially from 1 thereafter; and Intervention is coded 0 for pre‐intervention time points and 1 for post‐intervention time points. </p> <p>In this model, B1 estimates the slope of the pre‐intervention data, B2 estimates the slope of the post‐intervention data and B3 estimates the change in level of outcome as the difference between the estimated first point post‐intervention and the extrapolated first point post‐intervention if the pre‐intervention line was continued into the post‐intervention phase. The difference in slope is calculated by B2 − B1. We assumed the error term e(t) to be first order autoregressive. When possible, we calculated 95% confidence intervals (CIs). </p> </section> </section> <section id="CD011703-sec-0042"> <h4 class="title">Unit of analysis issues</h4> <p>We performed analysis at the same level as the allocation to avoid unit‐of‐analyses errors. Because we did not find any cluster studies, we did not implement the planned methods as described in the protocol (See <a href="#CD011703-sec-0127">Differences between protocol and review</a>). </p> </section> <section id="CD011703-sec-0043"> <h4 class="title">Dealing with missing data</h4> <p>We tried to contact study authors when important data were not available. If we were not able to obtain missing data, we reported the results that were available, provided they were not likely to be misleading — for example, if there was a unit of analysis error. </p> </section> <section id="CD011703-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>When there were sufficient numbers of comparisons for similar outcomes across studies, we planned to use graphical displays (e.g. 'box and whisker' plots) to visually explore heterogeneity of the results across studies. Likewise, we planned to use the I² statistic to assess the extent of variability beyond chance for each of the groups of studies assessing similar comparisons and outcomes (<a href="./references#CD011703-bbs2-0210" title="HigginsJPT , ThompsonSG , DeeksJJ .Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). </p> </section> <section id="CD011703-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>Provided that studies were similar enough to warrant a meta‐analysis and that there was a sufficient number of estimates for each outcome (at least 10), we planned to use a funnel plot to visually explore the risk of publication bias, using the population of the included jurisdictions in each study as a proxy of the precision of the estimate, and the adjusted risk ratio (RR) or risk difference (RD) as the intervention effect. In the interpretation of the results, we planned to consider other potential causes of funnel plot asymmetry such as small‐study effects (the tendency for the intervention effects estimated in smaller studies to differ from those estimated in larger studies), differences in methodological quality across studies, or true heterogeneity in intervention effects (<a href="./references#CD011703-bbs2-0243" title="SterneJAC , EggerM , Moher D (eds).Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011], The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Sterne 2011</a>). </p> </section> <section id="CD011703-sec-0046"> <h4 class="title">Data synthesis</h4> <p>We planned to prepare a table for each category of policies (who can provide drug insurance, who receives it, who pays for it, and who has the authority to make decisions about what is covered) including the following information: study identification, characteristics of the intervention, drug use, healthcare utilisation, health outcomes, and resource utilisation (costs). This, however, was not required as we identified studies meeting our inclusion criteria for only two policies (with analysable data) and most of the evidence was focused on a single policy (addressing all the categories of policies). Where possible, the findings were grouped by the healthcare setting in which studies were conducted. </p> <p>We planned to conduct a meta‐analysis only for studies that reported similar comparisons (interventions, comparisons and outcomes that were similar enough so that an average effect across those studies would be meaningful). For randomised trials, non‐randomised trials and controlled before‐after studies, we planned to record the number of events (in the case of health outcomes) and the total number in each group (for RR), or mean and standard deviation (SD) in each group (for mean difference [MD], e.g. in the case of drug utilisation). We have shown all outcome effects with their associated 95% CIs, when possible. Anticipating heterogeneity across studies, we planned to use a random‐effects model meta‐analysis. We planned to perform data synthesis using the Cochrane statistical software <a href="./references#CD011703-bbs2-0235" title="Review Manager 5 (RevMan 5).Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>. </p> <p>Because of differences in the populations, comparisons and methods used by the included studies (see <a href="#CD011703-sec-0060">Included studies</a>), we did not conduct a meta‐analysis (<a href="./references#CD011703-bbs2-0194" title="CampbellM , McKenzieJE , SowdenA , KatikireddiSV , BrennanSE , EllisS , et al.Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ2020;368:l6890.">Campbell 2020</a>). Instead we undertook a structured synthesis following the EPOC guidance on this topic (<a href="./references#CD011703-bbs2-0203" title="Cochrane Effective Practice and Organisation of Care (EPOC).Synthesising results when it does not make sense to do a meta-analysis. epoc.cochrane.org/epoc-specific-resources-review-authors (accessed 2 February 2020).">EPOC 2017c</a>). For each category of outcomes, we described the median and the range of (relative) effects found in the studies (more specifically, using the interquartile range (IQR or 25th and 75th percentiles) in order to leave extreme outliers outside the analysis). We did not apply any weighting to these estimates. </p> <p>We only included comparisons where we considered the control group minimally 'equivalent' to the group affected by the policy being assessed. When a non‐equivalent control group was used we analysed those studies as 'uncontrolled' designs. </p> </section> <section id="CD011703-sec-0047"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to consider the following potential effect modifiers when investigating heterogeneity: differences in the characteristics of the policies; differences in complementary policies; and differences in the settings. We planned these analyses to be exploratory. We planned no specific subgroup analyses a priori. Because there were not enough studies or comparisons available to explore heterogeneity in a reliable way, we did not conduct any subgroup analysis. </p> </section> <section id="CD011703-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses for missing data by imputing a plausible range of assumptions. We planned to discuss the potential implications of missing information. We also planned to perform sensitivity analyses if there were studies with differing risks of bias that addressed the same question by excluding studies with a high risk of bias as defined in the section <a href="#CD011703-sec-0038">Assessment of risk of bias in included studies</a>. Because there were not enough studies, we did not conduct any sensitivity analyses. </p> </section> <section id="CD011703-sec-0049"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Two review authors independently assessed the certainty of the evidence (high, moderate, low, and very low) using the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness, and publication bias (<a href="./references#CD011703-bbs2-0209" title="GuyattGH , OxmanAD , KunzR , VistGE , Falck-YtterY , SchünemannHJ , GRADE Working Group.What is 'quality of evidence' and why is it important to clinicians?BMJ2008;336(7651):995-8.">Guyatt 2008</a>)). We used methods and recommendations described in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011703-bbs2-0240" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , et al, Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group.Completing 'Summary of findings' tables and grading the certainty of the evidence. In: HigginsJPT , ThomasJ , editors(s). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester, UK: Wiley Blackwell, 2019:375-402.">Schünemann 2019</a>), and the EPOC worksheets (<a href="./references#CD011703-bbs2-0204" title="Cochrane Effective Practice and Organisation of Care (EPOC).EPOC worksheets for preparing a 'Summary of findings' table using GRADE . epoc.cochrane.org/epoc-specific-resources-review-authors  (accessed prior to 9 Jan 2022); .">EPOC 2017d</a>). We resolved disagreements on certainty ratings by discussion and provided justification for decisions to down‐ or upgrade the ratings using footnotes in the table; we also made comments to aid readers' understanding of the review, where necessary. We used plain language statements to report these findings in the review (<a href="./references#CD011703-bbs2-0204" title="Cochrane Effective Practice and Organisation of Care (EPOC).EPOC worksheets for preparing a 'Summary of findings' table using GRADE . epoc.cochrane.org/epoc-specific-resources-review-authors  (accessed prior to 9 Jan 2022); .">EPOC 2017d</a>) (see worksheet 4 ‐ key messages in plain language from Worksheets for preparing Summary of findings tables using GRADE<i>). </i> </p> <p>We summarised the findings in (a) Summary of findings table(s) for the main intervention comparison(s) and included the most important outcomes (grouped in the following categories: drug use; drug expenditure; healthcare utilisation; and health outcomes) in order to draw conclusions about the certainty of the evidence within the text of the review. <br/>  </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011703-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011703-sec-0050"></div> <section id="CD011703-sec-0051"> <h3 class="title">Description of studies</h3> <p>We identified 58 studies that met the inclusion criteria. However in eight of them (<a href="./references#CD011703-bbs2-0012" title="CaetanoPA , RaymondCB , MorganS , YanL .Income-based drug coverage in British Columbia: the impact on access to medicines. Healthcare Policy2006;2(2):e154-e169. ">Caetano 2006</a>; <a href="./references#CD011703-bbs2-0021" title="DranoveD , OdyC , StarcA .A dose of managed care: controlling drug spending in Medicaid . National Bureau of Economic Research Working Paper Working Paper 23956, October 2017 (available in www.nber.org/papers/w23956) (accessed on 28 January 2022). ">Dranove 2017</a>; <a href="./references#CD011703-bbs2-0024" title="EttnerSL , SteersWN , TurkN , QuiterES , MangioneCM .Drug benefit changes under Medicare Advantage Part D: heterogeneous effects on pharmaceutical use and expenditures. Journal of General Internal Medicine2011;26(10):1195-200. ">Ettner 2011</a>; <a href="./references#CD011703-bbs2-0040" title="MottDA , ThorpeJM , ThorpeCT , KrelingDH , GadkariAS .Effects of Medicare PartD on drug affordability and use: are seniors with prior high out-of-pocket drug spending affected more?Research in Social &amp; Administrative Pharmacy2010;6(2):90-9. ">Mott 2010</a>; <a href="./references#CD011703-bbs2-0042" title="OngMK , XuH , ZhangL , AzocarF , EttnerSL .Effect of medicare part D benzodiazepine exclusion on psychotropic use in benzodiazepine users. Journal of the American Geriatrics Society2012;60(7):1292-7. OngMK , ZhangL , XuH , AzocarF , EttnerSL .Effect of medicare part D benzodiazepine exclusion on psychotropic use among patients with new anxiety disorders. Journal of General Internal Medicine2011;26(1 Suppl):S137. OngMK , ZhangL , XuH , AzocarF , EttnerSL .Medicare Part D benzodiazepine exclusion and use of psychotropic medication by patients with new anxiety disorders. Psychiatric Services2012;63:637-42. ">Ong 2012</a>; <a href="./references#CD011703-bbs2-0047" title="SavernoK , MaloneDC , WarholakTL , ArmstrongEP , SlackM .Impact of Medicare Part D on pharmaceutical and medical utilization in Arizona's dual eligible population. Value in Health2012;15:A15. SavernoKR .Impact of Medicare Part D on Pharmaceutical and Medical Utilization in Arizona's Dual Eligible Population (PhD Dissertation). University of Arizona, 2011. ">Saverno 2011</a>; <a href="./references#CD011703-bbs2-0050" title="TanDHS , DashwoodTM , WiltonJ , KrochA , GomesT , MartinsD .Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015–2018). Canadian Journal of Public Health2021;112:89-96. ">Tan 2021</a>; <a href="./references#CD011703-bbs2-0051" title="TangW , XieJ , KongF , MaloneDC .Per-prescription drug expenditure by source of payment and income level in the United States, 1997 to 2015. Value in Health2019;22(8):871-7. ">Tang 2019</a>) we were not able to obtain reported data in an useful format for our quantitative analysis (see <a href="./references#CD011703-sec-0129" title="">Characteristics of included studies</a> for details). Most of the included studies (n = 54) assessed a single policy implemented in the US healthcare system: Medicare Part D (<a href="./references#CD011703-bbs2-0225" title="OberlanderJ .Through the looking glass: the politics of the Medicare Prescription Drug, Improvement, and Modernization Act. Journal of Health Politics, Policy and Law2007;32(2):187-219.">Oberlander 2007</a>). The other four studies assessed other drug insurance schemes in Canada (British Columbia Fair Pharma Care (<a href="./references#CD011703-bbs2-0012" title="CaetanoPA , RaymondCB , MorganS , YanL .Income-based drug coverage in British Columbia: the impact on access to medicines. Healthcare Policy2006;2(2):e154-e169. ">Caetano 2006</a>) and Ontario expansion of public drug coverage (<a href="./references#CD011703-bbs2-0050" title="TanDHS , DashwoodTM , WiltonJ , KrochA , GomesT , MartinsD .Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015–2018). Canadian Journal of Public Health2021;112:89-96. ">Tan 2021</a>)); the US (Affordable Care Act (ACA) Medicaid expansion (<a href="./references#CD011703-bbs2-0037" title="MacleanJC , HalpernMT , HillSC , PeskoMF .The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications. Health Services Research2020;55:399-410. ">Maclean 2020</a>); and the privatisation of Medicaid Drug Benefits (<a href="./references#CD011703-bbs2-0021" title="DranoveD , OdyC , StarcA .A dose of managed care: controlling drug spending in Medicaid . National Bureau of Economic Research Working Paper Working Paper 23956, October 2017 (available in www.nber.org/papers/w23956) (accessed on 28 January 2022). ">Dranove 2017</a>)); only one of these was included in the quantitative analysis (<a href="./references#CD011703-bbs2-0037" title="MacleanJC , HalpernMT , HillSC , PeskoMF .The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications. Health Services Research2020;55:399-410. ">Maclean 2020</a>). Before submitting for publication (September 2021), we additionally identified two further studies currently awaiting classification (<a href="./references#CD011703-bbs2-0188" title="AméricoP , RochaR .Subsidizing access to prescription drugs and health outcomes: the case of diabetes. Journal of Health Economics2020;72:102347. [DOI: 10.1016/j.jhealeco.2020.102347]">Americo 2020</a>; <a href="./references#CD011703-bbs2-0189" title="SabetyAH , SherryTB , MaestasN .Opioid use in older adults and Medicare Part D. Health Services Research2021;56(2):289-98. [DOI: 10.1111/1475-6773.13623]">Sabety 2021</a>). </p> <section id="CD011703-sec-0052"> <h4 class="title">Interventions</h4> <section id="CD011703-sec-0053"> <h5 class="title">Medicare Part D</h5> <p>In 2003, the Medicare Modernization Act (MMA) created this prescription drug benefit for the elderly (although up to 15%  of its recipients are under the age of 65). Its creation was motivated by the relatively large proportion of the elderly without prescription drug coverage, the growing financial burden of prescription drug spending among the elderly, and the significant and growing clinical importance of prescription drugs (<a href="./references#CD011703-bbs2-0229" title="OliverTR , LeePR , LiptonHL .A political history of Medicare and prescription drug coverage. Milbank Quarterly2004;82(2):283-354.">Oliver 2004</a>). The lack of coverage in this area resulted in substantial OOP spending, and the share of income spent on prescription drugs is likely to be larger for the elderly with low incomes and chronic diseases for whom prescription drugs are essential to maintaining good health. Part D's goal was, therefore, to improve beneficiaries’ access to, and the affordability of, essential medications. Although the MMA started in 2003, Medicare did not cover outpatient prescription drugs until January 1, 2006, when it implemented the Part D prescription drug benefit, authorised by Congress under the MMA. Individuals on Medicare were eligible for prescription drug coverage under a Part D plan if they were signed up for benefits under Medicare Part A or Part B (or both). Beneficiaries obtained the Part D drug benefit through two types of plans administered by private insurance companies: the beneficiaries can join a standalone Prescription Drug Plan (PDP) for drug coverage only or they can join a  Part C health plan that jointly covers all hospital and medical services covered by Medicare Part A and Part B at a minimum, and typically covers additional healthcare costs not covered by Medicare Parts A and B including prescription drugs (MA‐PD). </p> <p>The US government was concerned about the programme's budgetary impact. The standard Part D benefit was therefore designed to include a novel cost containment feature: the ‘coverage gap’. After drug spending reaches an initial threshold (USD 3750 per person in 2018) in a calendar year, beneficiaries enter the coverage gap, a period during which they are responsible for a large proportion of their drug costs (45% of the cost of brand‐name drugs and 65% of the cost of generic drugs). Beneficiaries remain in the coverage gap period either until out‐of‐pocket drug spending reaches a catastrophic coverage spending threshold (USD 5000 per person in 2018) at which time cost‐sharing is dramatically reduced, or until the benefit resets at the next calendar year. Low‐income beneficiaries receive subsidies to help them pay for drugs and thus are not responsible for their drug costs during the coverage gap period. </p> <p>As a policy, Medicare Part D therefore cuts across the four categories of drug insurance schemes previously mentioned (<a href="#CD011703-sec-0027">Types of interventions</a>). </p> </section> <section id="CD011703-sec-0054"> <h5 class="title">Other drug insurance schemes</h5> <section id="CD011703-sec-0055"> <h6 class="title">British Columbia Fair Pharma Care </h6> <p>British Columbia (BC) Pharma Care Program was characterised by a relatively comprehensive drug coverage for social assistance recipients and seniors (with temporary co‐payments for seniors), and fixed‐deductible coverage for catastrophic drug cost for all others. In May 2003, the fixed‐deductible catastrophic programme and the seniors’ programme were combined into a new, income‐based drug plan called Fair PharmaCare. Thus the change was from an age‐based to an income‐based drug benefits programme. As a policy, BC Fair Pharma Care was making a change mainly in who receives drug insurance. </p> </section> <section id="CD011703-sec-0056"> <h6 class="title">Ontario expansion of public drug coverage</h6> <p>In January 2018, Ontario expanded public drug coverage through its Ontario Drug Benefit (ODB) programme to include all Ontarians less than 25 years old, through a programme called OHIP+. In that sense, this was a policy making changes in who received drug insurance. </p> </section> <section id="CD011703-sec-0057"> <h6 class="title">Affordable Care Act Medicaid expansion</h6> <p>The Affordable Care Act (ACA) expanded Medicaid eligibility to allow enrolment of non‐elderly adults with incomes through 138 per cent of the federal poverty level. Prior to the ACA, Medicaid eligibility for non‐elderly adults in most states was limited to people with disabilities, pregnant women, and low‐income parents. Although initially the policy was compulsory, a 2012 Supreme Court decision left Medicaid expansion optional; that is, states could decide whether to expand this programme or not. As a policy, the ACA Medicaid expansion has made changes mainly in who receives drug insurance. </p> </section> <section id="CD011703-sec-0058"> <h6 class="title">Privatisation of Medicaid Drug Benefits</h6> <p>The ACA previously mentioned also made two substantive changes to Medicaid drug reimbursements, making the privatisation of pharmacy benefits (by Managed Care Organizations (MCO)) more attractive than state administration of the Medicaid drug benefit. The result was a dramatic shift of drug benefits away from states to MCOs. In that sense, this (part of the) policy was making changes mainly in who can provide drug insurance. </p> </section> </section> </section> <section id="CD011703-sec-0059"> <h4 class="title">Results of the search</h4> <p>The search strategy identified 8326 records; 7919 records after removing duplicates. After title/abstract screening, we excluded 7732 records, leaving 187 for full‐text assessment. From these, we excluded 129 records for different reasons (<a href="./references#CD011703-sec-0130" title="">Characteristics of excluded studies</a>), and 58 studies met the inclusion criteria for this review (<a href="./references#CD011703-sec-0129" title="">Characteristics of included studies</a>) (<a href="#CD011703-fig-0001">Figure 1</a>). In eight studies, we were not able to obtain reported data in an useful format for our quantitative analysis, leaving 50 studies for the quantitative synthesis (see <a href="./references#CD011703-sec-0129" title="">Characteristics of included studies</a> for details).  </p> <div class="figure" id="CD011703-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram" data-id="CD011703-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> </div> </section> <section id="CD011703-sec-0060"> <h4 class="title">Included studies</h4> <section id="CD011703-sec-0061"> <h5 class="title">Study design</h5> <p>Of the 58 studies that met the inclusion criteria, 25 used an interrupted time‐series study design (<a href="#CD011703-fig-0002">Figure 2</a>). Of these, eleven used some type of control group (<a href="./references#CD011703-bbs2-0006" title="BasuA , YinW , AlexanderGC .Impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Services Research2010;45(1):133-51. BasuA , YinW , AlexanderGC .The impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Value in Health2009;12(3):A83. KaestnerR , ShimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):595-628. ">Basu 2010</a>; <a href="./references#CD011703-bbs2-0008" title="BriesacherBA , SoumeraiSB , FieldTS , FouayziH , GurwitzJH .Nursing home residents and enrollment in Medicare Part D. Journal of the American Geriatrics Society2009;57(10):1902-7. ">Briesacher 2009</a>; <a href="./references#CD011703-bbs2-0031" title="Ketcham JD, SimonK .Medicare Part D's effects on elderly drug costs and utilization. National Bureau of Economic Research Working Paper 14326, September 2008 (www.nber.org/papers/w14326) (accessed 28 January 2022). KetchamJD , SimonKI .Medicare Part D’s effects on elderly patients’ drug costs and utilization. American Journal of Managed Care2008;14(11 Spec No.):SP14-SP22. ">Ketcham 2008</a>; <a href="./references#CD011703-bbs2-0033" title="LiR , GreggEW , BarkerLE , ZhangP , ZhangF , ZhuoX , et al.Medicare Part D is associated with reducing the financial burden of health care services in Medicare beneficiaries with diagnosed diabetes. Medical Care2013;51(10):888-93. ">Li 2013</a>; <a href="./references#CD011703-bbs2-0034" title="LichtenbergFR , SunSX .The Impact of Medicare Part D on Prescription Drug Use by the Elderly. Cheltenham (UK) and Northampton (Mass): Elgar Research Collection. International Library of Critical Writings in Economics, vol. 284, 2013. LichtenbergFR , SunSX .The impact of Medicare Part D on prescription drug use by the elderly. Health Affairs2007;26(6):1735-44. ">Lichtenberg 2007</a>; <a href="./references#CD011703-bbs2-0039" title="McWilliamsJM , ZaslavskyAM , HuskampHA .Effects of medicare prescription drug coverage on non-drug medical spending. Journal of General Internal Medicine2011;26(1 Suppl):S157. McWilliamsJM , ZaslavskyAM , HuskampHA .Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage. JAMA2011;306(4):402-9. ">McWilliams 2011</a>; <a href="./references#CD011703-bbs2-0047" title="SavernoK , MaloneDC , WarholakTL , ArmstrongEP , SlackM .Impact of Medicare Part D on pharmaceutical and medical utilization in Arizona's dual eligible population. Value in Health2012;15:A15. SavernoKR .Impact of Medicare Part D on Pharmaceutical and Medical Utilization in Arizona's Dual Eligible Population (PhD Dissertation). University of Arizona, 2011. ">Saverno 2011</a>; <a href="./references#CD011703-bbs2-0054" title="ZhangY , DonohueJM , LaveJR , O’DonnellG , NewhouseJP .The effect of Medicare Part D on drug and medical spending. New England Journal of Medicine2009;361(1):52. ">Zhang 2009</a>; <a href="./references#CD011703-bbs2-0055" title="ZhangY , LeeBY , DonohueJM .Ambulatory antibiotic use and prescription drug coverage in older adults. Archives of Internal Medicine2010;170(15):1308-14. ">Zhang 2010a</a>; <a href="./references#CD011703-bbs2-0056" title="ZhangY , LaveJR , NewhouseJP , DonohueJM .How the Medicare Part D drug benefit changed the distribution of out-of-pocket pharmacy spending among older beneficiaries. Journals of Gerontology. Series B, Psychological Sciences and Social Sciences2010;65(4):502-7. ">Zhang 2010b</a>; <a href="./references#CD011703-bbs2-0057" title="ZhangY , DonohueJM , LaveJR , GelladWF .The impact of Medicare Part D on medication treatment of hypertension. Health Services Research2011;46(1):185-98. ">Zhang 2011</a>); and fourteen were uncontrolled interrupted time‐series studies (<a href="./references#CD011703-bbs2-0001" title="AdamsAS , MaddenJM , ZhangF , SoumeraiSB , GildenD , GriggsJ , et al.Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage. Medical Care2014;52(8):695-703. ">Adams 2014</a>; <a href="./references#CD011703-bbs2-0009" title="BriesacherBA , SoumeraiSB , FieldTS , FouayziH , GurwitzJH .Medicare Part D’s exclusion of benzodiazepines and fracture risk in nursing homes. Archives of Internal Medicine2010;170(8):693-8. ">Briesacher 2010</a>; <a href="./references#CD011703-bbs2-0010" title="BriesacherBA , MaddenJM , ZhangF , FouayziH , Ross-DegnanD , GurwitzJH , et al.Did Medicare Part D affect national trends in health outcomes or hospitalizations?: a time-series analysis. Annals of Internal Medicine2015;162(12):825-33. ">Briesacher 2015</a>; <a href="./references#CD011703-bbs2-0011" title="BurnsM , BuschA , MaddenJ , LeCatesRF , ZhangF , AdamsA , et al.The effect of Medicare Part D on guideline-concordant pharmacotherapy for bipolar I disorder among dually enrolled beneficiaries. Psychiatric Services2014;65(3):323-9. ">Burns 2014</a>; <a href="./references#CD011703-bbs2-0012" title="CaetanoPA , RaymondCB , MorganS , YanL .Income-based drug coverage in British Columbia: the impact on access to medicines. Healthcare Policy2006;2(2):e154-e169. ">Caetano 2006</a>; <a href="./references#CD011703-bbs2-0014" title="ChenH , NwangwuA , AparasuR , EssienE , SunS , LeeK .The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatric Services2008;59(10):1191-7. ">Chen 2008</a>; <a href="./references#CD011703-bbs2-0025" title="FarleyJF , DusetzinaSB .Medicaid prescription drug utilization and expenditures following Part D. Journal of Health Care for the Poor and Underserved2010;21(2):715-28. ">Farley 2010</a>; <a href="./references#CD011703-bbs2-0038" title="MaddenJM , AdamsAS , LeCatesRF , Ross-DegnanD , ZhangF , HuskampHA , et al.Changes in drug coverage generosity and untreated serious mental illness transitioning from Medicaid to Medicare Part D. JAMA Psychiatry2015;72(2):179-88. ">Madden 2015</a>; <a href="./references#CD011703-bbs2-0045" title="PimentelCB , LapaneKL , RosenAB , GurwitzGH , BriesacherBA .Medicare Part D’s impact on pain management in dual-eligible nursing home residents with cancer: an interrupted time-series study. Pharmacoepidemiology and Drug Safety2015;24:131. PimentelCB , LapaneKL , RosenAB , GurwitzJH , BriesacherBA .Medicare part D's impact on pain management among nursing home residents with cancer: an interrupted time-series study. Journal of the American Geriatrics Society2015;63:S129. PimentelCB .Use of Opioids for Pain Management in Nursing Homes: A Dissertation. University of Massachusetts Medical School, 2015. [DOI: 10.13028/M2512]">Pimentel 2015</a>; <a href="./references#CD011703-bbs2-0046" title="PolinskiJM , BrookhartMA , GlynnRJ , SchneeweissS .Comparison between aggregate- and individual-level time-trend analyses to evaluate overall effects of Medicare Part D on use of antipsychotic medications. Pharmacoepidemiology and Drug Safety2011;20:S107. PolinskiJM , BrookhartMA , GlynnRJ , SchneeweissS .Medicare Part D’s impact on antipsychotic drug use and costs among elderly patients without prior drug insurance. Journal of Clinical Psychopharmacology2012;32(1):3-10. ">Polinski 2012</a>; <a href="./references#CD011703-bbs2-0048" title="SchneeweissS , PatrickAR , PedanA , VarastehL , LevinR , LiuN , et al.The effect Of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Affairs2009;28(2):w305-w316. ">Schneeweiss 2009</a>; <a href="./references#CD011703-bbs2-0049" title="ShrankWH , PatrickAR , PedanA , PolinskiJM , VarastehL , LevinR , et al.The effect of transitioning to Medicare Part D drug coverage in seniors dually eligible for Medicare and Medicaid. Journal of the American Geriatrics Society2008;56(12):2304-10. ">Shrank 2008</a>; <a href="./references#CD011703-bbs2-0050" title="TanDHS , DashwoodTM , WiltonJ , KrochA , GomesT , MartinsD .Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015–2018). Canadian Journal of Public Health2021;112:89-96. ">Tan 2021</a>; <a href="./references#CD011703-bbs2-0052" title="YinW , BasuA , ZhangJX , RabbaniA , MeltzerDO , AlexanderGC .The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Annals of Internal Medicine2008;148(3):169-77. ">Yin 2008</a>). </p> <div class="figure" id="CD011703-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Included studies by design type" data-id="CD011703-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Included studies by design type</p> </div> </div> </div> <p>Five of the eleven controlled interrupted time‐series (CITS) studies used a non‐equivalent control group (see <a href="#CD011703-sec-0051">Description of studies</a> section above) and were therefore included in the analysis as 'uncontrolled' ITS studies (<a href="./references#CD011703-bbs2-0006" title="BasuA , YinW , AlexanderGC .Impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Services Research2010;45(1):133-51. BasuA , YinW , AlexanderGC .The impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Value in Health2009;12(3):A83. KaestnerR , ShimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):595-628. ">Basu 2010</a>; <a href="./references#CD011703-bbs2-0008" title="BriesacherBA , SoumeraiSB , FieldTS , FouayziH , GurwitzJH .Nursing home residents and enrollment in Medicare Part D. Journal of the American Geriatrics Society2009;57(10):1902-7. ">Briesacher 2009</a>; <a href="./references#CD011703-bbs2-0031" title="Ketcham JD, SimonK .Medicare Part D's effects on elderly drug costs and utilization. National Bureau of Economic Research Working Paper 14326, September 2008 (www.nber.org/papers/w14326) (accessed 28 January 2022). KetchamJD , SimonKI .Medicare Part D’s effects on elderly patients’ drug costs and utilization. American Journal of Managed Care2008;14(11 Spec No.):SP14-SP22. ">Ketcham 2008</a>; <a href="./references#CD011703-bbs2-0033" title="LiR , GreggEW , BarkerLE , ZhangP , ZhangF , ZhuoX , et al.Medicare Part D is associated with reducing the financial burden of health care services in Medicare beneficiaries with diagnosed diabetes. Medical Care2013;51(10):888-93. ">Li 2013</a>; <a href="./references#CD011703-bbs2-0034" title="LichtenbergFR , SunSX .The Impact of Medicare Part D on Prescription Drug Use by the Elderly. Cheltenham (UK) and Northampton (Mass): Elgar Research Collection. International Library of Critical Writings in Economics, vol. 284, 2013. LichtenbergFR , SunSX .The impact of Medicare Part D on prescription drug use by the elderly. Health Affairs2007;26(6):1735-44. ">Lichtenberg 2007</a>). Another four CITS studies did not provide enough detailed data for a controlled interrupted time‐series analysis but presented effect estimates for a controlled before‐after analysis (<a href="./references#CD011703-bbs2-0039" title="McWilliamsJM , ZaslavskyAM , HuskampHA .Effects of medicare prescription drug coverage on non-drug medical spending. Journal of General Internal Medicine2011;26(1 Suppl):S157. McWilliamsJM , ZaslavskyAM , HuskampHA .Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage. JAMA2011;306(4):402-9. ">McWilliams 2011</a>; <a href="./references#CD011703-bbs2-0055" title="ZhangY , LeeBY , DonohueJM .Ambulatory antibiotic use and prescription drug coverage in older adults. Archives of Internal Medicine2010;170(15):1308-14. ">Zhang 2010a</a>; <a href="./references#CD011703-bbs2-0056" title="ZhangY , LaveJR , NewhouseJP , DonohueJM .How the Medicare Part D drug benefit changed the distribution of out-of-pocket pharmacy spending among older beneficiaries. Journals of Gerontology. Series B, Psychological Sciences and Social Sciences2010;65(4):502-7. ">Zhang 2010b</a>; <a href="./references#CD011703-bbs2-0057" title="ZhangY , DonohueJM , LaveJR , GelladWF .The impact of Medicare Part D on medication treatment of hypertension. Health Services Research2011;46(1):185-98. ">Zhang 2011</a>). The remaining two CITS were analysed as having an equivalent control group (<a href="./references#CD011703-bbs2-0047" title="SavernoK , MaloneDC , WarholakTL , ArmstrongEP , SlackM .Impact of Medicare Part D on pharmaceutical and medical utilization in Arizona's dual eligible population. Value in Health2012;15:A15. SavernoKR .Impact of Medicare Part D on Pharmaceutical and Medical Utilization in Arizona's Dual Eligible Population (PhD Dissertation). University of Arizona, 2011. ">Saverno 2011</a>; <a href="./references#CD011703-bbs2-0054" title="ZhangY , DonohueJM , LaveJR , O’DonnellG , NewhouseJP .The effect of Medicare Part D on drug and medical spending. New England Journal of Medicine2009;361(1):52. ">Zhang 2009</a>). Likewise, one of the 14 'uncontrolled' ITS studies (<a href="./references#CD011703-bbs2-0052" title="YinW , BasuA , ZhangJX , RabbaniA , MeltzerDO , AlexanderGC .The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Annals of Internal Medicine2008;148(3):169-77. ">Yin 2008</a>) only provided sufficient data for a controlled before‐after effect estimate that was used as the primary analysis (<a href="#CD011703-fig-0002">Figure 2</a>). </p> <p>The other 33 included studies were controlled before‐after studies. In summary, of the 58 included studies, 38 were analysed as CBA studies, 18 were analysed as ITS studies, and two were analysed as CITS studies (<a href="#CD011703-fig-0002">Figure 2</a>). </p> <p>Three out of the 18 studies analysed as interrupted time series required a full re‐analysis (<a href="./references#CD011703-bbs2-0008" title="BriesacherBA , SoumeraiSB , FieldTS , FouayziH , GurwitzJH .Nursing home residents and enrollment in Medicare Part D. Journal of the American Geriatrics Society2009;57(10):1902-7. ">Briesacher 2009</a>; <a href="./references#CD011703-bbs2-0031" title="Ketcham JD, SimonK .Medicare Part D's effects on elderly drug costs and utilization. National Bureau of Economic Research Working Paper 14326, September 2008 (www.nber.org/papers/w14326) (accessed 28 January 2022). KetchamJD , SimonKI .Medicare Part D’s effects on elderly patients’ drug costs and utilization. American Journal of Managed Care2008;14(11 Spec No.):SP14-SP22. ">Ketcham 2008</a>; <a href="./references#CD011703-bbs2-0034" title="LichtenbergFR , SunSX .The Impact of Medicare Part D on Prescription Drug Use by the Elderly. Cheltenham (UK) and Northampton (Mass): Elgar Research Collection. International Library of Critical Writings in Economics, vol. 284, 2013. LichtenbergFR , SunSX .The impact of Medicare Part D on prescription drug use by the elderly. Health Affairs2007;26(6):1735-44. ">Lichtenberg 2007</a>), whereby data points were extracted from the scanned figures and the parameters estimated. However, most of the ITS studies required some degree of additional analysis. The change in level was estimated for one study (<a href="./references#CD011703-bbs2-0006" title="BasuA , YinW , AlexanderGC .Impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Services Research2010;45(1):133-51. BasuA , YinW , AlexanderGC .The impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Value in Health2009;12(3):A83. KaestnerR , ShimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):595-628. ">Basu 2010</a>), and this required extending the predicted line from the pre‐intervention to the post‐intervention phase as if the intervention never occurred and taking the difference between this and the line presented in the figure. For the relative change calculation, the last pre‐intervention time point either had to be extracted from the figures (<a href="./references#CD011703-bbs2-0006" title="BasuA , YinW , AlexanderGC .Impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Services Research2010;45(1):133-51. BasuA , YinW , AlexanderGC .The impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Value in Health2009;12(3):A83. KaestnerR , ShimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):595-628. ">Basu 2010</a>; <a href="./references#CD011703-bbs2-0009" title="BriesacherBA , SoumeraiSB , FieldTS , FouayziH , GurwitzJH .Medicare Part D’s exclusion of benzodiazepines and fracture risk in nursing homes. Archives of Internal Medicine2010;170(8):693-8. ">Briesacher 2010</a>; <a href="./references#CD011703-bbs2-0010" title="BriesacherBA , MaddenJM , ZhangF , FouayziH , Ross-DegnanD , GurwitzJH , et al.Did Medicare Part D affect national trends in health outcomes or hospitalizations?: a time-series analysis. Annals of Internal Medicine2015;162(12):825-33. ">Briesacher 2015</a>; <a href="./references#CD011703-bbs2-0033" title="LiR , GreggEW , BarkerLE , ZhangP , ZhangF , ZhuoX , et al.Medicare Part D is associated with reducing the financial burden of health care services in Medicare beneficiaries with diagnosed diabetes. Medical Care2013;51(10):888-93. ">Li 2013</a>; <a href="./references#CD011703-bbs2-0045" title="PimentelCB , LapaneKL , RosenAB , GurwitzGH , BriesacherBA .Medicare Part D’s impact on pain management in dual-eligible nursing home residents with cancer: an interrupted time-series study. Pharmacoepidemiology and Drug Safety2015;24:131. PimentelCB , LapaneKL , RosenAB , GurwitzJH , BriesacherBA .Medicare part D's impact on pain management among nursing home residents with cancer: an interrupted time-series study. Journal of the American Geriatrics Society2015;63:S129. PimentelCB .Use of Opioids for Pain Management in Nursing Homes: A Dissertation. University of Massachusetts Medical School, 2015. [DOI: 10.13028/M2512]">Pimentel 2015</a>; <a href="./references#CD011703-bbs2-0048" title="SchneeweissS , PatrickAR , PedanA , VarastehL , LevinR , LiuN , et al.The effect Of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Affairs2009;28(2):w305-w316. ">Schneeweiss 2009</a>; <a href="./references#CD011703-bbs2-0049" title="ShrankWH , PatrickAR , PedanA , PolinskiJM , VarastehL , LevinR , et al.The effect of transitioning to Medicare Part D drug coverage in seniors dually eligible for Medicare and Medicaid. Journal of the American Geriatrics Society2008;56(12):2304-10. ">Shrank 2008</a>); or calculated from the results presented in the paper (intercept + baseline trend * last pre‐intervention time point) (<a href="./references#CD011703-bbs2-0001" title="AdamsAS , MaddenJM , ZhangF , SoumeraiSB , GildenD , GriggsJ , et al.Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage. Medical Care2014;52(8):695-703. ">Adams 2014</a>; <a href="./references#CD011703-bbs2-0011" title="BurnsM , BuschA , MaddenJ , LeCatesRF , ZhangF , AdamsA , et al.The effect of Medicare Part D on guideline-concordant pharmacotherapy for bipolar I disorder among dually enrolled beneficiaries. Psychiatric Services2014;65(3):323-9. ">Burns 2014</a>; <a href="./references#CD011703-bbs2-0014" title="ChenH , NwangwuA , AparasuR , EssienE , SunS , LeeK .The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatric Services2008;59(10):1191-7. ">Chen 2008</a>; <a href="./references#CD011703-bbs2-0025" title="FarleyJF , DusetzinaSB .Medicaid prescription drug utilization and expenditures following Part D. Journal of Health Care for the Poor and Underserved2010;21(2):715-28. ">Farley 2010</a>; <a href="./references#CD011703-bbs2-0046" title="PolinskiJM , BrookhartMA , GlynnRJ , SchneeweissS .Comparison between aggregate- and individual-level time-trend analyses to evaluate overall effects of Medicare Part D on use of antipsychotic medications. Pharmacoepidemiology and Drug Safety2011;20:S107. PolinskiJM , BrookhartMA , GlynnRJ , SchneeweissS .Medicare Part D’s impact on antipsychotic drug use and costs among elderly patients without prior drug insurance. Journal of Clinical Psychopharmacology2012;32(1):3-10. ">Polinski 2012</a>). One study (<a href="./references#CD011703-bbs2-0038" title="MaddenJM , AdamsAS , LeCatesRF , Ross-DegnanD , ZhangF , HuskampHA , et al.Changes in drug coverage generosity and untreated serious mental illness transitioning from Medicaid to Medicare Part D. JAMA Psychiatry2015;72(2):179-88. ">Madden 2015</a>) provided all relevant estimates and required no further analyses. For two studies, we were not able to obtain reported data in an useful format for our quantitative analysis (<a href="./references#CD011703-bbs2-0012" title="CaetanoPA , RaymondCB , MorganS , YanL .Income-based drug coverage in British Columbia: the impact on access to medicines. Healthcare Policy2006;2(2):e154-e169. ">Caetano 2006</a>; <a href="./references#CD011703-bbs2-0050" title="TanDHS , DashwoodTM , WiltonJ , KrochA , GomesT , MartinsD .Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015–2018). Canadian Journal of Public Health2021;112:89-96. ">Tan 2021</a>). </p> <p>For the CITS studies, in one of them (<a href="./references#CD011703-bbs2-0054" title="ZhangY , DonohueJM , LaveJR , O’DonnellG , NewhouseJP .The effect of Medicare Part D on drug and medical spending. New England Journal of Medicine2009;361(1):52. ">Zhang 2009</a>), all effect estimates were extracted from the study report and for the other (<a href="./references#CD011703-bbs2-0047" title="SavernoK , MaloneDC , WarholakTL , ArmstrongEP , SlackM .Impact of Medicare Part D on pharmaceutical and medical utilization in Arizona's dual eligible population. Value in Health2012;15:A15. SavernoKR .Impact of Medicare Part D on Pharmaceutical and Medical Utilization in Arizona's Dual Eligible Population (PhD Dissertation). University of Arizona, 2011. ">Saverno 2011</a>) we were not able to obtain relative effect estimates. </p> <p>We used either 100 x (effect estimate ‐ 1)% for increase or 100 x (1 ‐ effect estimate)% for decrease to calculate the relative effects for CBA studies that provided odds ratios or relative risks (<a href="./references#CD011703-bbs2-0002" title="AfendilusCC , HeY , ZaslavskyAM , ChernewME .The impact of Medicare Part D on hospitalization rates. Health Services Research2011;46(4):1022-38. ">Afendilus 2011</a>; <a href="./references#CD011703-bbs2-0015" title="ChenC , LinH , SeoD .Medicare Part D implementation and associated health impact among older adults in the United States. International Journal of Health Services2018;48(1):42-56. ">Chen 2018</a>; <a href="./references#CD011703-bbs2-0018" title="DoD .The impact of Medicare Part D on opioid use among U.S. older adults. Drug and Alcohol Dependence2020;212:108069. ">Do 2020</a> (drug use: any prescription opioid); <a href="./references#CD011703-bbs2-0019" title="DonohueJM , ZhangY , LaveJ , GelladWF , PereraS , MenA , et al.Impact of expanding pharmacy benefits on treatment of congestive heart failure: the case of Medicare Part D. Value in Health2009;12(7):A342. DonohueJM , ZhangY , LaveJR , GelladWF , MenA , PereraS , et al.The Medicare drug benefit (Part D) and treatment of heart failure in older adults. American Heart Journal2010;160(1):159-65. ">Donohue 2010</a>; <a href="./references#CD011703-bbs2-0020" title="DonohueJM , ZhangY , AijuM , PereraS , LaveJR , HanlonJT , et al.Impact of Medicare Part D on antidepressant treatment, medication choice, and adherence among older adults with depression. American Journal of Geriatric Psychiatry2011;19(12):989-97. ">Donohue 2011</a>; <a href="./references#CD011703-bbs2-0026" title="FowlerN , ChenYF .Impact of prescription drug coverage on use of anti-dementia drugs. Alzheimer and Dementia2011;7(4S Part 18):S643. FowlerNR , ChenY , ThurtonCA , MenA , RodriguezEG , DonohueJM .The impact of Medicare prescription drug coverage on the use of antidementia drugs. BMC Geriatrics2013;13:37. ">Fowler 2013</a>; <a href="./references#CD011703-bbs2-0027" title="HuhJ , ReifJ .Did Medicare Part D reduce mortality?Journal of Health Economics2017;53:17-37. ">Huh 2017</a>; <a href="./references#CD011703-bbs2-0035" title="LimD , JungK , ShiY .National trends in the use of antidepressants between 1997 and 2009 and the role of Medicare Part D implementation. Psychiatric Services (Washington, D.C.)2013;64(10):1038-42. ">Lim 2013</a>; <a href="./references#CD011703-bbs2-0041" title="NelsonRE , NelsonSL , HuttnerB , GundlapalliA .The effect of Medicare Part D on health care utilization for non-elderly Medicare recipients with disabilities. Disability and Health Journal2014;7:64-9. ">Nelson 2014</a> (health outcomes, drug use, healthcare utilisation outcomes); <a href="./references#CD011703-bbs2-0044" title="ParkT , JungJ .The effect of Medicare Part D on prescription drug spending and health care use: 6 years of follow-up, 2007-2012. Journal of Managed Care &amp; Specialty Pharmacy2017;23(1):5-12. ">Park 2017</a> (drug use and healthcare utilisation outcomes); <a href="./references#CD011703-bbs2-0053" title="ZhangJX , JinW , SunSX , AlexanderGC .The impact of the Medicare Part D prescription benefit on generic drug use. Journal of General Internal Medicine2008;23(10):1673-8. ">Zhang 2008</a>; <a href="./references#CD011703-bbs2-0055" title="ZhangY , LeeBY , DonohueJM .Ambulatory antibiotic use and prescription drug coverage in older adults. Archives of Internal Medicine2010;170(15):1308-14. ">Zhang 2010a</a>; <a href="./references#CD011703-bbs2-0057" title="ZhangY , DonohueJM , LaveJR , GelladWF .The impact of Medicare Part D on medication treatment of hypertension. Health Services Research2011;46(1):185-98. ">Zhang 2011</a>). For continuous outcomes, we used a variety of methods to compute effect estimates from study reports. In twelve studies: (<a href="./references#CD011703-bbs2-0003" title="AsfawAA .The effect of prescription drug insurance on health behavior: evidence from Medicare Part D. Health Economics2019;28(3):403-18. ">Asfaw 2019</a>; <a href="./references#CD011703-bbs2-0004" title="AyyagariP , ShaneDM .Does prescription drug coverage improve mental health? Evidence from Medicare Part D. Journal of Health Economics2015;41:46-58. ">Ayyagari 2015</a>; <a href="./references#CD011703-bbs2-0005" title="AyyagariP , ShaneDM , WehbyGL .The Impact of Medicare Part D on Emergency Department visits. Health Economics2017;26(4):536-44. ">Ayyagari 2017</a>; <a href="./references#CD011703-bbs2-0016" title="ChoiYJ , JiaH , GrossT , WeingerK , StonePW , SmaldoneAM .Impact of medicare part D on out-of-pocket prescription drug costs among elderly with diabetes. Diabetes2015;64:A70. ChoiYJ , JiaH , GrossT , WeingerK , StonePW , SmaldoneAM .The impact of Medicare Part D on the proportion of out-of-pocket prescription drug costs among older adults with diabetes. Diabetes Care2017;40:502-8. ">Choi 2017</a>; <a href="./references#CD011703-bbs2-0023" title="EngelhardtGV , GruberJ .Medicare Part D and the financial protection of the elderly. American Economic Journal: Economic Policy2011;3(4):77-102. EngelhardtGV , GruberJ .Medicare Part D and the financial protection of the elderly. National Bureau of Economic Research Working Paper 16155, July 2010 (www.nber.org/papers/w16155.pdf) (accessed 28 January 2022). ">Engelhardt 2011</a> (drug use); <a href="./references#CD011703-bbs2-0029" title="KaestnerR , KhanN .Medicare Part D and its effect on the use of prescription drugs, use of other health care services and health of the elderly. National Bureau of Economic Research Working Paper 16011, May 2010 (available at www.nber.org/papers/w16011) (accessed 28 January 2022). KaestnerR , KhanN .Medicare Part D and its effect on the use of prescription drugs and use of other health care services of the elderly. Journal of Policy Analysis and Management2012;31(2):253-79. KaestnerR , McCoyK .Understanding the effects of Medicare prescription drug insurance. IGPA Policy Forum2010;23(1):1-7. ">Kaestner 2012</a>; <a href="./references#CD011703-bbs2-0030" title="Kaestner R, SchimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):525-628. KaestnerR , LongC , AlexanderCG .Effect of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. National Bureau of Economic Research Working Paper 19948, February 2014 (www.nber.org/papers/w19948) (accessed 28 January 2022). ">Kaestner 2014</a>; <a href="./references#CD011703-bbs2-0037" title="MacleanJC , HalpernMT , HillSC , PeskoMF .The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications. Health Services Research2020;55:399-410. ">Maclean 2020</a>; <a href="./references#CD011703-bbs2-0039" title="McWilliamsJM , ZaslavskyAM , HuskampHA .Effects of medicare prescription drug coverage on non-drug medical spending. Journal of General Internal Medicine2011;26(1 Suppl):S157. McWilliamsJM , ZaslavskyAM , HuskampHA .Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage. JAMA2011;306(4):402-9. ">McWilliams 2011</a>; <a href="./references#CD011703-bbs2-0043" title="PakT , KimG .The impact of Medicare Part D on cognitive functioning at older ages. Social Science &amp; Medicine2017;193:118-26. ">Pak 2017</a>; <a href="./references#CD011703-bbs2-0044" title="ParkT , JungJ .The effect of Medicare Part D on prescription drug spending and health care use: 6 years of follow-up, 2007-2012. Journal of Managed Care &amp; Specialty Pharmacy2017;23(1):5-12. ">Park 2017</a> (drug expenditure outcome); <a href="./references#CD011703-bbs2-0058" title="ZimmerD .The effect of Medicare Part D on prescription drug composition and demand. Journal of Economic Studies2015;42(2):170-85. ">Zimmer 2015</a>), we used the published relative effects estimates. In five studies, we divided the reported effect estimate either by the pre‐intervention mean in the intervention arm (<a href="./references#CD011703-bbs2-0013" title="CarvalhoN , PetrieD , ChenL , SalomonJA , ClarkeP .The impact of Medicare part D on income-related inequality in pharmaceutical expenditure. International Journal for Equity in Health2019;18:57. ">Carvalho 2019</a>) or pre‐intervention mean in the control arm (<a href="./references#CD011703-bbs2-0018" title="DoD .The impact of Medicare Part D on opioid use among U.S. older adults. Drug and Alcohol Dependence2020;212:108069. ">Do 2020</a> (number of prescriptions); <a href="./references#CD011703-bbs2-0023" title="EngelhardtGV , GruberJ .Medicare Part D and the financial protection of the elderly. American Economic Journal: Economic Policy2011;3(4):77-102. EngelhardtGV , GruberJ .Medicare Part D and the financial protection of the elderly. National Bureau of Economic Research Working Paper 16155, July 2010 (www.nber.org/papers/w16155.pdf) (accessed 28 January 2022). ">Engelhardt 2011</a> (OOP and total prescription drug); <a href="./references#CD011703-bbs2-0032" title="KircherSM , JohansenM , RichardsonC , DavisMM .Impact of Medicare Part D on out-of-pocket pharmaceutical costs for patients with cancer. Journal of Clinical Oncology2013;31(Nº 15 Suppl):6517. KircherSM , JohansenME , NimeiriHS , RichardsonCR , DavisMM .Impact of Medicare Part D on out-of-pocket drug costs and medical use for patients with cancer. Cancer2014;120(21):3378-84. ">Kircher 2014</a>; <a href="./references#CD011703-bbs2-0036" title="LiuFX , AlexanderGC , CrawfordSY , PickardAS , HedekerD , WaltonSM .The impact of Medicare Part D on health care utilization and health of the Medicare beneficiaries. Value in Health2010;13:A7. LiuFX , AlexanderGC , CrawfordSY , PickardAS , HedekerD , WaltonSM .The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility. Health Services Research2011;46(4):1104-23. LiuFX , WaltonSM , CrawfordSY , PickardAS .The impact of Medicare Part D on health care utilization and health outcomes for Medicare beneficiaries without previous drug coverage. Value in Health2009;12:A170. ">Liu 2011</a>). In three studies (<a href="./references#CD011703-bbs2-0017" title="DieboldJ .The effects of Medicare Part D on health outcomes of newly covered Medicare beneficiaries. Journal of Gerontology, Series B: Psychological Sciences &amp; Social Sciences2016;6:6. DieboldJ .The effects of Medicare Part D on health outcomes of newly covered Medicare beneficiaries. Journal of Gerontology, Series B: Psychological Sciences &amp; Social Sciences2018;73(5):890-900. ">Diebold 2018</a>; <a href="./references#CD011703-bbs2-0028" title="JungC , PadmanR , AnwarS .The impact of Medicare part D prescription drug benefit program on generic drug prescription. A study in long-term care facilities. Medicine2019;98(32 ):e16646. ">Jung 2019</a>; <a href="./references#CD011703-bbs2-0041" title="NelsonRE , NelsonSL , HuttnerB , GundlapalliA .The effect of Medicare Part D on health care utilization for non-elderly Medicare recipients with disabilities. Disability and Health Journal2014;7:64-9. ">Nelson 2014</a> (drug expenditure outcome)), the relative effect estimate was calculated by multiplying the reported effect estimate by 100. In one study (<a href="./references#CD011703-bbs2-0056" title="ZhangY , LaveJR , NewhouseJP , DonohueJM .How the Medicare Part D drug benefit changed the distribution of out-of-pocket pharmacy spending among older beneficiaries. Journals of Gerontology. Series B, Psychological Sciences and Social Sciences2010;65(4):502-7. ">Zhang 2010b</a>), we extracted the data from the figure presented in the report. Finally in <a href="./references#CD011703-bbs2-0007" title="BelenkyN , PenceBW , ColeSR , DusetzinaSB , EdmondsA , OberlanderJ , et al.Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV. AIDS Care2019;31(4):505-12. ">Belenky 2019</a>, we used the method described above in the section <a href="#CD011703-sec-0039">Measures of treatment effect</a>. </p> </section> <section id="CD011703-sec-0062"> <h5 class="title">Comparisons</h5> <p>Forty‐four studies included some type of comparison in the form of controlled interrupted time series (<a href="./references#CD011703-bbs2-0006" title="BasuA , YinW , AlexanderGC .Impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Services Research2010;45(1):133-51. BasuA , YinW , AlexanderGC .The impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Value in Health2009;12(3):A83. KaestnerR , ShimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):595-628. ">Basu 2010</a>; <a href="./references#CD011703-bbs2-0008" title="BriesacherBA , SoumeraiSB , FieldTS , FouayziH , GurwitzJH .Nursing home residents and enrollment in Medicare Part D. Journal of the American Geriatrics Society2009;57(10):1902-7. ">Briesacher 2009</a>; <a href="./references#CD011703-bbs2-0031" title="Ketcham JD, SimonK .Medicare Part D's effects on elderly drug costs and utilization. National Bureau of Economic Research Working Paper 14326, September 2008 (www.nber.org/papers/w14326) (accessed 28 January 2022). KetchamJD , SimonKI .Medicare Part D’s effects on elderly patients’ drug costs and utilization. American Journal of Managed Care2008;14(11 Spec No.):SP14-SP22. ">Ketcham 2008</a>; <a href="./references#CD011703-bbs2-0033" title="LiR , GreggEW , BarkerLE , ZhangP , ZhangF , ZhuoX , et al.Medicare Part D is associated with reducing the financial burden of health care services in Medicare beneficiaries with diagnosed diabetes. Medical Care2013;51(10):888-93. ">Li 2013</a>; <a href="./references#CD011703-bbs2-0034" title="LichtenbergFR , SunSX .The Impact of Medicare Part D on Prescription Drug Use by the Elderly. Cheltenham (UK) and Northampton (Mass): Elgar Research Collection. International Library of Critical Writings in Economics, vol. 284, 2013. LichtenbergFR , SunSX .The impact of Medicare Part D on prescription drug use by the elderly. Health Affairs2007;26(6):1735-44. ">Lichtenberg 2007</a>; <a href="./references#CD011703-bbs2-0039" title="McWilliamsJM , ZaslavskyAM , HuskampHA .Effects of medicare prescription drug coverage on non-drug medical spending. Journal of General Internal Medicine2011;26(1 Suppl):S157. McWilliamsJM , ZaslavskyAM , HuskampHA .Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage. JAMA2011;306(4):402-9. ">McWilliams 2011</a>;<a href="./references#CD011703-bbs2-0047" title="SavernoK , MaloneDC , WarholakTL , ArmstrongEP , SlackM .Impact of Medicare Part D on pharmaceutical and medical utilization in Arizona's dual eligible population. Value in Health2012;15:A15. SavernoKR .Impact of Medicare Part D on Pharmaceutical and Medical Utilization in Arizona's Dual Eligible Population (PhD Dissertation). University of Arizona, 2011. ">Saverno 2011</a>; <a href="./references#CD011703-bbs2-0054" title="ZhangY , DonohueJM , LaveJR , O’DonnellG , NewhouseJP .The effect of Medicare Part D on drug and medical spending. New England Journal of Medicine2009;361(1):52. ">Zhang 2009</a>; <a href="./references#CD011703-bbs2-0055" title="ZhangY , LeeBY , DonohueJM .Ambulatory antibiotic use and prescription drug coverage in older adults. Archives of Internal Medicine2010;170(15):1308-14. ">Zhang 2010a</a>; <a href="./references#CD011703-bbs2-0057" title="ZhangY , DonohueJM , LaveJR , GelladWF .The impact of Medicare Part D on medication treatment of hypertension. Health Services Research2011;46(1):185-98. ">Zhang 2011</a>; <a href="./references#CD011703-bbs2-0056" title="ZhangY , LaveJR , NewhouseJP , DonohueJM .How the Medicare Part D drug benefit changed the distribution of out-of-pocket pharmacy spending among older beneficiaries. Journals of Gerontology. Series B, Psychological Sciences and Social Sciences2010;65(4):502-7. ">Zhang 2010b</a>) or controlled before‐and‐after designs (<a href="./references#CD011703-bbs2-0002" title="AfendilusCC , HeY , ZaslavskyAM , ChernewME .The impact of Medicare Part D on hospitalization rates. Health Services Research2011;46(4):1022-38. ">Afendilus 2011</a>; <a href="./references#CD011703-bbs2-0003" title="AsfawAA .The effect of prescription drug insurance on health behavior: evidence from Medicare Part D. Health Economics2019;28(3):403-18. ">Asfaw 2019</a>; <a href="./references#CD011703-bbs2-0004" title="AyyagariP , ShaneDM .Does prescription drug coverage improve mental health? Evidence from Medicare Part D. Journal of Health Economics2015;41:46-58. ">Ayyagari 2015</a>; <a href="./references#CD011703-bbs2-0005" title="AyyagariP , ShaneDM , WehbyGL .The Impact of Medicare Part D on Emergency Department visits. Health Economics2017;26(4):536-44. ">Ayyagari 2017</a>; <a href="./references#CD011703-bbs2-0007" title="BelenkyN , PenceBW , ColeSR , DusetzinaSB , EdmondsA , OberlanderJ , et al.Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV. AIDS Care2019;31(4):505-12. ">Belenky 2019</a>; <a href="./references#CD011703-bbs2-0013" title="CarvalhoN , PetrieD , ChenL , SalomonJA , ClarkeP .The impact of Medicare part D on income-related inequality in pharmaceutical expenditure. International Journal for Equity in Health2019;18:57. ">Carvalho 2019</a>; <a href="./references#CD011703-bbs2-0015" title="ChenC , LinH , SeoD .Medicare Part D implementation and associated health impact among older adults in the United States. International Journal of Health Services2018;48(1):42-56. ">Chen 2018</a>; <a href="./references#CD011703-bbs2-0016" title="ChoiYJ , JiaH , GrossT , WeingerK , StonePW , SmaldoneAM .Impact of medicare part D on out-of-pocket prescription drug costs among elderly with diabetes. Diabetes2015;64:A70. ChoiYJ , JiaH , GrossT , WeingerK , StonePW , SmaldoneAM .The impact of Medicare Part D on the proportion of out-of-pocket prescription drug costs among older adults with diabetes. Diabetes Care2017;40:502-8. ">Choi 2017</a>; <a href="./references#CD011703-bbs2-0017" title="DieboldJ .The effects of Medicare Part D on health outcomes of newly covered Medicare beneficiaries. Journal of Gerontology, Series B: Psychological Sciences &amp; Social Sciences2016;6:6. DieboldJ .The effects of Medicare Part D on health outcomes of newly covered Medicare beneficiaries. Journal of Gerontology, Series B: Psychological Sciences &amp; Social Sciences2018;73(5):890-900. ">Diebold 2018</a>; <a href="./references#CD011703-bbs2-0018" title="DoD .The impact of Medicare Part D on opioid use among U.S. older adults. Drug and Alcohol Dependence2020;212:108069. ">Do 2020</a>; <a href="./references#CD011703-bbs2-0019" title="DonohueJM , ZhangY , LaveJ , GelladWF , PereraS , MenA , et al.Impact of expanding pharmacy benefits on treatment of congestive heart failure: the case of Medicare Part D. Value in Health2009;12(7):A342. DonohueJM , ZhangY , LaveJR , GelladWF , MenA , PereraS , et al.The Medicare drug benefit (Part D) and treatment of heart failure in older adults. American Heart Journal2010;160(1):159-65. ">Donohue 2010</a>; <a href="./references#CD011703-bbs2-0020" title="DonohueJM , ZhangY , AijuM , PereraS , LaveJR , HanlonJT , et al.Impact of Medicare Part D on antidepressant treatment, medication choice, and adherence among older adults with depression. American Journal of Geriatric Psychiatry2011;19(12):989-97. ">Donohue 2011</a>; <a href="./references#CD011703-bbs2-0021" title="DranoveD , OdyC , StarcA .A dose of managed care: controlling drug spending in Medicaid . National Bureau of Economic Research Working Paper Working Paper 23956, October 2017 (available in www.nber.org/papers/w23956) (accessed on 28 January 2022). ">Dranove 2017</a>; <a href="./references#CD011703-bbs2-0022" title="DunnA , ShapiroAH .Does Medicare Part D save lives?American Journal of Health Economics2019;5(1):126-64. DunnA , ShapiroAH .Does Medicare Part D save lives?Federal Reserve of San Francisco Working Paper Series. Working paper 2015-04 ( www.frbsf.org/economic-research/publications/working-papers/wp2015-04.pdf ) (accessed 28 January 2022). ">Dunn 2019</a>; <a href="./references#CD011703-bbs2-0023" title="EngelhardtGV , GruberJ .Medicare Part D and the financial protection of the elderly. American Economic Journal: Economic Policy2011;3(4):77-102. EngelhardtGV , GruberJ .Medicare Part D and the financial protection of the elderly. National Bureau of Economic Research Working Paper 16155, July 2010 (www.nber.org/papers/w16155.pdf) (accessed 28 January 2022). ">Engelhardt 2011</a>; <a href="./references#CD011703-bbs2-0024" title="EttnerSL , SteersWN , TurkN , QuiterES , MangioneCM .Drug benefit changes under Medicare Advantage Part D: heterogeneous effects on pharmaceutical use and expenditures. Journal of General Internal Medicine2011;26(10):1195-200. ">Ettner 2011</a>; <a href="./references#CD011703-bbs2-0026" title="FowlerN , ChenYF .Impact of prescription drug coverage on use of anti-dementia drugs. Alzheimer and Dementia2011;7(4S Part 18):S643. FowlerNR , ChenY , ThurtonCA , MenA , RodriguezEG , DonohueJM .The impact of Medicare prescription drug coverage on the use of antidementia drugs. BMC Geriatrics2013;13:37. ">Fowler 2013</a>; <a href="./references#CD011703-bbs2-0027" title="HuhJ , ReifJ .Did Medicare Part D reduce mortality?Journal of Health Economics2017;53:17-37. ">Huh 2017</a>; <a href="./references#CD011703-bbs2-0028" title="JungC , PadmanR , AnwarS .The impact of Medicare part D prescription drug benefit program on generic drug prescription. A study in long-term care facilities. Medicine2019;98(32 ):e16646. ">Jung 2019</a>; <a href="./references#CD011703-bbs2-0029" title="KaestnerR , KhanN .Medicare Part D and its effect on the use of prescription drugs, use of other health care services and health of the elderly. National Bureau of Economic Research Working Paper 16011, May 2010 (available at www.nber.org/papers/w16011) (accessed 28 January 2022). KaestnerR , KhanN .Medicare Part D and its effect on the use of prescription drugs and use of other health care services of the elderly. Journal of Policy Analysis and Management2012;31(2):253-79. KaestnerR , McCoyK .Understanding the effects of Medicare prescription drug insurance. IGPA Policy Forum2010;23(1):1-7. ">Kaestner 2012</a>; <a href="./references#CD011703-bbs2-0030" title="Kaestner R, SchimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):525-628. KaestnerR , LongC , AlexanderCG .Effect of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. National Bureau of Economic Research Working Paper 19948, February 2014 (www.nber.org/papers/w19948) (accessed 28 January 2022). ">Kaestner 2014</a>; <a href="./references#CD011703-bbs2-0032" title="KircherSM , JohansenM , RichardsonC , DavisMM .Impact of Medicare Part D on out-of-pocket pharmaceutical costs for patients with cancer. Journal of Clinical Oncology2013;31(Nº 15 Suppl):6517. KircherSM , JohansenME , NimeiriHS , RichardsonCR , DavisMM .Impact of Medicare Part D on out-of-pocket drug costs and medical use for patients with cancer. Cancer2014;120(21):3378-84. ">Kircher 2014</a>; <a href="./references#CD011703-bbs2-0035" title="LimD , JungK , ShiY .National trends in the use of antidepressants between 1997 and 2009 and the role of Medicare Part D implementation. Psychiatric Services (Washington, D.C.)2013;64(10):1038-42. ">Lim 2013</a>; <a href="./references#CD011703-bbs2-0036" title="LiuFX , AlexanderGC , CrawfordSY , PickardAS , HedekerD , WaltonSM .The impact of Medicare Part D on health care utilization and health of the Medicare beneficiaries. Value in Health2010;13:A7. LiuFX , AlexanderGC , CrawfordSY , PickardAS , HedekerD , WaltonSM .The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility. Health Services Research2011;46(4):1104-23. LiuFX , WaltonSM , CrawfordSY , PickardAS .The impact of Medicare Part D on health care utilization and health outcomes for Medicare beneficiaries without previous drug coverage. Value in Health2009;12:A170. ">Liu 2011</a>; <a href="./references#CD011703-bbs2-0037" title="MacleanJC , HalpernMT , HillSC , PeskoMF .The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications. Health Services Research2020;55:399-410. ">Maclean 2020</a>; <a href="./references#CD011703-bbs2-0040" title="MottDA , ThorpeJM , ThorpeCT , KrelingDH , GadkariAS .Effects of Medicare PartD on drug affordability and use: are seniors with prior high out-of-pocket drug spending affected more?Research in Social &amp; Administrative Pharmacy2010;6(2):90-9. ">Mott 2010</a>; <a href="./references#CD011703-bbs2-0041" title="NelsonRE , NelsonSL , HuttnerB , GundlapalliA .The effect of Medicare Part D on health care utilization for non-elderly Medicare recipients with disabilities. Disability and Health Journal2014;7:64-9. ">Nelson 2014</a>; <a href="./references#CD011703-bbs2-0042" title="OngMK , XuH , ZhangL , AzocarF , EttnerSL .Effect of medicare part D benzodiazepine exclusion on psychotropic use in benzodiazepine users. Journal of the American Geriatrics Society2012;60(7):1292-7. OngMK , ZhangL , XuH , AzocarF , EttnerSL .Effect of medicare part D benzodiazepine exclusion on psychotropic use among patients with new anxiety disorders. Journal of General Internal Medicine2011;26(1 Suppl):S137. OngMK , ZhangL , XuH , AzocarF , EttnerSL .Medicare Part D benzodiazepine exclusion and use of psychotropic medication by patients with new anxiety disorders. Psychiatric Services2012;63:637-42. ">Ong 2012</a>; <a href="./references#CD011703-bbs2-0043" title="PakT , KimG .The impact of Medicare Part D on cognitive functioning at older ages. Social Science &amp; Medicine2017;193:118-26. ">Pak 2017</a>; <a href="./references#CD011703-bbs2-0044" title="ParkT , JungJ .The effect of Medicare Part D on prescription drug spending and health care use: 6 years of follow-up, 2007-2012. Journal of Managed Care &amp; Specialty Pharmacy2017;23(1):5-12. ">Park 2017</a>; <a href="./references#CD011703-bbs2-0051" title="TangW , XieJ , KongF , MaloneDC .Per-prescription drug expenditure by source of payment and income level in the United States, 1997 to 2015. Value in Health2019;22(8):871-7. ">Tang 2019</a>; <a href="./references#CD011703-bbs2-0053" title="ZhangJX , JinW , SunSX , AlexanderGC .The impact of the Medicare Part D prescription benefit on generic drug use. Journal of General Internal Medicine2008;23(10):1673-8. ">Zhang 2008</a>; <a href="./references#CD011703-bbs2-0058" title="ZimmerD .The effect of Medicare Part D on prescription drug composition and demand. Journal of Economic Studies2015;42(2):170-85. ">Zimmer 2015</a>). Those comparisons could be categorised in two broad groups: those in which the comparator was a 'near‐elderly' or 'age‐ineligible' (younger) group; and those in which the comparator was a group with generous coverage before the introduction of the benefit and was therefore unlikely to be incorporated into the policy. In all the included CBA studies, we considered the comparison group equivalent, but in five out of 11 controlled ITS studies (<a href="./references#CD011703-bbs2-0006" title="BasuA , YinW , AlexanderGC .Impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Services Research2010;45(1):133-51. BasuA , YinW , AlexanderGC .The impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Value in Health2009;12(3):A83. KaestnerR , ShimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):595-628. ">Basu 2010</a>; <a href="./references#CD011703-bbs2-0008" title="BriesacherBA , SoumeraiSB , FieldTS , FouayziH , GurwitzJH .Nursing home residents and enrollment in Medicare Part D. Journal of the American Geriatrics Society2009;57(10):1902-7. ">Briesacher 2009</a>; <a href="./references#CD011703-bbs2-0031" title="Ketcham JD, SimonK .Medicare Part D's effects on elderly drug costs and utilization. National Bureau of Economic Research Working Paper 14326, September 2008 (www.nber.org/papers/w14326) (accessed 28 January 2022). KetchamJD , SimonKI .Medicare Part D’s effects on elderly patients’ drug costs and utilization. American Journal of Managed Care2008;14(11 Spec No.):SP14-SP22. ">Ketcham 2008</a>; <a href="./references#CD011703-bbs2-0033" title="LiR , GreggEW , BarkerLE , ZhangP , ZhangF , ZhuoX , et al.Medicare Part D is associated with reducing the financial burden of health care services in Medicare beneficiaries with diagnosed diabetes. Medical Care2013;51(10):888-93. ">Li 2013</a>; <a href="./references#CD011703-bbs2-0034" title="LichtenbergFR , SunSX .The Impact of Medicare Part D on Prescription Drug Use by the Elderly. Cheltenham (UK) and Northampton (Mass): Elgar Research Collection. International Library of Critical Writings in Economics, vol. 284, 2013. LichtenbergFR , SunSX .The impact of Medicare Part D on prescription drug use by the elderly. Health Affairs2007;26(6):1735-44. ">Lichtenberg 2007</a>), we considered the comparison groups as non‐equivalent  and these studies were analysed as 'uncontrolled' ITS. </p> </section> <section id="CD011703-sec-0063"> <h5 class="title">Participants</h5> <p>As in several other pharmaceutical policies' reviews (<a href="./references#CD011703-bbs2-0190" title="AaserudM , DahlgrenAT , SturmH , KöstersJP , HillS , FurbergCD , et al.Pharmaceutical policies: effects on rational drug use, an overview of 13 reviews. Cochrane Database of Systematic Reviews2006, Issue 2. Art. No: CD004397. [DOI: 10.1002/14651858.CD004397.pub2]">Aaserud 2006</a>; <a href="./references#CD011703-bbs2-0208" title="GreenCJ , MaclureM , FortinPM , RamsayCR , AaserudM , BardalS .Pharmaceutical policies: effects of restrictions on reimbursement. Cochrane Database of Systematic Reviews2010, Issue 8. Art. No: CD008654. [DOI: 10.1002/14651858.CD008654]">Green 2010</a>), the data sources in all the included studies were administrative datasets. The primary purpose of these datasets was to track transactions within the plan rather than support research projects. </p> <p>Participants were beneficiaries of the US national public health insurance programmes for the elderly (Medicare) or for the poor (Medicaid) who obtained drug benefits through specific plans normally administered at the state level. For the two studies from Canada (<a href="./references#CD011703-bbs2-0012" title="CaetanoPA , RaymondCB , MorganS , YanL .Income-based drug coverage in British Columbia: the impact on access to medicines. Healthcare Policy2006;2(2):e154-e169. ">Caetano 2006</a>; <a href="./references#CD011703-bbs2-0050" title="TanDHS , DashwoodTM , WiltonJ , KrochA , GomesT , MartinsD .Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015–2018). Canadian Journal of Public Health2021;112:89-96. ">Tan 2021</a>), participants were described as adults (19 years of age and over) from British Columbia and the beneficiaries (especially those less than 25 years) of the Ontario Drug Benefit programme, respectively. 'Dual‐eligible' beneficiaries (those beneficiaries qualifying for both Medicare and Medicaid benefits) were the focus of six studies (<a href="./references#CD011703-bbs2-0001" title="AdamsAS , MaddenJM , ZhangF , SoumeraiSB , GildenD , GriggsJ , et al.Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage. Medical Care2014;52(8):695-703. ">Adams 2014</a>; <a href="./references#CD011703-bbs2-0006" title="BasuA , YinW , AlexanderGC .Impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Services Research2010;45(1):133-51. BasuA , YinW , AlexanderGC .The impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Value in Health2009;12(3):A83. KaestnerR , ShimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):595-628. ">Basu 2010</a>; <a href="./references#CD011703-bbs2-0011" title="BurnsM , BuschA , MaddenJ , LeCatesRF , ZhangF , AdamsA , et al.The effect of Medicare Part D on guideline-concordant pharmacotherapy for bipolar I disorder among dually enrolled beneficiaries. Psychiatric Services2014;65(3):323-9. ">Burns 2014</a>; <a href="./references#CD011703-bbs2-0025" title="FarleyJF , DusetzinaSB .Medicaid prescription drug utilization and expenditures following Part D. Journal of Health Care for the Poor and Underserved2010;21(2):715-28. ">Farley 2010</a>; <a href="./references#CD011703-bbs2-0047" title="SavernoK , MaloneDC , WarholakTL , ArmstrongEP , SlackM .Impact of Medicare Part D on pharmaceutical and medical utilization in Arizona's dual eligible population. Value in Health2012;15:A15. SavernoKR .Impact of Medicare Part D on Pharmaceutical and Medical Utilization in Arizona's Dual Eligible Population (PhD Dissertation). University of Arizona, 2011. ">Saverno 2011</a>; <a href="./references#CD011703-bbs2-0049" title="ShrankWH , PatrickAR , PedanA , PolinskiJM , VarastehL , LevinR , et al.The effect of transitioning to Medicare Part D drug coverage in seniors dually eligible for Medicare and Medicaid. Journal of the American Geriatrics Society2008;56(12):2304-10. ">Shrank 2008</a>). Five studies focused on nursing home residents (<a href="./references#CD011703-bbs2-0008" title="BriesacherBA , SoumeraiSB , FieldTS , FouayziH , GurwitzJH .Nursing home residents and enrollment in Medicare Part D. Journal of the American Geriatrics Society2009;57(10):1902-7. ">Briesacher 2009</a>; <a href="./references#CD011703-bbs2-0009" title="BriesacherBA , SoumeraiSB , FieldTS , FouayziH , GurwitzJH .Medicare Part D’s exclusion of benzodiazepines and fracture risk in nursing homes. Archives of Internal Medicine2010;170(8):693-8. ">Briesacher 2010</a>; <a href="./references#CD011703-bbs2-0028" title="JungC , PadmanR , AnwarS .The impact of Medicare part D prescription drug benefit program on generic drug prescription. A study in long-term care facilities. Medicine2019;98(32 ):e16646. ">Jung 2019</a>; <a href="./references#CD011703-bbs2-0038" title="MaddenJM , AdamsAS , LeCatesRF , Ross-DegnanD , ZhangF , HuskampHA , et al.Changes in drug coverage generosity and untreated serious mental illness transitioning from Medicaid to Medicare Part D. JAMA Psychiatry2015;72(2):179-88. ">Madden 2015</a>; <a href="./references#CD011703-bbs2-0045" title="PimentelCB , LapaneKL , RosenAB , GurwitzGH , BriesacherBA .Medicare Part D’s impact on pain management in dual-eligible nursing home residents with cancer: an interrupted time-series study. Pharmacoepidemiology and Drug Safety2015;24:131. PimentelCB , LapaneKL , RosenAB , GurwitzJH , BriesacherBA .Medicare part D's impact on pain management among nursing home residents with cancer: an interrupted time-series study. Journal of the American Geriatrics Society2015;63:S129. PimentelCB .Use of Opioids for Pain Management in Nursing Homes: A Dissertation. University of Massachusetts Medical School, 2015. [DOI: 10.13028/M2512]">Pimentel 2015</a>); and thirteen studies included participants with specific clinical conditions: diabetes mellitus (<a href="./references#CD011703-bbs2-0001" title="AdamsAS , MaddenJM , ZhangF , SoumeraiSB , GildenD , GriggsJ , et al.Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage. Medical Care2014;52(8):695-703. ">Adams 2014</a>; <a href="./references#CD011703-bbs2-0016" title="ChoiYJ , JiaH , GrossT , WeingerK , StonePW , SmaldoneAM .Impact of medicare part D on out-of-pocket prescription drug costs among elderly with diabetes. Diabetes2015;64:A70. ChoiYJ , JiaH , GrossT , WeingerK , StonePW , SmaldoneAM .The impact of Medicare Part D on the proportion of out-of-pocket prescription drug costs among older adults with diabetes. Diabetes Care2017;40:502-8. ">Choi 2017</a>; <a href="./references#CD011703-bbs2-0033" title="LiR , GreggEW , BarkerLE , ZhangP , ZhangF , ZhuoX , et al.Medicare Part D is associated with reducing the financial burden of health care services in Medicare beneficiaries with diagnosed diabetes. Medical Care2013;51(10):888-93. ">Li 2013</a>); mental health disorders (<a href="./references#CD011703-bbs2-0004" title="AyyagariP , ShaneDM .Does prescription drug coverage improve mental health? Evidence from Medicare Part D. Journal of Health Economics2015;41:46-58. ">Ayyagari 2015</a>; <a href="./references#CD011703-bbs2-0011" title="BurnsM , BuschA , MaddenJ , LeCatesRF , ZhangF , AdamsA , et al.The effect of Medicare Part D on guideline-concordant pharmacotherapy for bipolar I disorder among dually enrolled beneficiaries. Psychiatric Services2014;65(3):323-9. ">Burns 2014</a>; <a href="./references#CD011703-bbs2-0014" title="ChenH , NwangwuA , AparasuR , EssienE , SunS , LeeK .The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatric Services2008;59(10):1191-7. ">Chen 2008</a>; <a href="./references#CD011703-bbs2-0020" title="DonohueJM , ZhangY , AijuM , PereraS , LaveJR , HanlonJT , et al.Impact of Medicare Part D on antidepressant treatment, medication choice, and adherence among older adults with depression. American Journal of Geriatric Psychiatry2011;19(12):989-97. ">Donohue 2011</a>; <a href="./references#CD011703-bbs2-0035" title="LimD , JungK , ShiY .National trends in the use of antidepressants between 1997 and 2009 and the role of Medicare Part D implementation. Psychiatric Services (Washington, D.C.)2013;64(10):1038-42. ">Lim 2013</a>); cancer (<a href="./references#CD011703-bbs2-0032" title="KircherSM , JohansenM , RichardsonC , DavisMM .Impact of Medicare Part D on out-of-pocket pharmaceutical costs for patients with cancer. Journal of Clinical Oncology2013;31(Nº 15 Suppl):6517. KircherSM , JohansenME , NimeiriHS , RichardsonCR , DavisMM .Impact of Medicare Part D on out-of-pocket drug costs and medical use for patients with cancer. Cancer2014;120(21):3378-84. ">Kircher 2014</a>),  HIV (<a href="./references#CD011703-bbs2-0007" title="BelenkyN , PenceBW , ColeSR , DusetzinaSB , EdmondsA , OberlanderJ , et al.Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV. AIDS Care2019;31(4):505-12. ">Belenky 2019</a>; <a href="./references#CD011703-bbs2-0050" title="TanDHS , DashwoodTM , WiltonJ , KrochA , GomesT , MartinsD .Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015–2018). Canadian Journal of Public Health2021;112:89-96. ">Tan 2021</a>); dementia (<a href="./references#CD011703-bbs2-0026" title="FowlerN , ChenYF .Impact of prescription drug coverage on use of anti-dementia drugs. Alzheimer and Dementia2011;7(4S Part 18):S643. FowlerNR , ChenY , ThurtonCA , MenA , RodriguezEG , DonohueJM .The impact of Medicare prescription drug coverage on the use of antidementia drugs. BMC Geriatrics2013;13:37. ">Fowler 2013</a>); and heart failure (<a href="./references#CD011703-bbs2-0019" title="DonohueJM , ZhangY , LaveJ , GelladWF , PereraS , MenA , et al.Impact of expanding pharmacy benefits on treatment of congestive heart failure: the case of Medicare Part D. Value in Health2009;12(7):A342. DonohueJM , ZhangY , LaveJR , GelladWF , MenA , PereraS , et al.The Medicare drug benefit (Part D) and treatment of heart failure in older adults. American Heart Journal2010;160(1):159-65. ">Donohue 2010</a>).  </p> </section> <section id="CD011703-sec-0064"> <h5 class="title">Drug classes</h5> <p>Eight drug classes were individually targeted by the studies included in the review: psychotropic drugs (<a href="./references#CD011703-bbs2-0004" title="AyyagariP , ShaneDM .Does prescription drug coverage improve mental health? Evidence from Medicare Part D. Journal of Health Economics2015;41:46-58. ">Ayyagari 2015</a>; <a href="./references#CD011703-bbs2-0007" title="BelenkyN , PenceBW , ColeSR , DusetzinaSB , EdmondsA , OberlanderJ , et al.Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV. AIDS Care2019;31(4):505-12. ">Belenky 2019</a>; <a href="./references#CD011703-bbs2-0009" title="BriesacherBA , SoumeraiSB , FieldTS , FouayziH , GurwitzJH .Medicare Part D’s exclusion of benzodiazepines and fracture risk in nursing homes. Archives of Internal Medicine2010;170(8):693-8. ">Briesacher 2010</a>; <a href="./references#CD011703-bbs2-0011" title="BurnsM , BuschA , MaddenJ , LeCatesRF , ZhangF , AdamsA , et al.The effect of Medicare Part D on guideline-concordant pharmacotherapy for bipolar I disorder among dually enrolled beneficiaries. Psychiatric Services2014;65(3):323-9. ">Burns 2014</a>; <a href="./references#CD011703-bbs2-0014" title="ChenH , NwangwuA , AparasuR , EssienE , SunS , LeeK .The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatric Services2008;59(10):1191-7. ">Chen 2008</a>; <a href="./references#CD011703-bbs2-0018" title="DoD .The impact of Medicare Part D on opioid use among U.S. older adults. Drug and Alcohol Dependence2020;212:108069. ">Do 2020</a>; <a href="./references#CD011703-bbs2-0020" title="DonohueJM , ZhangY , AijuM , PereraS , LaveJR , HanlonJT , et al.Impact of Medicare Part D on antidepressant treatment, medication choice, and adherence among older adults with depression. American Journal of Geriatric Psychiatry2011;19(12):989-97. ">Donohue 2011</a>; <a href="./references#CD011703-bbs2-0035" title="LimD , JungK , ShiY .National trends in the use of antidepressants between 1997 and 2009 and the role of Medicare Part D implementation. Psychiatric Services (Washington, D.C.)2013;64(10):1038-42. ">Lim 2013</a>; <a href="./references#CD011703-bbs2-0042" title="OngMK , XuH , ZhangL , AzocarF , EttnerSL .Effect of medicare part D benzodiazepine exclusion on psychotropic use in benzodiazepine users. Journal of the American Geriatrics Society2012;60(7):1292-7. OngMK , ZhangL , XuH , AzocarF , EttnerSL .Effect of medicare part D benzodiazepine exclusion on psychotropic use among patients with new anxiety disorders. Journal of General Internal Medicine2011;26(1 Suppl):S137. OngMK , ZhangL , XuH , AzocarF , EttnerSL .Medicare Part D benzodiazepine exclusion and use of psychotropic medication by patients with new anxiety disorders. Psychiatric Services2012;63:637-42. ">Ong 2012</a>; <a href="./references#CD011703-bbs2-0045" title="PimentelCB , LapaneKL , RosenAB , GurwitzGH , BriesacherBA .Medicare Part D’s impact on pain management in dual-eligible nursing home residents with cancer: an interrupted time-series study. Pharmacoepidemiology and Drug Safety2015;24:131. PimentelCB , LapaneKL , RosenAB , GurwitzJH , BriesacherBA .Medicare part D's impact on pain management among nursing home residents with cancer: an interrupted time-series study. Journal of the American Geriatrics Society2015;63:S129. PimentelCB .Use of Opioids for Pain Management in Nursing Homes: A Dissertation. University of Massachusetts Medical School, 2015. [DOI: 10.13028/M2512]">Pimentel 2015</a>; <a href="./references#CD011703-bbs2-0046" title="PolinskiJM , BrookhartMA , GlynnRJ , SchneeweissS .Comparison between aggregate- and individual-level time-trend analyses to evaluate overall effects of Medicare Part D on use of antipsychotic medications. Pharmacoepidemiology and Drug Safety2011;20:S107. PolinskiJM , BrookhartMA , GlynnRJ , SchneeweissS .Medicare Part D’s impact on antipsychotic drug use and costs among elderly patients without prior drug insurance. Journal of Clinical Psychopharmacology2012;32(1):3-10. ">Polinski 2012</a>; <a href="./references#CD011703-bbs2-0047" title="SavernoK , MaloneDC , WarholakTL , ArmstrongEP , SlackM .Impact of Medicare Part D on pharmaceutical and medical utilization in Arizona's dual eligible population. Value in Health2012;15:A15. SavernoKR .Impact of Medicare Part D on Pharmaceutical and Medical Utilization in Arizona's Dual Eligible Population (PhD Dissertation). University of Arizona, 2011. ">Saverno 2011</a>); antihypertensive drugs (<a href="./references#CD011703-bbs2-0012" title="CaetanoPA , RaymondCB , MorganS , YanL .Income-based drug coverage in British Columbia: the impact on access to medicines. Healthcare Policy2006;2(2):e154-e169. ">Caetano 2006</a>; <a href="./references#CD011703-bbs2-0057" title="ZhangY , DonohueJM , LaveJR , GelladWF .The impact of Medicare Part D on medication treatment of hypertension. Health Services Research2011;46(1):185-98. ">Zhang 2011</a>); lipid‐lowering (LL) drugs (<a href="./references#CD011703-bbs2-0001" title="AdamsAS , MaddenJM , ZhangF , SoumeraiSB , GildenD , GriggsJ , et al.Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage. Medical Care2014;52(8):695-703. ">Adams 2014</a>; <a href="./references#CD011703-bbs2-0012" title="CaetanoPA , RaymondCB , MorganS , YanL .Income-based drug coverage in British Columbia: the impact on access to medicines. Healthcare Policy2006;2(2):e154-e169. ">Caetano 2006</a>; <a href="./references#CD011703-bbs2-0054" title="ZhangY , DonohueJM , LaveJR , O’DonnellG , NewhouseJP .The effect of Medicare Part D on drug and medical spending. New England Journal of Medicine2009;361(1):52. ">Zhang 2009</a>); antidiabetic medications (<a href="./references#CD011703-bbs2-0033" title="LiR , GreggEW , BarkerLE , ZhangP , ZhangF , ZhuoX , et al.Medicare Part D is associated with reducing the financial burden of health care services in Medicare beneficiaries with diagnosed diabetes. Medical Care2013;51(10):888-93. ">Li 2013</a>; <a href="./references#CD011703-bbs2-0054" title="ZhangY , DonohueJM , LaveJR , O’DonnellG , NewhouseJP .The effect of Medicare Part D on drug and medical spending. New England Journal of Medicine2009;361(1):52. ">Zhang 2009</a>); heart failure medications (<a href="./references#CD011703-bbs2-0019" title="DonohueJM , ZhangY , LaveJ , GelladWF , PereraS , MenA , et al.Impact of expanding pharmacy benefits on treatment of congestive heart failure: the case of Medicare Part D. Value in Health2009;12(7):A342. DonohueJM , ZhangY , LaveJR , GelladWF , MenA , PereraS , et al.The Medicare drug benefit (Part D) and treatment of heart failure in older adults. American Heart Journal2010;160(1):159-65. ">Donohue 2010</a>); medications for dementia (<a href="./references#CD011703-bbs2-0026" title="FowlerN , ChenYF .Impact of prescription drug coverage on use of anti-dementia drugs. Alzheimer and Dementia2011;7(4S Part 18):S643. FowlerNR , ChenY , ThurtonCA , MenA , RodriguezEG , DonohueJM .The impact of Medicare prescription drug coverage on the use of antidementia drugs. BMC Geriatrics2013;13:37. ">Fowler 2013</a>); anti‐retrovirals for HIV (<a href="./references#CD011703-bbs2-0050" title="TanDHS , DashwoodTM , WiltonJ , KrochA , GomesT , MartinsD .Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015–2018). Canadian Journal of Public Health2021;112:89-96. ">Tan 2021</a>); and antibiotics (<a href="./references#CD011703-bbs2-0055" title="ZhangY , LeeBY , DonohueJM .Ambulatory antibiotic use and prescription drug coverage in older adults. Archives of Internal Medicine2010;170(15):1308-14. ">Zhang 2010a</a>). Four studies assessed the effect of Medicare Part D on multiple drug classes (such as statins, proton pump inhibitors, warfarin, clopidogrel and benzodiazepines) (<a href="./references#CD011703-bbs2-0025" title="FarleyJF , DusetzinaSB .Medicaid prescription drug utilization and expenditures following Part D. Journal of Health Care for the Poor and Underserved2010;21(2):715-28. ">Farley 2010</a>; <a href="./references#CD011703-bbs2-0028" title="JungC , PadmanR , AnwarS .The impact of Medicare part D prescription drug benefit program on generic drug prescription. A study in long-term care facilities. Medicine2019;98(32 ):e16646. ">Jung 2019</a>; <a href="./references#CD011703-bbs2-0048" title="SchneeweissS , PatrickAR , PedanA , VarastehL , LevinR , LiuN , et al.The effect Of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Affairs2009;28(2):w305-w316. ">Schneeweiss 2009</a>; <a href="./references#CD011703-bbs2-0049" title="ShrankWH , PatrickAR , PedanA , PolinskiJM , VarastehL , LevinR , et al.The effect of transitioning to Medicare Part D drug coverage in seniors dually eligible for Medicare and Medicaid. Journal of the American Geriatrics Society2008;56(12):2304-10. ">Shrank 2008</a>). In the other studies, no specific drug classes were targeted for evaluation. </p> </section> <section id="CD011703-sec-0065"> <h5 class="title">Outcomes</h5> <p>Drug use and drug expenditures were the most frequently assessed outcomes in 34 and 23 studies, respectively. Eighteen studies assessed both of them. Healthcare utilisation was measured in 12 studies and health outcomes were assessed in nine studies. </p> </section> </section> <section id="CD011703-sec-0066"> <h4 class="title">Excluded studies</h4> <p>We excluded 129 studies. The most common reason for exclusion (n = 77) was having a non‐eligible study design. More details are described in the table <a href="./references#CD011703-sec-0130" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD011703-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>For details of our assessments of risk of bias, see the Risk of bias tables for each study (<a href="./references#CD011703-sec-0129" title="">Characteristics of included studies</a>). The risk of bias graphs and the summary assessments of risk of bias for the CBA studies are presented in <a href="#CD011703-fig-0003">Figure 3</a> and <a href="#CD011703-fig-0004">Figure 4</a> and for the ITS/CITS studies in <a href="#CD011703-fig-0005">Figure 5</a> and <a href="#CD011703-fig-0006">Figure 6</a>. Overall, we assessed most of the interrupted time‐series studies as having some limitations (moderate risk of bias) mainly because of uncertainties about the completeness of outcome data and the risk that the intervention was not independent of other policy changes. On the other hand, we assessed all the controlled before‐after studies as having serious limitations (high risk of bias) because of a high risk of baseline differences in outcomes and other characteristics between the intervention and comparison groups. </p> <div class="figure" id="CD011703-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph for CBA studies: review authors' judgements about each risk of bias item presented as percentages across all included CBA studies" data-id="CD011703-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph for CBA studies: review authors' judgements about each risk of bias item presented as percentages across all included CBA studies </p> </div> </div> </div> <div class="figure" id="CD011703-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary for CBA studies: review authors' judgements about each risk of bias item for each included CBA study" data-id="CD011703-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary for CBA studies: review authors' judgements about each risk of bias item for each included CBA study </p> </div> </div> </div> <div class="figure" id="CD011703-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Risk of bias graph for ITS/CITS studies: review authors' judgements about each risk of bias item presented as percentages across all included ITS/CITS studies" data-id="CD011703-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph for ITS/CITS studies: review authors' judgements about each risk of bias item presented as percentages across all included ITS/CITS studies </p> </div> </div> </div> <div class="figure" id="CD011703-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Risk of bias summary for ITS/CITS studies: review authors' judgements about each risk of bias item for each included ITS and CITS study" data-id="CD011703-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary for ITS/CITS studies: review authors' judgements about each risk of bias item for each included ITS and CITS study </p> </div> </div> </div> </section> <section id="CD011703-sec-0068"> <h3 class="title" id="CD011703-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD011703-tbl-0001"><b>Summary of findings 1</b> Summary of findings</a> </p> <p>We present an overall summary of the effects of drug insurance schemes (mainly focused on Medicare Part D) on drug use, drug expenditure, healthcare utilisation and health outcomes in the <a href="./full#CD011703-tbl-0001">summary of findings Table 1</a>. Although one study included in the quantitative analysis (<a href="./references#CD011703-bbs2-0037" title="MacleanJC , HalpernMT , HillSC , PeskoMF .The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications. Health Services Research2020;55:399-410. ">Maclean 2020</a>) assessed the effect of a policy different to Medicare Part D (ACA Medicaid expansion), this provided only one effect estimate out of 116 effect estimates for drug use. Therefore, we considered that most of the evidence available in our review was for the comparison between those enrolling in drug insurance schemes as Medicare Part D and those who were not able to be enrolled. We provided detailed results from the included studies in four separate tables for drug use, drug expenditures, healthcare utilisation and health outcomes respectively (<a href="./appendices#CD011703-sec-0093">Appendix 3</a>; <a href="./appendices#CD011703-sec-0100">Appendix 4</a>; <a href="./appendices#CD011703-sec-0107">Appendix 5</a>; <a href="./appendices#CD011703-sec-0116">Appendix 6</a>).  </p> <section id="CD011703-sec-0069"> <h4 class="title">Enrolment in a drug insurance scheme compared to no enrolment in the scheme</h4> <section id="CD011703-sec-0070"> <h5 class="title">Drug use</h5> <p>Drug use was an outcome in 34 studies. We were not able to re‐analyse one of these because of the way in which data were presented (as a log scale difference) (<a href="./references#CD011703-bbs2-0034" title="LichtenbergFR , SunSX .The Impact of Medicare Part D on Prescription Drug Use by the Elderly. Cheltenham (UK) and Northampton (Mass): Elgar Research Collection. International Library of Critical Writings in Economics, vol. 284, 2013. LichtenbergFR , SunSX .The impact of Medicare Part D on prescription drug use by the elderly. Health Affairs2007;26(6):1735-44. ">Lichtenberg 2007</a>). Of the other 33 with analysable data, we analysed 12 as interrupted time‐series studies, one as a CITS study and 20 as controlled before‐after studies. We present detailed results for immediate, short‐ and long‐term absolute and relative change for each study in <a href="./appendices#CD011703-sec-0093">Appendix 3</a>.  </p> <section id="CD011703-sec-0071"> <h6 class="title">Immediate post‐policy implementation</h6> <p>Eight ITS studies (<a href="./references#CD011703-bbs2-0001" title="AdamsAS , MaddenJM , ZhangF , SoumeraiSB , GildenD , GriggsJ , et al.Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage. Medical Care2014;52(8):695-703. ">Adams 2014</a>; <a href="./references#CD011703-bbs2-0009" title="BriesacherBA , SoumeraiSB , FieldTS , FouayziH , GurwitzJH .Medicare Part D’s exclusion of benzodiazepines and fracture risk in nursing homes. Archives of Internal Medicine2010;170(8):693-8. ">Briesacher 2010</a>; <a href="./references#CD011703-bbs2-0014" title="ChenH , NwangwuA , AparasuR , EssienE , SunS , LeeK .The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatric Services2008;59(10):1191-7. ">Chen 2008</a>; <a href="./references#CD011703-bbs2-0025" title="FarleyJF , DusetzinaSB .Medicaid prescription drug utilization and expenditures following Part D. Journal of Health Care for the Poor and Underserved2010;21(2):715-28. ">Farley 2010</a>; <a href="./references#CD011703-bbs2-0045" title="PimentelCB , LapaneKL , RosenAB , GurwitzGH , BriesacherBA .Medicare Part D’s impact on pain management in dual-eligible nursing home residents with cancer: an interrupted time-series study. Pharmacoepidemiology and Drug Safety2015;24:131. PimentelCB , LapaneKL , RosenAB , GurwitzJH , BriesacherBA .Medicare part D's impact on pain management among nursing home residents with cancer: an interrupted time-series study. Journal of the American Geriatrics Society2015;63:S129. PimentelCB .Use of Opioids for Pain Management in Nursing Homes: A Dissertation. University of Massachusetts Medical School, 2015. [DOI: 10.13028/M2512]">Pimentel 2015</a>; <a href="./references#CD011703-bbs2-0046" title="PolinskiJM , BrookhartMA , GlynnRJ , SchneeweissS .Comparison between aggregate- and individual-level time-trend analyses to evaluate overall effects of Medicare Part D on use of antipsychotic medications. Pharmacoepidemiology and Drug Safety2011;20:S107. PolinskiJM , BrookhartMA , GlynnRJ , SchneeweissS .Medicare Part D’s impact on antipsychotic drug use and costs among elderly patients without prior drug insurance. Journal of Clinical Psychopharmacology2012;32(1):3-10. ">Polinski 2012</a>; <a href="./references#CD011703-bbs2-0048" title="SchneeweissS , PatrickAR , PedanA , VarastehL , LevinR , LiuN , et al.The effect Of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Affairs2009;28(2):w305-w316. ">Schneeweiss 2009</a>; <a href="./references#CD011703-bbs2-0049" title="ShrankWH , PatrickAR , PedanA , PolinskiJM , VarastehL , LevinR , et al.The effect of transitioning to Medicare Part D drug coverage in seniors dually eligible for Medicare and Medicaid. Journal of the American Geriatrics Society2008;56(12):2304-10. ">Shrank 2008</a>)  (32 effect estimates) reported absolute and/or relative changes in levels of drug use up to four months after the introduction of the policy. All of these studies presented effect estimates for Medicare Part D. They showed that the introduction of (or changes to) this drug insurance scheme may increase drug use immediately after the implementation of the policy (median relative effect adjusted for baseline differences: increase 3.74%; low‐certainty evidence). However, the IQR showed that the policy may decrease or increase drug use (IQR −9.41% to 22.98%; low‐certainty evidence). When effect estimates related to the use of benzodiazepines, a group of drugs not covered by Medicare Part D, were removed from the analysis, the studies showed similar changes in the median relative effect (increase of 7.99% (IQR 0.38% to 37.02%; 24 effect estimates; low‐certainty evidence).  </p> </section> <section id="CD011703-sec-0072"> <h6 class="title">Six months after policy implementation</h6> <p>Nine ITS studies (<a href="./references#CD011703-bbs2-0001" title="AdamsAS , MaddenJM , ZhangF , SoumeraiSB , GildenD , GriggsJ , et al.Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage. Medical Care2014;52(8):695-703. ">Adams 2014</a>; <a href="./references#CD011703-bbs2-0006" title="BasuA , YinW , AlexanderGC .Impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Services Research2010;45(1):133-51. BasuA , YinW , AlexanderGC .The impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Value in Health2009;12(3):A83. KaestnerR , ShimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):595-628. ">Basu 2010</a>; <a href="./references#CD011703-bbs2-0008" title="BriesacherBA , SoumeraiSB , FieldTS , FouayziH , GurwitzJH .Nursing home residents and enrollment in Medicare Part D. Journal of the American Geriatrics Society2009;57(10):1902-7. ">Briesacher 2009</a>; <a href="./references#CD011703-bbs2-0014" title="ChenH , NwangwuA , AparasuR , EssienE , SunS , LeeK .The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatric Services2008;59(10):1191-7. ">Chen 2008</a>; <a href="./references#CD011703-bbs2-0025" title="FarleyJF , DusetzinaSB .Medicaid prescription drug utilization and expenditures following Part D. Journal of Health Care for the Poor and Underserved2010;21(2):715-28. ">Farley 2010</a>; <a href="./references#CD011703-bbs2-0031" title="Ketcham JD, SimonK .Medicare Part D's effects on elderly drug costs and utilization. National Bureau of Economic Research Working Paper 14326, September 2008 (www.nber.org/papers/w14326) (accessed 28 January 2022). KetchamJD , SimonKI .Medicare Part D’s effects on elderly patients’ drug costs and utilization. American Journal of Managed Care2008;14(11 Spec No.):SP14-SP22. ">Ketcham 2008</a>; <a href="./references#CD011703-bbs2-0046" title="PolinskiJM , BrookhartMA , GlynnRJ , SchneeweissS .Comparison between aggregate- and individual-level time-trend analyses to evaluate overall effects of Medicare Part D on use of antipsychotic medications. Pharmacoepidemiology and Drug Safety2011;20:S107. PolinskiJM , BrookhartMA , GlynnRJ , SchneeweissS .Medicare Part D’s impact on antipsychotic drug use and costs among elderly patients without prior drug insurance. Journal of Clinical Psychopharmacology2012;32(1):3-10. ">Polinski 2012</a>; <a href="./references#CD011703-bbs2-0048" title="SchneeweissS , PatrickAR , PedanA , VarastehL , LevinR , LiuN , et al.The effect Of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Affairs2009;28(2):w305-w316. ">Schneeweiss 2009</a>; <a href="./references#CD011703-bbs2-0049" title="ShrankWH , PatrickAR , PedanA , PolinskiJM , VarastehL , LevinR , et al.The effect of transitioning to Medicare Part D drug coverage in seniors dually eligible for Medicare and Medicaid. Journal of the American Geriatrics Society2008;56(12):2304-10. ">Shrank 2008</a>) and one CBA study (<a href="./references#CD011703-bbs2-0053" title="ZhangJX , JinW , SunSX , AlexanderGC .The impact of the Medicare Part D prescription benefit on generic drug use. Journal of General Internal Medicine2008;23(10):1673-8. ">Zhang 2008</a>) (25 effect estimates) reported absolute and/or relative changes in levels of drug use six months after the introduction of the policy. All of these studies presented effect estimates for Medicare Part D. They showed that Medicare Part D may increase drug use six months after the implementation of the policy (median relative effect adjusted by baseline differences 8.4%, IQR ‐2.88% to 25.19%; low‐certainty evidence). When effect estimates related to the use of benzodiazepines, a group of drugs not covered by the policy, were not included in the analysis, the studies also showed that Medicare Part D may increase drug use by a median relative effect (adjusted for baseline differences) of 11.73% (IQR 3.77% to 37.67%; 23 effect estimates; low‐certainty evidence). </p> </section> <section id="CD011703-sec-0073"> <h6 class="title">Twelve months or more after policy implementation</h6> <p>Ten ITS studies (<a href="./references#CD011703-bbs2-0001" title="AdamsAS , MaddenJM , ZhangF , SoumeraiSB , GildenD , GriggsJ , et al.Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage. Medical Care2014;52(8):695-703. ">Adams 2014</a>; <a href="./references#CD011703-bbs2-0006" title="BasuA , YinW , AlexanderGC .Impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Services Research2010;45(1):133-51. BasuA , YinW , AlexanderGC .The impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Value in Health2009;12(3):A83. KaestnerR , ShimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):595-628. ">Basu 2010</a>; <a href="./references#CD011703-bbs2-0008" title="BriesacherBA , SoumeraiSB , FieldTS , FouayziH , GurwitzJH .Nursing home residents and enrollment in Medicare Part D. Journal of the American Geriatrics Society2009;57(10):1902-7. ">Briesacher 2009</a>; <a href="./references#CD011703-bbs2-0014" title="ChenH , NwangwuA , AparasuR , EssienE , SunS , LeeK .The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatric Services2008;59(10):1191-7. ">Chen 2008</a>; <a href="./references#CD011703-bbs2-0025" title="FarleyJF , DusetzinaSB .Medicaid prescription drug utilization and expenditures following Part D. Journal of Health Care for the Poor and Underserved2010;21(2):715-28. ">Farley 2010</a>; <a href="./references#CD011703-bbs2-0031" title="Ketcham JD, SimonK .Medicare Part D's effects on elderly drug costs and utilization. National Bureau of Economic Research Working Paper 14326, September 2008 (www.nber.org/papers/w14326) (accessed 28 January 2022). KetchamJD , SimonKI .Medicare Part D’s effects on elderly patients’ drug costs and utilization. American Journal of Managed Care2008;14(11 Spec No.):SP14-SP22. ">Ketcham 2008</a>; <a href="./references#CD011703-bbs2-0038" title="MaddenJM , AdamsAS , LeCatesRF , Ross-DegnanD , ZhangF , HuskampHA , et al.Changes in drug coverage generosity and untreated serious mental illness transitioning from Medicaid to Medicare Part D. JAMA Psychiatry2015;72(2):179-88. ">Madden 2015</a> <a href="./references#CD011703-bbs2-0046" title="PolinskiJM , BrookhartMA , GlynnRJ , SchneeweissS .Comparison between aggregate- and individual-level time-trend analyses to evaluate overall effects of Medicare Part D on use of antipsychotic medications. Pharmacoepidemiology and Drug Safety2011;20:S107. PolinskiJM , BrookhartMA , GlynnRJ , SchneeweissS .Medicare Part D’s impact on antipsychotic drug use and costs among elderly patients without prior drug insurance. Journal of Clinical Psychopharmacology2012;32(1):3-10. ">Polinski 2012</a>; <a href="./references#CD011703-bbs2-0048" title="SchneeweissS , PatrickAR , PedanA , VarastehL , LevinR , LiuN , et al.The effect Of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Affairs2009;28(2):w305-w316. ">Schneeweiss 2009</a>; <a href="./references#CD011703-bbs2-0049" title="ShrankWH , PatrickAR , PedanA , PolinskiJM , VarastehL , LevinR , et al.The effect of transitioning to Medicare Part D drug coverage in seniors dually eligible for Medicare and Medicaid. Journal of the American Geriatrics Society2008;56(12):2304-10. ">Shrank 2008</a>), one CITS study (<a href="./references#CD011703-bbs2-0054" title="ZhangY , DonohueJM , LaveJR , O’DonnellG , NewhouseJP .The effect of Medicare Part D on drug and medical spending. New England Journal of Medicine2009;361(1):52. ">Zhang 2009</a>) and 19 CBA studies (<a href="./references#CD011703-bbs2-0003" title="AsfawAA .The effect of prescription drug insurance on health behavior: evidence from Medicare Part D. Health Economics2019;28(3):403-18. ">Asfaw 2019</a>; <a href="./references#CD011703-bbs2-0004" title="AyyagariP , ShaneDM .Does prescription drug coverage improve mental health? Evidence from Medicare Part D. Journal of Health Economics2015;41:46-58. ">Ayyagari 2015</a>; <a href="./references#CD011703-bbs2-0007" title="BelenkyN , PenceBW , ColeSR , DusetzinaSB , EdmondsA , OberlanderJ , et al.Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV. AIDS Care2019;31(4):505-12. ">Belenky 2019</a>; <a href="./references#CD011703-bbs2-0018" title="DoD .The impact of Medicare Part D on opioid use among U.S. older adults. Drug and Alcohol Dependence2020;212:108069. ">Do 2020</a>; <a href="./references#CD011703-bbs2-0019" title="DonohueJM , ZhangY , LaveJ , GelladWF , PereraS , MenA , et al.Impact of expanding pharmacy benefits on treatment of congestive heart failure: the case of Medicare Part D. Value in Health2009;12(7):A342. DonohueJM , ZhangY , LaveJR , GelladWF , MenA , PereraS , et al.The Medicare drug benefit (Part D) and treatment of heart failure in older adults. American Heart Journal2010;160(1):159-65. ">Donohue 2010</a>; <a href="./references#CD011703-bbs2-0020" title="DonohueJM , ZhangY , AijuM , PereraS , LaveJR , HanlonJT , et al.Impact of Medicare Part D on antidepressant treatment, medication choice, and adherence among older adults with depression. American Journal of Geriatric Psychiatry2011;19(12):989-97. ">Donohue 2011</a>; <a href="./references#CD011703-bbs2-0026" title="FowlerN , ChenYF .Impact of prescription drug coverage on use of anti-dementia drugs. Alzheimer and Dementia2011;7(4S Part 18):S643. FowlerNR , ChenY , ThurtonCA , MenA , RodriguezEG , DonohueJM .The impact of Medicare prescription drug coverage on the use of antidementia drugs. BMC Geriatrics2013;13:37. ">Fowler 2013</a>; <a href="./references#CD011703-bbs2-0028" title="JungC , PadmanR , AnwarS .The impact of Medicare part D prescription drug benefit program on generic drug prescription. A study in long-term care facilities. Medicine2019;98(32 ):e16646. ">Jung 2019</a>; <a href="./references#CD011703-bbs2-0029" title="KaestnerR , KhanN .Medicare Part D and its effect on the use of prescription drugs, use of other health care services and health of the elderly. National Bureau of Economic Research Working Paper 16011, May 2010 (available at www.nber.org/papers/w16011) (accessed 28 January 2022). KaestnerR , KhanN .Medicare Part D and its effect on the use of prescription drugs and use of other health care services of the elderly. Journal of Policy Analysis and Management2012;31(2):253-79. KaestnerR , McCoyK .Understanding the effects of Medicare prescription drug insurance. IGPA Policy Forum2010;23(1):1-7. ">Kaestner 2012</a>; <a href="./references#CD011703-bbs2-0032" title="KircherSM , JohansenM , RichardsonC , DavisMM .Impact of Medicare Part D on out-of-pocket pharmaceutical costs for patients with cancer. Journal of Clinical Oncology2013;31(Nº 15 Suppl):6517. KircherSM , JohansenME , NimeiriHS , RichardsonCR , DavisMM .Impact of Medicare Part D on out-of-pocket drug costs and medical use for patients with cancer. Cancer2014;120(21):3378-84. ">Kircher 2014</a>; <a href="./references#CD011703-bbs2-0035" title="LimD , JungK , ShiY .National trends in the use of antidepressants between 1997 and 2009 and the role of Medicare Part D implementation. Psychiatric Services (Washington, D.C.)2013;64(10):1038-42. ">Lim 2013</a>; <a href="./references#CD011703-bbs2-0036" title="LiuFX , AlexanderGC , CrawfordSY , PickardAS , HedekerD , WaltonSM .The impact of Medicare Part D on health care utilization and health of the Medicare beneficiaries. Value in Health2010;13:A7. LiuFX , AlexanderGC , CrawfordSY , PickardAS , HedekerD , WaltonSM .The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility. Health Services Research2011;46(4):1104-23. LiuFX , WaltonSM , CrawfordSY , PickardAS .The impact of Medicare Part D on health care utilization and health outcomes for Medicare beneficiaries without previous drug coverage. Value in Health2009;12:A170. ">Liu 2011</a>; <a href="./references#CD011703-bbs2-0037" title="MacleanJC , HalpernMT , HillSC , PeskoMF .The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications. Health Services Research2020;55:399-410. ">Maclean 2020</a>; <a href="./references#CD011703-bbs2-0041" title="NelsonRE , NelsonSL , HuttnerB , GundlapalliA .The effect of Medicare Part D on health care utilization for non-elderly Medicare recipients with disabilities. Disability and Health Journal2014;7:64-9. ">Nelson 2014</a>; <a href="./references#CD011703-bbs2-0044" title="ParkT , JungJ .The effect of Medicare Part D on prescription drug spending and health care use: 6 years of follow-up, 2007-2012. Journal of Managed Care &amp; Specialty Pharmacy2017;23(1):5-12. ">Park 2017</a>; <a href="./references#CD011703-bbs2-0052" title="YinW , BasuA , ZhangJX , RabbaniA , MeltzerDO , AlexanderGC .The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Annals of Internal Medicine2008;148(3):169-77. ">Yin 2008</a>; <a href="./references#CD011703-bbs2-0055" title="ZhangY , LeeBY , DonohueJM .Ambulatory antibiotic use and prescription drug coverage in older adults. Archives of Internal Medicine2010;170(15):1308-14. ">Zhang 2010a</a>; <a href="./references#CD011703-bbs2-0057" title="ZhangY , DonohueJM , LaveJR , GelladWF .The impact of Medicare Part D on medication treatment of hypertension. Health Services Research2011;46(1):185-98. ">Zhang 2011</a>; <a href="./references#CD011703-bbs2-0058" title="ZimmerD .The effect of Medicare Part D on prescription drug composition and demand. Journal of Economic Studies2015;42(2):170-85. ">Zimmer 2015</a>) (59 effect estimates) reported absolute and/or relative changes in levels of drug use one year or more (up to 24 months) after the introduction of the policy (Medicare Part D and ACA Medicaid expansion). All of these studies, except one (<a href="./references#CD011703-bbs2-0037" title="MacleanJC , HalpernMT , HillSC , PeskoMF .The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications. Health Services Research2020;55:399-410. ">Maclean 2020</a>), presented effect estimates for Medicare Part D. They showed that the policies may increase drug use up to 24 months after the implementation of the policy (median relative effect adjusted by baseline differences 14.73%, IQR 3.11% to 36.0%; low‐certainty evidence). When the only effect estimate not related to Medicare Part D (from <a href="./references#CD011703-bbs2-0037" title="MacleanJC , HalpernMT , HillSC , PeskoMF .The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications. Health Services Research2020;55:399-410. ">Maclean 2020</a>) was removed from the analysis, there was no change in the direction or size of the effect (median relative effect adjusted by baseline differences 14.84%, IQR 4.0% to 38.0%; low‐certainty evidence). Likewise, when effect estimates related to the use of benzodiazepines, a group of drugs not covered by Medicare Part D, were not included in the analysis, the studies showed that these polies may increase drug use by a median relative effect (adjusted for baseline differences) of 17.51% (IQR 4.67% to 38.46%; 56 effect estimates; low‐certainty evidence).  </p> </section> </section> <section id="CD011703-sec-0074"> <h5 class="title">Drug expenditure</h5> <p>Drug expenditures were assessed in 23 studies. We were not able to re‐analyse two of the studies because the study authors did not present raw absolute data (for instance, they reported share of the out‐of‐pocket medication costs as a proportion of the total medication costs without presenting the total amount of medication costs) (<a href="./references#CD011703-bbs2-0008" title="BriesacherBA , SoumeraiSB , FieldTS , FouayziH , GurwitzJH .Nursing home residents and enrollment in Medicare Part D. Journal of the American Geriatrics Society2009;57(10):1902-7. ">Briesacher 2009</a>); or because they only presented before‐and‐after data for drug expenditures without any data from a comparison group (<a href="./references#CD011703-bbs2-0014" title="ChenH , NwangwuA , AparasuR , EssienE , SunS , LeeK .The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatric Services2008;59(10):1191-7. ">Chen 2008</a>). Of the 21 studies with analysable data, we analysed eight as interrupted time‐series studies, one as a CITS study and 12 as controlled before‐after studies. We presented detailed results for immediate, short‐ and long‐term absolute and relative changes for each study in <a href="./appendices#CD011703-sec-0100">Appendix 4</a>. Seventy‐one out of the 81 effect estimates analysed in those studies were expenditures made by the patient/healthcare user only (OOP medication costs). The remaining 10 effect estimates were for total drug expenditures. </p> <section id="CD011703-sec-0075"> <h6 class="title">Immediate post‐policy implementation</h6> <p>Four ITS studies (15 effect estimates) reported absolute and/or relative changes in drug expenditures up to four months after the introduction of the drug insurance policy (<a href="./references#CD011703-bbs2-0025" title="FarleyJF , DusetzinaSB .Medicaid prescription drug utilization and expenditures following Part D. Journal of Health Care for the Poor and Underserved2010;21(2):715-28. ">Farley 2010</a>; <a href="./references#CD011703-bbs2-0046" title="PolinskiJM , BrookhartMA , GlynnRJ , SchneeweissS .Comparison between aggregate- and individual-level time-trend analyses to evaluate overall effects of Medicare Part D on use of antipsychotic medications. Pharmacoepidemiology and Drug Safety2011;20:S107. PolinskiJM , BrookhartMA , GlynnRJ , SchneeweissS .Medicare Part D’s impact on antipsychotic drug use and costs among elderly patients without prior drug insurance. Journal of Clinical Psychopharmacology2012;32(1):3-10. ">Polinski 2012</a>; <a href="./references#CD011703-bbs2-0048" title="SchneeweissS , PatrickAR , PedanA , VarastehL , LevinR , LiuN , et al.The effect Of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Affairs2009;28(2):w305-w316. ">Schneeweiss 2009</a>; <a href="./references#CD011703-bbs2-0049" title="ShrankWH , PatrickAR , PedanA , PolinskiJM , VarastehL , LevinR , et al.The effect of transitioning to Medicare Part D drug coverage in seniors dually eligible for Medicare and Medicaid. Journal of the American Geriatrics Society2008;56(12):2304-10. ">Shrank 2008</a>). One study (one effect estimate) reported total expenditures (<a href="./references#CD011703-bbs2-0025" title="FarleyJF , DusetzinaSB .Medicaid prescription drug utilization and expenditures following Part D. Journal of Health Care for the Poor and Underserved2010;21(2):715-28. ">Farley 2010</a>); and the other three studies (14 effect estimates) reported OOP expenditures. Overall, these studies showed that the drug insurance policy (Medicare Part D) may decrease drug expenditures immediately after the implementation of the policy (median relative effect adjusted by baseline differences −59.07%, IQR −66.33% to −26.27%; low‐certainty evidence). When only effect estimates reporting OOP expenditures were included in the analysis, the effects on drug expenditure were similar to the main analysis (median relative effect adjusted by baseline differences −59.32%, IQR −66.33% to −26.27%). </p> </section> <section id="CD011703-sec-0076"> <h6 class="title">Six months post‐policy implementation</h6> <p>Seven ITS studies (19 effect estimates) reported absolute and/or relative changes in drug expenditures six months after the introduction of the drug insurance policy (<a href="./references#CD011703-bbs2-0006" title="BasuA , YinW , AlexanderGC .Impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Services Research2010;45(1):133-51. BasuA , YinW , AlexanderGC .The impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Value in Health2009;12(3):A83. KaestnerR , ShimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):595-628. ">Basu 2010</a>; <a href="./references#CD011703-bbs2-0025" title="FarleyJF , DusetzinaSB .Medicaid prescription drug utilization and expenditures following Part D. Journal of Health Care for the Poor and Underserved2010;21(2):715-28. ">Farley 2010</a>; <a href="./references#CD011703-bbs2-0031" title="Ketcham JD, SimonK .Medicare Part D's effects on elderly drug costs and utilization. National Bureau of Economic Research Working Paper 14326, September 2008 (www.nber.org/papers/w14326) (accessed 28 January 2022). KetchamJD , SimonKI .Medicare Part D’s effects on elderly patients’ drug costs and utilization. American Journal of Managed Care2008;14(11 Spec No.):SP14-SP22. ">Ketcham 2008</a>; <a href="./references#CD011703-bbs2-0034" title="LichtenbergFR , SunSX .The Impact of Medicare Part D on Prescription Drug Use by the Elderly. Cheltenham (UK) and Northampton (Mass): Elgar Research Collection. International Library of Critical Writings in Economics, vol. 284, 2013. LichtenbergFR , SunSX .The impact of Medicare Part D on prescription drug use by the elderly. Health Affairs2007;26(6):1735-44. ">Lichtenberg 2007</a>; <a href="./references#CD011703-bbs2-0046" title="PolinskiJM , BrookhartMA , GlynnRJ , SchneeweissS .Comparison between aggregate- and individual-level time-trend analyses to evaluate overall effects of Medicare Part D on use of antipsychotic medications. Pharmacoepidemiology and Drug Safety2011;20:S107. PolinskiJM , BrookhartMA , GlynnRJ , SchneeweissS .Medicare Part D’s impact on antipsychotic drug use and costs among elderly patients without prior drug insurance. Journal of Clinical Psychopharmacology2012;32(1):3-10. ">Polinski 2012</a>; <a href="./references#CD011703-bbs2-0048" title="SchneeweissS , PatrickAR , PedanA , VarastehL , LevinR , LiuN , et al.The effect Of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Affairs2009;28(2):w305-w316. ">Schneeweiss 2009</a>; <a href="./references#CD011703-bbs2-0049" title="ShrankWH , PatrickAR , PedanA , PolinskiJM , VarastehL , LevinR , et al.The effect of transitioning to Medicare Part D drug coverage in seniors dually eligible for Medicare and Medicaid. Journal of the American Geriatrics Society2008;56(12):2304-10. ">Shrank 2008</a>). One study (one effect estimate) reported only total expenditures (<a href="./references#CD011703-bbs2-0025" title="FarleyJF , DusetzinaSB .Medicaid prescription drug utilization and expenditures following Part D. Journal of Health Care for the Poor and Underserved2010;21(2):715-28. ">Farley 2010</a>); one study (two effect estimates) reported both total and OOP expenditures (<a href="./references#CD011703-bbs2-0006" title="BasuA , YinW , AlexanderGC .Impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Services Research2010;45(1):133-51. BasuA , YinW , AlexanderGC .The impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Value in Health2009;12(3):A83. KaestnerR , ShimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):595-628. ">Basu 2010</a>); and the other five studies (16 effect estimates) reported only OOP expenditures. Overall, these studies showed that the drug insurance policy (Medicare Part D) may decrease drug expenditures six months after the implementation of the policy (median relative effect adjusted by baseline differences −46.96%, IQR −65.98% to −22.84%; low‐certainty evidence). When only effect estimates reporting OOP expenditures were included in the analysis, the effects on drug expenditure were similar to the main analysis (median relative effect adjusted by baseline differences −50.22%, IQR −65.98% to −27.84%). </p> </section> <section id="CD011703-sec-0077"> <h6 class="title">Twelve months or more after policy implementation</h6> <p>Eight ITS studies, one CITS study and 12 CBA studies (48 effect estimates) reported absolute and/or relative changes in drug expenditure one year or more (up to 36 months) after the introduction of the drug insurance policy (Medicare Part D). One study (one effect estimate) reported only total expenditures (<a href="./references#CD011703-bbs2-0025" title="FarleyJF , DusetzinaSB .Medicaid prescription drug utilization and expenditures following Part D. Journal of Health Care for the Poor and Underserved2010;21(2):715-28. ">Farley 2010</a>); one study (two effect estimates) reported both total and OOP expenditures (<a href="./references#CD011703-bbs2-0006" title="BasuA , YinW , AlexanderGC .Impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Services Research2010;45(1):133-51. BasuA , YinW , AlexanderGC .The impact of medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Value in Health2009;12(3):A83. KaestnerR , ShimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):595-628. ">Basu 2010</a>). All the other studies (36 effect estimates) reported only OOP expenditures. Overall, these studies showed that the drug insurance policy may decrease drug expenditures up to 36 months after their implementation (median relative effect adjusted by baseline differences −43.17%, IQR −57.40% to −19.77%; low‐certainty evidence). When only effect estimates reporting OOP expenditures were included in the analysis, the effects on drug expenditure were similar to the main analysis (median relative effect adjusted by baseline differences −45.87%, IQR −61.36% to −22.08%). </p> </section> </section> <section id="CD011703-sec-0078"> <h5 class="title">Health care utilisation</h5> <p>See <a href="./appendices#CD011703-sec-0107">Appendix 5</a>. </p> <p>Healthcare utilisation outcomes such as emergency department (ED) visits (<a href="./references#CD011703-bbs2-0005" title="AyyagariP , ShaneDM , WehbyGL .The Impact of Medicare Part D on Emergency Department visits. Health Economics2017;26(4):536-44. ">Ayyagari 2017</a>; <a href="./references#CD011703-bbs2-0010" title="BriesacherBA , MaddenJM , ZhangF , FouayziH , Ross-DegnanD , GurwitzJH , et al.Did Medicare Part D affect national trends in health outcomes or hospitalizations?: a time-series analysis. Annals of Internal Medicine2015;162(12):825-33. ">Briesacher 2015</a>; <a href="./references#CD011703-bbs2-0011" title="BurnsM , BuschA , MaddenJ , LeCatesRF , ZhangF , AdamsA , et al.The effect of Medicare Part D on guideline-concordant pharmacotherapy for bipolar I disorder among dually enrolled beneficiaries. Psychiatric Services2014;65(3):323-9. ">Burns 2014</a>; <a href="./references#CD011703-bbs2-0032" title="KircherSM , JohansenM , RichardsonC , DavisMM .Impact of Medicare Part D on out-of-pocket pharmaceutical costs for patients with cancer. Journal of Clinical Oncology2013;31(Nº 15 Suppl):6517. KircherSM , JohansenME , NimeiriHS , RichardsonCR , DavisMM .Impact of Medicare Part D on out-of-pocket drug costs and medical use for patients with cancer. Cancer2014;120(21):3378-84. ">Kircher 2014</a>; <a href="./references#CD011703-bbs2-0036" title="LiuFX , AlexanderGC , CrawfordSY , PickardAS , HedekerD , WaltonSM .The impact of Medicare Part D on health care utilization and health of the Medicare beneficiaries. Value in Health2010;13:A7. LiuFX , AlexanderGC , CrawfordSY , PickardAS , HedekerD , WaltonSM .The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility. Health Services Research2011;46(4):1104-23. LiuFX , WaltonSM , CrawfordSY , PickardAS .The impact of Medicare Part D on health care utilization and health outcomes for Medicare beneficiaries without previous drug coverage. Value in Health2009;12:A170. ">Liu 2011</a>; <a href="./references#CD011703-bbs2-0041" title="NelsonRE , NelsonSL , HuttnerB , GundlapalliA .The effect of Medicare Part D on health care utilization for non-elderly Medicare recipients with disabilities. Disability and Health Journal2014;7:64-9. ">Nelson 2014</a>), hospital admissions (<a href="./references#CD011703-bbs2-0002" title="AfendilusCC , HeY , ZaslavskyAM , ChernewME .The impact of Medicare Part D on hospitalization rates. Health Services Research2011;46(4):1022-38. ">Afendilus 2011</a>; <a href="./references#CD011703-bbs2-0007" title="BelenkyN , PenceBW , ColeSR , DusetzinaSB , EdmondsA , OberlanderJ , et al.Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV. AIDS Care2019;31(4):505-12. ">Belenky 2019</a>; <a href="./references#CD011703-bbs2-0010" title="BriesacherBA , MaddenJM , ZhangF , FouayziH , Ross-DegnanD , GurwitzJH , et al.Did Medicare Part D affect national trends in health outcomes or hospitalizations?: a time-series analysis. Annals of Internal Medicine2015;162(12):825-33. ">Briesacher 2015</a>; <a href="./references#CD011703-bbs2-0030" title="Kaestner R, SchimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):525-628. KaestnerR , LongC , AlexanderCG .Effect of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. National Bureau of Economic Research Working Paper 19948, February 2014 (www.nber.org/papers/w19948) (accessed 28 January 2022). ">Kaestner 2014</a>; <a href="./references#CD011703-bbs2-0032" title="KircherSM , JohansenM , RichardsonC , DavisMM .Impact of Medicare Part D on out-of-pocket pharmaceutical costs for patients with cancer. Journal of Clinical Oncology2013;31(Nº 15 Suppl):6517. KircherSM , JohansenME , NimeiriHS , RichardsonCR , DavisMM .Impact of Medicare Part D on out-of-pocket drug costs and medical use for patients with cancer. Cancer2014;120(21):3378-84. ">Kircher 2014</a>; <a href="./references#CD011703-bbs2-0036" title="LiuFX , AlexanderGC , CrawfordSY , PickardAS , HedekerD , WaltonSM .The impact of Medicare Part D on health care utilization and health of the Medicare beneficiaries. Value in Health2010;13:A7. LiuFX , AlexanderGC , CrawfordSY , PickardAS , HedekerD , WaltonSM .The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility. Health Services Research2011;46(4):1104-23. LiuFX , WaltonSM , CrawfordSY , PickardAS .The impact of Medicare Part D on health care utilization and health outcomes for Medicare beneficiaries without previous drug coverage. Value in Health2009;12:A170. ">Liu 2011</a>; <a href="./references#CD011703-bbs2-0041" title="NelsonRE , NelsonSL , HuttnerB , GundlapalliA .The effect of Medicare Part D on health care utilization for non-elderly Medicare recipients with disabilities. Disability and Health Journal2014;7:64-9. ">Nelson 2014</a>), or number of outpatient physician visits (<a href="./references#CD011703-bbs2-0032" title="KircherSM , JohansenM , RichardsonC , DavisMM .Impact of Medicare Part D on out-of-pocket pharmaceutical costs for patients with cancer. Journal of Clinical Oncology2013;31(Nº 15 Suppl):6517. KircherSM , JohansenME , NimeiriHS , RichardsonCR , DavisMM .Impact of Medicare Part D on out-of-pocket drug costs and medical use for patients with cancer. Cancer2014;120(21):3378-84. ">Kircher 2014</a>; <a href="./references#CD011703-bbs2-0041" title="NelsonRE , NelsonSL , HuttnerB , GundlapalliA .The effect of Medicare Part D on health care utilization for non-elderly Medicare recipients with disabilities. Disability and Health Journal2014;7:64-9. ">Nelson 2014</a>; <a href="./references#CD011703-bbs2-0044" title="ParkT , JungJ .The effect of Medicare Part D on prescription drug spending and health care use: 6 years of follow-up, 2007-2012. Journal of Managed Care &amp; Specialty Pharmacy2017;23(1):5-12. ">Park 2017</a>) were reported in two interrupted time‐series studies, one CITS study and nine CBA studies. For this group of outcomes, we also considered studies assessing non‐drug medical spending as a proxy for healthcare utilisation, including spending on a number of health services such as inpatient and skilled nursing services, physician and ancillary services  (<a href="./references#CD011703-bbs2-0030" title="Kaestner R, SchimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):525-628. KaestnerR , LongC , AlexanderCG .Effect of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. National Bureau of Economic Research Working Paper 19948, February 2014 (www.nber.org/papers/w19948) (accessed 28 January 2022). ">Kaestner 2014</a>; <a href="./references#CD011703-bbs2-0039" title="McWilliamsJM , ZaslavskyAM , HuskampHA .Effects of medicare prescription drug coverage on non-drug medical spending. Journal of General Internal Medicine2011;26(1 Suppl):S157. McWilliamsJM , ZaslavskyAM , HuskampHA .Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage. JAMA2011;306(4):402-9. ">McWilliams 2011</a>; <a href="./references#CD011703-bbs2-0054" title="ZhangY , DonohueJM , LaveJR , O’DonnellG , NewhouseJP .The effect of Medicare Part D on drug and medical spending. New England Journal of Medicine2009;361(1):52. ">Zhang 2009</a>).  </p> <p>Six studies (two ITS and four CBAs) reported absolute and/or relative changes in ED visits after the introduction of the drug insurance policy (Medicare Part D). Overall, these studies showed that the drug insurance policy may lead to a small increase in the number or frequency of ED visits by beneficiaries of the drug insurance scheme (median relative effect adjusted by baseline differences 9.74%, IQR  3.29% to 18.64%; low‐certainty evidence).  </p> <p>Seven studies (one ITS and six CBAs) reported absolute and/or relative changes in hospital admissions after the introduction of the drug insurance policy (Medicare Part D). Overall, the effect of this policy on hospital admissions is uncertain because the certainty of the evidence is very low. </p> <p>Three CBA studies reported absolute and/or relative changes in the number of outpatient physician visits after the introduction of the drug insurance policy (Medicare Part D). Overall, it is uncertain if the policy increases or reduces outpatient physician visits because the certainty of the evidence is very low. </p> <p>Three studies (one CITS and two CBA studies) reported absolute and/or relative changes in non‐drug medical spending after the introduction of the drug insurance policy (Medicare Part D). Overall, it is uncertain if the policy increases or decreases non‐drug medical spending because the certainty of the evidence is very low. </p> </section> <section id="CD011703-sec-0079"> <h5 class="title">Health Outcomes</h5> <p>See <a href="./appendices#CD011703-sec-0116">Appendix 6</a>. </p> <p>Health outcomes such as mortality,  impairment in activities of daily living, self‐rated health status, likelihood of engaging in physical activity, or depressive symptoms were reported in one ITS study (<a href="./references#CD011703-bbs2-0010" title="BriesacherBA , MaddenJM , ZhangF , FouayziH , Ross-DegnanD , GurwitzJH , et al.Did Medicare Part D affect national trends in health outcomes or hospitalizations?: a time-series analysis. Annals of Internal Medicine2015;162(12):825-33. ">Briesacher 2015</a>) and six CBA studies (<a href="./references#CD011703-bbs2-0003" title="AsfawAA .The effect of prescription drug insurance on health behavior: evidence from Medicare Part D. Health Economics2019;28(3):403-18. ">Asfaw 2019</a>; <a href="./references#CD011703-bbs2-0004" title="AyyagariP , ShaneDM .Does prescription drug coverage improve mental health? Evidence from Medicare Part D. Journal of Health Economics2015;41:46-58. ">Ayyagari 2015</a>; <a href="./references#CD011703-bbs2-0007" title="BelenkyN , PenceBW , ColeSR , DusetzinaSB , EdmondsA , OberlanderJ , et al.Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV. AIDS Care2019;31(4):505-12. ">Belenky 2019</a>; <a href="./references#CD011703-bbs2-0014" title="ChenH , NwangwuA , AparasuR , EssienE , SunS , LeeK .The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatric Services2008;59(10):1191-7. ">Chen 2008</a>; <a href="./references#CD011703-bbs2-0017" title="DieboldJ .The effects of Medicare Part D on health outcomes of newly covered Medicare beneficiaries. Journal of Gerontology, Series B: Psychological Sciences &amp; Social Sciences2016;6:6. DieboldJ .The effects of Medicare Part D on health outcomes of newly covered Medicare beneficiaries. Journal of Gerontology, Series B: Psychological Sciences &amp; Social Sciences2018;73(5):890-900. ">Diebold 2018</a>; <a href="./references#CD011703-bbs2-0043" title="PakT , KimG .The impact of Medicare Part D on cognitive functioning at older ages. Social Science &amp; Medicine2017;193:118-26. ">Pak 2017</a>). Three studies (<a href="./references#CD011703-bbs2-0010" title="BriesacherBA , MaddenJM , ZhangF , FouayziH , Ross-DegnanD , GurwitzJH , et al.Did Medicare Part D affect national trends in health outcomes or hospitalizations?: a time-series analysis. Annals of Internal Medicine2015;162(12):825-33. ">Briesacher 2015</a>; <a href="./references#CD011703-bbs2-0027" title="HuhJ , ReifJ .Did Medicare Part D reduce mortality?Journal of Health Economics2017;53:17-37. ">Huh 2017</a>; <a href="./references#CD011703-bbs2-0030" title="Kaestner R, SchimanC , AlexanderGC .Effects of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. Journal of Risk and Insurance2019;86(3):525-628. KaestnerR , LongC , AlexanderCG .Effect of prescription drug insurance on hospitalization and mortality: evidence from Medicare Part D. National Bureau of Economic Research Working Paper 19948, February 2014 (www.nber.org/papers/w19948) (accessed 28 January 2022). ">Kaestner 2014</a>) reported absolute and/or relative changes in mortality. Overall, it is uncertain if the policy increases or reduces mortality because the certainty of the evidence is very low. Seven studies reported absolute and/or relative changes in non‐mortality health outcomes. However, because of the diversity of outcomes and the diversity of timing of outcomes assessment, it  was not possible to obtain a meaningful summary effect estimate for this group of outcomes; the individual results are presented in <a href="./appendices#CD011703-sec-0116">Appendix 6</a>. Overall, the effects include both small positive and negative impacts for these outcomes and the certainty of the evidence is very low. </p> <p> </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011703-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011703-sec-0080"></div> <section id="CD011703-sec-0081"> <h3 class="title" id="CD011703-sec-0081">Summary of main results</h3> <p>The introduction of a drug insurance scheme (such as Medicare Part D) may increase prescription drug use and may decrease drug expenditure (mostly OOP spending) in populations with no previous drug insurance coverage. Likewise, this type of drug insurance policy may lead to a small increase in the number or frequency of ED visits by beneficiaries of the scheme. It is uncertain whether this kind of policy increases or decreases other types of healthcare utilisation, or whether it has an effect on health outcomes, because the certainty of the evidence for these outcomes is very low. All the studies included in the quantitative analysis were conducted in the US and all but one assessed a single policy change (Medicare Part D). </p> </section> <section id="CD011703-sec-0082"> <h3 class="title" id="CD011703-sec-0082">Overall completeness and applicability of evidence</h3> <p>Almost all of the studies included in this review assessed a single policy implemented in the US healthcare system (Medicare Part D); we identified only one eligible study with analysable data assessing another intervention (<a href="./references#CD011703-bbs2-0037" title="MacleanJC , HalpernMT , HillSC , PeskoMF .The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications. Health Services Research2020;55:399-410. ">Maclean 2020</a>). However, this study only provided one effect estimate for drug use, and the median effect estimates for this outcome did not change based on whether we included this study or not. Additionally, we identified another three studies assessing other related policies in the US (<a href="./references#CD011703-bbs2-0021" title="DranoveD , OdyC , StarcA .A dose of managed care: controlling drug spending in Medicaid . National Bureau of Economic Research Working Paper Working Paper 23956, October 2017 (available in www.nber.org/papers/w23956) (accessed on 28 January 2022). ">Dranove 2017</a>) and Canada (<a href="./references#CD011703-bbs2-0012" title="CaetanoPA , RaymondCB , MorganS , YanL .Income-based drug coverage in British Columbia: the impact on access to medicines. Healthcare Policy2006;2(2):e154-e169. ">Caetano 2006</a>; <a href="./references#CD011703-bbs2-0050" title="TanDHS , DashwoodTM , WiltonJ , KrochA , GomesT , MartinsD .Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015–2018). Canadian Journal of Public Health2021;112:89-96. ">Tan 2021</a>), but none of these reported data that we were able to incorporate into our quantitative analysis. Our results, therefore, largely represented the effects of Medicare Part D in the US healthcare system. There are important differences in on‐the‐ground realities (such as the important role of the pharmaceutical industry and the high pharmaceutical expenditure in the US), in health systems arrangements (such as funding based mostly on private insurance with public funding only for the poor and the elderly), and in baseline conditions (such as the proportion of population already covered by private insurance) between US health system and other health systems (especially in low‐income countries). These differences make the findings of this review less likely to be transferable to other settings, particularly low‐income settings. However, considering the consistency of the findings regarding drug use and OOP expenditures across the included studies together with previous reviews (<a href="./references#CD011703-bbs2-0231" title="PimentelCB , LapaneKL , BriesacherBA .Medicare Part D and long-term care: a systematic review of quantitative and qualitative evidence. Drugs Aging2013;30:701-20.">Pimentel 2013</a>; <a href="./references#CD011703-bbs2-0232" title="PolinskiJM , KilabukE , SchneeweissS , BrennanT , ShrankWH .Changes in drug utilization and out-of-pocket costs associated with Medicare Part D implementation: a systematic review. Journal of the American Geriatrics Society2010;58(9):1764–79.">Polinski 2010</a>), we think that it is reasonable to expect similar effects in other countries where this type of pharmaceutical policy has not yet been implemented. </p> <p>Although the body of evidence included in this review seems to be a complete representation of what has been published about the impact of Medicare Part D, we acknowledge that there is a body of literature published about other drug insurance schemes such as PHARMAC in New Zealand or British Columbia Pharmacare in Canada (<a href="./references#CD011703-bbs2-0192" title="BraaeR , McNeeW , MooreD .Managing pharmaceutical expenditure while increasing access. The pharmaceutical management agency (PHARMAC) experience. Pharmacoeconomics1999;16(6):649-60.">Braae 1999</a>; <a href="./references#CD011703-bbs2-0198" title="DawJR , MorganSG .Stitching the gap in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes from 2000 to 2010. Health Policy2012;104(1):19-26.">Daw 2012</a>; <a href="./references#CD011703-bbs2-0221" title="MorganSG , DawJR .Canadian Pharmacare: looking back, looking forward. Healthcare Policy2012;8(1):14-23.">Morgan 2012</a>; <a href="./references#CD011703-bbs2-0222" title="MorganSG , MartinD , GagnonMA , MintzesB , DawJR , LechinJ .Pharmacare 2020: The Future of Drug Coverage in Canada. Vancouver: Pharmaceutical Policy Research Collaboration, University of British Columbia, 2015.">Morgan 2015</a>; <a href="./references#CD011703-bbs2-0223" title="MorganSG , GagnonMA , CharbonneauM , VadeboncoeurA .Evaluating the effects of Quebec’s private–public drug insurance system. Canadian Medical Association Journal2017;189(40):E1259-63.">Morgan 2017</a>). However, the evaluation studies that we identified of these policies included components beyond the scope of this review (such as changes in user fees [caps and co‐payments], stopping coverage or reimbursement [restriction on reimbursement], or reference pricing) or were assessed using methods not eligible for this review. </p> <p>Although we searched in September 2021 for articles citing the 58 included studies, the last full search for studies for this review was conducted in September 2020. It is therefore possible that some recently published studies are not included in our review, limiting the completeness of the evidence presented. However, given the large number of included studies in the current version of the review, we think it is unlikely that those recent studies would change substantively the review results. </p> <section id="CD011703-sec-0083"> <h4 class="title">Certainty of the evidence</h4> <p>The certainty of the evidence was low or very low for all the primary outcomes in this review.  For drug use and expenditures, the contributing studies have some methodological limitations (uncertainties about incomplete outcome data and the potential presence of other policies at the time when part D was implemented) and there were also concerns about unexplained inconsistency in the direction of effect in some of those studies. We were also uncertain whether this type of policy  leads to an increase or decrease in healthcare utilisation (apart from ED visits) or health outcomes, because the studies had important methodological limitations (most of the evidence was from CBA studies with some concerns about whether baseline characteristics and baselines outcome measurements were sufficiently similar between the intervention and comparison groups) and there was serious imprecision around the estimated median effect. </p> </section> </section> <section id="CD011703-sec-0084"> <h3 class="title" id="CD011703-sec-0084">Potential biases in the review process</h3> <p>Although we carried out a thorough search, a systematic assessment of the risk of bias of included studies and a detailed analysis and re‐analysis of data included in the studies, we have identified a number of potential biases in our review. </p> <p>First, despite a sensitive search strategy, most of the studies that we identified that fulfilled our inclusion criteria assessed a single and very specific policy: Medicare Part D. We do not know if this is because of the lack of research available evaluating other policies or because we were not able to identify those studies. Therefore, a search strategy focused on locating the 'hard to find' studies (for example, those published in policy or government reports) should be carried out for future updates of this review. </p> <p>Second, because of the way in which studies in this field are designed, it was not possible to ascertain if all the potential beneficiaries of Medicare Part D for which outcome data were collected were also officially enrolled in the policy. This could potentially lead to under‐ or over‐estimation of the effect of this policy.  </p> <p>Third, there were a number of studies using multiple comparison groups, such as different levels of drug insurance coverage previous to the implementation of the drug insurance scheme (<a href="./references#CD011703-bbs2-0019" title="DonohueJM , ZhangY , LaveJ , GelladWF , PereraS , MenA , et al.Impact of expanding pharmacy benefits on treatment of congestive heart failure: the case of Medicare Part D. Value in Health2009;12(7):A342. DonohueJM , ZhangY , LaveJR , GelladWF , MenA , PereraS , et al.The Medicare drug benefit (Part D) and treatment of heart failure in older adults. American Heart Journal2010;160(1):159-65. ">Donohue 2010</a>; <a href="./references#CD011703-bbs2-0020" title="DonohueJM , ZhangY , AijuM , PereraS , LaveJR , HanlonJT , et al.Impact of Medicare Part D on antidepressant treatment, medication choice, and adherence among older adults with depression. American Journal of Geriatric Psychiatry2011;19(12):989-97. ">Donohue 2011</a>; <a href="./references#CD011703-bbs2-0054" title="ZhangY , DonohueJM , LaveJR , O’DonnellG , NewhouseJP .The effect of Medicare Part D on drug and medical spending. New England Journal of Medicine2009;361(1):52. ">Zhang 2009</a>; <a href="./references#CD011703-bbs2-0055" title="ZhangY , LeeBY , DonohueJM .Ambulatory antibiotic use and prescription drug coverage in older adults. Archives of Internal Medicine2010;170(15):1308-14. ">Zhang 2010a</a>; <a href="./references#CD011703-bbs2-0056" title="ZhangY , LaveJR , NewhouseJP , DonohueJM .How the Medicare Part D drug benefit changed the distribution of out-of-pocket pharmacy spending among older beneficiaries. Journals of Gerontology. Series B, Psychological Sciences and Social Sciences2010;65(4):502-7. ">Zhang 2010b</a>; <a href="./references#CD011703-bbs2-0057" title="ZhangY , DonohueJM , LaveJR , GelladWF .The impact of Medicare Part D on medication treatment of hypertension. Health Services Research2011;46(1):185-98. ">Zhang 2011</a>). Because the focus of this review was on assessing the impact of alternative policies for regulating drug insurance schemes, we only considered comparisons between those with clearly different types of insurance coverage. In the case of studies assessing Medicare Part D, we only considered the comparisons between those with no previous coverage (likely to move to the scheme) and those with previous generous coverage (unlikely to move to the scheme) because the focus of the review was on assessing the impact of policies on those moving to the specific drug insurance scheme. Both of these issues could potentially introduce bias because of the selection of specific comparisons that could show substantially different effect estimates from other comparisons. </p> </section> <section id="CD011703-sec-0085"> <h3 class="title" id="CD011703-sec-0085">Agreements and disagreements with other studies or reviews</h3> <p>An earlier systematic review of the effects of Medicare Part D implementation in the USA found a 6% to 13% increase in drug utilisation and 13% to 18% decrease in patients’ costs, based on interrupted time‐series and cross‐sectional studies (<a href="./references#CD011703-bbs2-0232" title="PolinskiJM , KilabukE , SchneeweissS , BrennanT , ShrankWH .Changes in drug utilization and out-of-pocket costs associated with Medicare Part D implementation: a systematic review. Journal of the American Geriatrics Society2010;58(9):1764–79.">Polinski 2010</a>). Although this review only searched a single electronic database (Medline) from 2006 to 2009 in the early stages of implementation of this policy, the findings are consistent with those of our review. Another systematic review by <a href="./references#CD011703-bbs2-0206" title="FadenL , Vialle-ValentinC , Ross-DegnanD , WagnerA .Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: a systematic review of current evidence. Health Policy2011;100(2-3):134-43.">Faden 2011</a> revealed that drug insurance may increase access to medicines and reduce self‐medication, and provided conflicting evidence about the effect on medication spending. It is, however, difficult to compare this review with our findings because its scope was broader including studies assessing the effect of which medicines were procured or supplied, which medical services were provided, and the implementation of programmes to improve drug prescribing and use. </p> <p>Although a number of countries, such as Canada, the Netherlands, Switzerland and Russia, have been discussing different alternatives for implementing drug insurance schemes in their health systems, we were not able to locate any specific study or review allowing a reliable comparison of our results with results from other systems, countries, or both. This was because, in the reports describing those cases, the methods used were not clear or were based mainly on expert opinion from consultants (<a href="./references#CD011703-bbs2-0198" title="DawJR , MorganSG .Stitching the gap in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes from 2000 to 2010. Health Policy2012;104(1):19-26.">Daw 2012</a>; <a href="./references#CD011703-bbs2-0205" title="EsmailN , BaruaB .Drug coverage for low-income families. www.fraserinstitute.org/sites/default/files/drug-coverage-for-low-income-families-rev.pdf (accessed prior to 10 Jan 2022).">Esmail 2015</a>; <a href="./references#CD011703-bbs2-0213" title="HongP , ThomasM , KanjiA .Russia's national drug insurance: healthy society, healthy economy. www.es.kearney.com/health/article?/a/russia-s-national-drug-insurance-healthy-society-healthy-economy (accessed prior to 10 Jan 2022).">Hong 2012</a>; <a href="./references#CD011703-bbs2-0223" title="MorganSG , GagnonMA , CharbonneauM , VadeboncoeurA .Evaluating the effects of Quebec’s private–public drug insurance system. Canadian Medical Association Journal2017;189(40):E1259-63.">Morgan 2017</a>; <a href="./references#CD011703-bbs2-0236" title="RovereM , BaruaB .Opportunity for health reform: lessons from Switzerland. Fraser Forum (www.fraserinstitute.org/research/fraser-forum-julyaugust-2012-mandatory-country-origin) (accessed prior to 28 March 2022);(July/August):24-7.">Rovere 2012a</a>; <a href="./references#CD011703-bbs2-0237" title="RovereM , BaruaB .Opportunity for health reform: lessons from the Netherlands. Fraser Forum (www.fraserinstitute.org/research/fraser-forum-septemberoctober-2012-mining-policy-canada-and-world) (accessed prior to 28 March 2022);(September/October):25-9.">Rovere 2012b</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011703-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/urn:x-wiley:14651858:media:CD011703:CD011703-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram" data-id="CD011703-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_t/tCD011703-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011703-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/urn:x-wiley:14651858:media:CD011703:CD011703-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Included studies by design type" data-id="CD011703-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_t/tCD011703-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Included studies by design type</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011703-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/urn:x-wiley:14651858:media:CD011703:CD011703-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph for CBA studies: review authors' judgements about each risk of bias item presented as percentages across all included CBA studies" data-id="CD011703-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_t/tCD011703-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph for CBA studies: review authors' judgements about each risk of bias item presented as percentages across all included CBA studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011703-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/urn:x-wiley:14651858:media:CD011703:CD011703-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary for CBA studies: review authors' judgements about each risk of bias item for each included CBA study" data-id="CD011703-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_t/tCD011703-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary for CBA studies: review authors' judgements about each risk of bias item for each included CBA study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011703-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/urn:x-wiley:14651858:media:CD011703:CD011703-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph for ITS/CITS studies: review authors' judgements about each risk of bias item presented as percentages across all included ITS/CITS studies" data-id="CD011703-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_t/tCD011703-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Risk of bias graph for ITS/CITS studies: review authors' judgements about each risk of bias item presented as percentages across all included ITS/CITS studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011703-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/urn:x-wiley:14651858:media:CD011703:CD011703-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary for ITS/CITS studies: review authors' judgements about each risk of bias item for each included ITS and CITS study" data-id="CD011703-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_t/tCD011703-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Risk of bias summary for ITS/CITS studies: review authors' judgements about each risk of bias item for each included ITS and CITS study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/media/CDSR/CD011703/image_n/nCD011703-FIG-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011703-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Enrolment in the drug insurance scheme compared to no enrolment in the scheme</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population: People entitled to the drug insurance scheme (elderly and/or poor population)</b> </p> <p><b>Settings: United States healthcare system</b> </p> <p><b>Intervention: Drug insurance scheme (Medicare Part D or ACA Medicaid expansion) </b> </p> <p><b>Comparison: No enrolment, non‐eligible for enrolment or low likelihood of enrolment into the drug insurance scheme</b> </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Median adjusted<sup>1</sup> relative effect<br/>(IQR)</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of<br/>studies (Nº effect estimates)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Drug use</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Immediately after policy implementation<br/>+3.74% </p> <p>(−9.40% to 22.98%)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 ITS studies<br/>(32 effect estimates) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>2</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Drug insurance policies (such as Medicare Part D) may increase drug use immediately after until up to 12 months after the implementation of the policy. However, the range indicates that the policy may slightly decrease or may increase drug use. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 to 11 months after policy implementation<br/>+8.40% </p> <p>(‐2.88% to 25.19%)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 ITS studies, 1 CBA study<br/>(25 effect estimates) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 year or more after policy implementation<br/>+14.73% (3.11% to 36.0%) </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 CITS study, 10 ITS and 19 CBA studies<br/>(59 effect estimates) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug insurance policies (such as Medicare Part D) may increase drug use from 1 year until up to 60 months after the implementation of the policy.  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Drug expenditure</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Immediately after policy implementation</p> <p>−59.07%</p> <p>(−66.33% to −26.27%)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 ITS studies<br/>(15 effect estimates) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Drug insurance policies (such as Medicare Part D) may decrease drug expenditures immediately and for up to 36 months after the implementation of the policy. </p> <p> </p> <p>When only out‐of‐pocket expenditures were considered (14, 18 and 39 effect estimates, respectively), there was no change in either the magnitude or variability of the summary effect estimates for any of the 3 outcome time points. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 to 11 months after policy implementation</p> <p>−46.96%</p> <p>(−65.98% to −22.98%)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 ITS studies<br/>(19 effect estimates) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>4</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 year or more after policy implementation</p> <p>−43.17%</p> <p>(−57.40% to −19.77%)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 CITS study, 8 ITS studies<br/>and 12 CBA studies (48 effect estimates) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>3</sup> </b> </p> <p> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="4" scope="col" valign="top"> <p><b>Healthcare</b> utilis<b>ation</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Emergency Department visits</p> <p>+9.74%</p> <p>(3.29% to 18.64%)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 ITS studies and 4 CBA studies<br/>(14 effect estimates) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug insurance policies (such as Medicare Part D) may lead to a small increase in  the number or frequency of Emergency Department visits by beneficiaries of the drug insurance scheme. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Hospital admissions</p> <p>‐2.65% (‐9.35% to 0.33%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 ITS study and 6 CBA studies </p> <p>(8 effect estimates)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>The effects of drug insurance policies (such as Medicare Part D) on hospital admissions, outpatient visits and non‐drug medical spending were uncertain because the certainty of the evidence was very low. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Outpatient visits</p> <p>‐28.6%</p> <p>(−69.25% to 22.7%)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> 3 CBA studies<br/>(3 effect estimates) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>7</sup> </b> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Non‐drug medical spending</p> <p>‐11.4% </p> <p>(‐11.5% to ‐8.37%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 CITS and 2 CBA studies </p> <p>(3 effect estimates)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>8</sup> </b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Health outcomes</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> <p> ‐0.50% </p> <p>(‐1.35% to ‐0.35%)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 ITS and 2 CBA studies </p> <p>(3 effect estimates)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>9</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effects of drug insurance policies (such as Medicare Part D) on mortality were uncertain because the certainty of the evidence was very low. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Non‐mortality outcomes: depressive symptoms, activities of daily living  (ADL) limitations, change in specific behaviours, self‐perception of health: the effects included both small positive and negative impacts for these outcomes. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 ITS and 6 CBA studies </p> <p>(17 effect estimates)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>10</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effects of drug insurance policies (such as Medicare Part D) on non‐mortality outcomes were uncertain because the certainty of the evidence was very low. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/>  </p> <p><b>High certainty</b> = This research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different** is low. </p> <p><b>Moderate</b> <b>certainty</b> = This research provides a good indication of the likely effect. The likelihood that the effect will be substantially different** is moderate. </p> <p><b>Low</b> <b>certainty</b> = This research provides some indication of the likely effect. However, the likelihood that it will be substantially different** is high. </p> <p><b>Very low</b> <b>certainty</b> = This research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different** is very high. </p> <p>** Substantially different = a large enough difference that it might affect a decision</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup> Adjusted for baseline differences </p> <p><sup>2</sup> For these outcomes, because most of the body of evidence came from ITS studies, we started at a moderate grade and downgraded by 1 level because of methodological limitations (uncertainties about incomplete outcome data and the potential presence of other policies at the time when part D was implemented) and some concerns about unexplained inconsistency in the direction of effect. </p> <p><sup>3</sup> CBA studies started at a low‐certainty grade due to concerns about methodological limitations. There were no additional concerns. </p> <p><sup>4</sup> For these outcomes, because most of the body of evidence came from ITS studies, we started at a moderate grade and downgraded by 1 level because of methodological limitations (uncertainties about incomplete outcome data and the potential presence of other policies at the time when Part D was implemented).  </p> <p><sup>5</sup> Starting at a low grade (as most of the contributing evidence came from CBA studies), we did not have any additional concerns. </p> <p><sup>6</sup> Starting at a low grade (as most of the  contributing evidence came from CBA studies), we downgraded by 1 level because of some concerns about methodological limitations and some concerns about unexplained inconsistency in the direction of effect. </p> <p><sup>7</sup> Starting at a low grade (as all of the contributing evidence came from CBA studies), we downgraded by 1 level because of some concerns about unexplained inconsistency in the direction of effect and some imprecision. </p> <p><sup>8</sup> Starting at a low grade (as most of the contributing evidence came from CBA studies), we downgraded by 1 level because of concerns about indirectness. </p> <p><sup>9</sup> Starting at a low grade (as most of the contributing evidence came from CBA studies), we downgraded by 1 level because of concerns about imprecision. </p> <p><sup>10</sup> Starting at a low grade (as most of the contributing evidence cane from CBA studies), we downgraded by 1 level because of concerns about imprecision. </p> <p>CBA = Controlled before‐after study<br/>ITS = Interrupted time‐series study </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011703-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Ways in which different policies regarding who provides drug insurance might affect outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Universal coverage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Equitable access</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Catastrophic payments</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cost containment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Availability of essential drugs</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Public drug insurance</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Governments might have incentives to provide universal coverage.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Governments might have incentives to provide equitable access.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Governments might have incentives to protect people from catastrophic payments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Public drug insurance might raise public (government) expenditures.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA*</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Private for‐profit drug insurance</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The key incentive of for‐profit insurance schemes is profit generation. For‐profit schemes might not have incentives to provide universal coverage and are unlikely to provide universal coverage unless subsidised or mandated by the government. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For‐profit schemes might not have incentives to provide equitable access.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For‐profit schemes might not have incentives to provide protection against catastrophic payments. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For‐profit schemes might be motivated to decrease their own costs. However, this might shift costs from the scheme to the insured or the government. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Private not‐for‐profit drug insurance</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Private not‐for‐profit drug insurance schemes are unlikely to provide universal coverage unless subsidised or mandated by the government. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Private not‐for‐profit drug insurance schemes might be motivated to provide access to vulnerable populations (e.g. charitable organisations). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Private not‐for‐profit drug insurance schemes might be motivated to provide protection against catastrophic payments. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Private not‐for‐profit drug insurance schemes should be as concerned with cost‐containment as any other scheme. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>*NA = not applicable; i.e. no obvious way that the outcome might be affected</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Ways in which different policies regarding who provides drug insurance might affect outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011703-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Ways in which different policies regarding who receives drug insurance might affect outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Universal coverage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Equitable access</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Catastrophic payments</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cost containment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Availability of essential drugs</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Universal coverage</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Provided this policy is implemented, it would ensure universal coverage. However, limited resources or implementation might result in some people not being covered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Universal coverage might guarantee equitable access.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Universal coverage might protect against catastrophic payments, but this would depend on what is covered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Public spending on drugs might increase. At the same time, drug costs might be reduced due to pooling funds and facilitating the implementation of other policies (e.g. purchasing policies). Effects on total healthcare spending might depend on the cost‐effectiveness of drugs that are covered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Universal coverage might guarantee access to essential drugs, but this would depend on what is covered. </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Compulsory coverage</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Provided this policy is implemented, it would ensure universal coverage. However, limited compliance, resources or implementation might result in some people not being covered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compulsory coverage might guarantee equitable access.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Public spending on drugs might increase. At the same time, drug costs might be reduced due to pooling funds and facilitating the implementation of other policies (e.g. purchasing policies), although potentially less than universal coverage due to multiple pools. Effects on total healthcare spending might depend on the cost‐effectiveness of drugs that are covered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compulsory coverage might or might not guarantee access to essential drugs.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Coverage of employed population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited to employed population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vulnerable populations might not be covered.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might or might not have maximum payments or protection against catastrophic payments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Public spending might decrease. Employers’ spending might increase.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Access to essential drugs might be provided only to the employed population.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Coverage of vulnerable populations</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited to vulnerable populations. If coverage used to supplement private insurance (and other populations for the most part have insurance), this might lead to universal coverage. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Providing insurance to the most vulnerable populations might decrease inequities.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Catastrophic payments in vulnerable populations might be prevented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Public spending on pharmaceuticals might increase. Effects on total healthcare spending might depend on the cost‐effectiveness of drugs that are covered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Access to essential drugs might be provided to vulnerable groups.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Optional coverage</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited to those who can afford insurance and elect to purchase it</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vulnerable populations might be less likely to be able to afford and to purchase insurance.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might not have maximum payments or protection against catastrophic payments and vulnerable populations might be less likely to be covered </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effects on public spending would depend on the extent to which healthcare costs are paid directly for people who need care and cannot afford OOP payments. Effects on OOP spending would depend on how many people elect to purchase coverage. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Access to essential drugs limited to those who can afford insurance</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>OOP = Out‐of‐pocket payments<br/>NA = not applicable; i.e. no obvious way that the outcome might be affected </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Ways in which different policies regarding who receives drug insurance might affect outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011703-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Ways in which different policies regarding who pays for drug insurance might affect outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Universal coverage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Equitable access</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Catastrophic payments</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cost containment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Availability of essential drugs</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Payment out of general tax revenue</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might facilitate universal coverage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might be progressive and might facilitate access for vulnerable populations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might lead to increased public spending on drugs. Effects on total healthcare spending might depend on the cost‐effectiveness of drugs that are covered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might facilitate coverage with essential drugs</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Payment out of earmarked tax</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might facilitate universal coverage. Might be progressive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might be progressive and might facilitate access for vulnerable populations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might lead to increased public spending on drugs. Effects on total healthcare spending might depend on the cost‐effectiveness of drugs that are covered. Might lead to more transparent collection and spending of funds </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might be more likely to facilitate coverage for essential drugs than payment out of general tax revenue </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Payment by employers</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Restricted to employed people unless there are supplementary policies to ensure coverage for other populations </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vulnerable populations might not have access.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might not have maximum payments or protection against catastrophic payments and vulnerable populations might be less likely to be covered </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Employers’ spending might increase.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Direct payment by individuals</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Restricted to those who can afford insurance unless subsidised by the government</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vulnerable populations might not have access if not subsidised or regulated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might not have maximum payments or protection against catastrophic payments and vulnerable populations might be less likely to be covered </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might increase OOP spending</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>OOP = Out‐of‐pocket payments<br/>NA = not applicable; i.e. no obvious way that the outcome might be affected </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Ways in which different policies regarding who pays for drug insurance might affect outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011703-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Ways in which different policies regarding who makes decisions about which conditions and drugs are covered might affect outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Universal coverage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Equitable access</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Catastrophic payments</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cost containment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Availability of essential drugs</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Government</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government might have incentives to ensure access to all patients for cost‐effective drugs. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might protect against catastrophic payments for high‐cost drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might raise public expenditures on drugs due to covering expensive drugs, corruption or lobbying. Effects on total healthcare spending might depend on the cost‐effectiveness of drugs that are covered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government might have incentives to provide access to essential drugs.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Public body, authorised by government</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Public body might have incentives to ensure access to all patients.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might protect against catastrophic payments for high‐cost drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might help ensure well‐informed and cost‐effective decisions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might help ensure well‐informed decisions resulting in access to effective drugs</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>For‐profit insurance company</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Motivation to maximise profit might result in decisions that reduce coverage and increase inequities. Competition might mitigate this. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Motivation to maximise profit might result in decisions that reduce coverage and increase the risk of catastrophic payments. Competition might mitigate this. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might shift costs to government or OOP expenditures. Profit and competition might motivate cost‐effective decisions and management. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Not‐for‐profit insurance company</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effects on equity might vary depending on the populations that are targeted, motivation and the size of the risk pool. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effects on catastrophic payments might vary depending on the populations that are targeted, motivation and size of the risk pool. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effects on cost containment might vary depending on the populations that are targeted, motivation and the size of the risk pool. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Might have incentives to provide access to essential drugs</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>NA = not applicable; i.e. no obvious way that the outcome might be affected</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Ways in which different policies regarding who makes decisions about which conditions and drugs are covered might affect outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011703.pub2/full#CD011703-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011703.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011703-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011703-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011703-note-0016">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD011703-note-0014">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD011703-note-0012">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD011703-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD011703-note-0010">Português</a> </li> <li class="section-language"> <a class="" href="th#CD011703-note-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011703-note-0008">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011703-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011703\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011703\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011703\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011703\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011703\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011703\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011703\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011703\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011703\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011703\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011703\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011703\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011703\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011703\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011703\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011703\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011703\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011703\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011703.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011703.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011703.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011703.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011703.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719705248"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011703.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719705252"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011703.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918def3a0eb69371',t:'MTc0MDcxOTcwNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 